#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Abnormal asymmetries in subcortical brain volume in schizophrenia
#Text=Subcortical structures, which include the basal ganglia and parts of the limbic system, have key roles in learning, motor control and emotion, but also contribute to higher-order executive functions.
1-1	0-8	Abnormal	_	
1-2	9-20	asymmetries	_	
1-3	21-23	in	_	
1-4	24-35	subcortical	_	
1-5	36-41	brain	_	
1-6	42-48	volume	_	
1-7	49-51	in	_	
1-8	52-65	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-9	66-77	Subcortical	_	
1-10	78-88	structures	_	
1-11	88-89	,	_	
1-12	90-95	which	_	
1-13	96-103	include	_	
1-14	104-107	the	_	
1-15	108-113	basal	_	
1-16	114-121	ganglia	_	
1-17	122-125	and	_	
1-18	126-131	parts	_	
1-19	132-134	of	_	
1-20	135-138	the	_	
1-21	139-145	limbic	_	
1-22	146-152	system	_	
1-23	152-153	,	_	
1-24	154-158	have	_	
1-25	159-162	key	_	
1-26	163-168	roles	_	
1-27	169-171	in	_	
1-28	172-180	learning	_	
1-29	180-181	,	_	
1-30	182-187	motor	_	
1-31	188-195	control	_	
1-32	196-199	and	_	
1-33	200-207	emotion	_	
1-34	207-208	,	_	
1-35	209-212	but	_	
1-36	213-217	also	_	
1-37	218-228	contribute	_	
1-38	229-231	to	_	
1-39	232-244	higher-order	_	
1-40	245-254	executive	_	
1-41	255-264	functions	_	
1-42	264-265	.	_	

#Text=Prior studies have reported volumetric alterations in subcortical regions in schizophrenia.
2-1	266-271	Prior	_	
2-2	272-279	studies	_	
2-3	280-284	have	_	
2-4	285-293	reported	_	
2-5	294-304	volumetric	_	
2-6	305-316	alterations	_	
2-7	317-319	in	_	
2-8	320-331	subcortical	_	
2-9	332-339	regions	_	
2-10	340-342	in	_	
2-11	343-356	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-12	356-357	.	_	

#Text=Reported results have sometimes been heterogeneous, and few large-scale investigations have been conducted.
3-1	358-366	Reported	_	
3-2	367-374	results	_	
3-3	375-379	have	_	
3-4	380-389	sometimes	_	
3-5	390-394	been	_	
3-6	395-408	heterogeneous	_	
3-7	408-409	,	_	
3-8	410-413	and	_	
3-9	414-417	few	_	
3-10	418-429	large-scale	_	
3-11	430-444	investigations	_	
3-12	445-449	have	_	
3-13	450-454	been	_	
3-14	455-464	conducted	_	
3-15	464-465	.	_	

#Text=Moreover, few large-scale studies have assessed asymmetries of subcortical volumes in schizophrenia.
4-1	466-474	Moreover	_	
4-2	474-475	,	_	
4-3	476-479	few	_	
4-4	480-491	large-scale	_	
4-5	492-499	studies	_	
4-6	500-504	have	_	
4-7	505-513	assessed	_	
4-8	514-525	asymmetries	_	
4-9	526-528	of	_	
4-10	529-540	subcortical	_	
4-11	541-548	volumes	_	
4-12	549-551	in	_	
4-13	552-565	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-14	565-566	.	_	

#Text=Here, as a work completely independent of a study performed by the ENIGMA consortium, we conducted a large-scale multisite study of subcortical volumetric differences between patients with schizophrenia and controls.
5-1	567-571	Here	_	
5-2	571-572	,	_	
5-3	573-575	as	_	
5-4	576-577	a	_	
5-5	578-582	work	_	
5-6	583-593	completely	_	
5-7	594-605	independent	_	
5-8	606-608	of	_	
5-9	609-610	a	_	
5-10	611-616	study	_	
5-11	617-626	performed	_	
5-12	627-629	by	_	
5-13	630-633	the	_	
5-14	634-640	ENIGMA	_	
5-15	641-651	consortium	_	
5-16	651-652	,	_	
5-17	653-655	we	_	
5-18	656-665	conducted	_	
5-19	666-667	a	_	
5-20	668-679	large-scale	_	
5-21	680-689	multisite	_	
5-22	690-695	study	_	
5-23	696-698	of	_	
5-24	699-710	subcortical	_	
5-25	711-721	volumetric	_	
5-26	722-733	differences	_	
5-27	734-741	between	_	
5-28	742-750	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
5-29	751-755	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
5-30	756-769	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
5-31	770-773	and	_	
5-32	774-782	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
5-33	782-783	.	_	

#Text=We also explored the laterality of subcortical regions to identify characteristic similarities and differences between them.
6-1	784-786	We	_	
6-2	787-791	also	_	
6-3	792-800	explored	_	
6-4	801-804	the	_	
6-5	805-815	laterality	_	
6-6	816-818	of	_	
6-7	819-830	subcortical	_	
6-8	831-838	regions	_	
6-9	839-841	to	_	
6-10	842-850	identify	_	
6-11	851-865	characteristic	_	
6-12	866-878	similarities	_	
6-13	879-882	and	_	
6-14	883-894	differences	_	
6-15	895-902	between	_	
6-16	903-907	them	_	
6-17	907-908	.	_	

#Text=T1-weighted images from 1680 healthy individuals and 884 patients with schizophrenia, obtained with 15 imaging protocols at 11 sites, were processed with FreeSurfer.
7-1	909-911	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[2]	
7-2	911-912	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[2]	
7-3	912-920	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[2]	
7-4	921-927	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[2]	
7-5	928-932	from	_	
7-6	933-937	1680	_	
7-7	938-945	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
7-8	946-957	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
7-9	958-961	and	_	
7-10	962-965	884	_	
7-11	966-974	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
7-12	975-979	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
7-13	980-993	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
7-14	993-994	,	_	
7-15	995-1003	obtained	_	
7-16	1004-1008	with	_	
7-17	1009-1011	15	_	
7-18	1012-1019	imaging	_	
7-19	1020-1029	protocols	_	
7-20	1030-1032	at	_	
7-21	1033-1035	11	_	
7-22	1036-1041	sites	_	
7-23	1041-1042	,	_	
7-24	1043-1047	were	_	
7-25	1048-1057	processed	_	
7-26	1058-1062	with	_	
7-27	1063-1073	FreeSurfer	_	
7-28	1073-1074	.	_	

#Text=Group differences were calculated for each protocol and meta-analyzed.
8-1	1075-1080	Group	_	
8-2	1081-1092	differences	_	
8-3	1093-1097	were	_	
8-4	1098-1108	calculated	_	
8-5	1109-1112	for	_	
8-6	1113-1117	each	_	
8-7	1118-1126	protocol	_	
8-8	1127-1130	and	_	
8-9	1131-1144	meta-analyzed	_	
8-10	1144-1145	.	_	

#Text=Compared with controls, patients with schizophrenia demonstrated smaller bilateral hippocampus, amygdala, thalamus and accumbens volumes as well as intracranial volume, but larger bilateral caudate, putamen, pallidum and lateral ventricle volumes.
9-1	1146-1154	Compared	_	
9-2	1155-1159	with	_	
9-3	1160-1168	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-4	1168-1169	,	_	
9-5	1170-1178	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
9-6	1179-1183	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
9-7	1184-1197	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
9-8	1198-1210	demonstrated	_	
9-9	1211-1218	smaller	_	
9-10	1219-1228	bilateral	_	
9-11	1229-1240	hippocampus	_	
9-12	1240-1241	,	_	
9-13	1242-1250	amygdala	_	
9-14	1250-1251	,	_	
9-15	1252-1260	thalamus	_	
9-16	1261-1264	and	_	
9-17	1265-1274	accumbens	_	
9-18	1275-1282	volumes	_	
9-19	1283-1285	as	_	
9-20	1286-1290	well	_	
9-21	1291-1293	as	_	
9-22	1294-1306	intracranial	_	
9-23	1307-1313	volume	_	
9-24	1313-1314	,	_	
9-25	1315-1318	but	_	
9-26	1319-1325	larger	_	
9-27	1326-1335	bilateral	_	
9-28	1336-1343	caudate	_	
9-29	1343-1344	,	_	
9-30	1345-1352	putamen	_	
9-31	1352-1353	,	_	
9-32	1354-1362	pallidum	_	
9-33	1363-1366	and	_	
9-34	1367-1374	lateral	_	
9-35	1375-1384	ventricle	_	
9-36	1385-1392	volumes	_	
9-37	1392-1393	.	_	

#Text=We replicated the rank order of effect sizes for subcortical volumetric changes in schizophrenia reported by the ENIGMA consortium.
10-1	1394-1396	We	_	
10-2	1397-1407	replicated	_	
10-3	1408-1411	the	_	
10-4	1412-1416	rank	_	
10-5	1417-1422	order	_	
10-6	1423-1425	of	_	
10-7	1426-1432	effect	_	
10-8	1433-1438	sizes	_	
10-9	1439-1442	for	_	
10-10	1443-1454	subcortical	_	
10-11	1455-1465	volumetric	_	
10-12	1466-1473	changes	_	
10-13	1474-1476	in	_	
10-14	1477-1490	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
10-15	1491-1499	reported	_	
10-16	1500-1502	by	_	
10-17	1503-1506	the	_	
10-18	1507-1513	ENIGMA	_	
10-19	1514-1524	consortium	_	
10-20	1524-1525	.	_	

#Text=Further, we revealed leftward asymmetry for thalamus, lateral ventricle, caudate and putamen volumes, and rightward asymmetry for amygdala and hippocampal volumes in both controls and patients with schizophrenia.
11-1	1526-1533	Further	_	
11-2	1533-1534	,	_	
11-3	1535-1537	we	_	
11-4	1538-1546	revealed	_	
11-5	1547-1555	leftward	_	
11-6	1556-1565	asymmetry	_	
11-7	1566-1569	for	_	
11-8	1570-1578	thalamus	_	
11-9	1578-1579	,	_	
11-10	1580-1587	lateral	_	
11-11	1588-1597	ventricle	_	
11-12	1597-1598	,	_	
11-13	1599-1606	caudate	_	
11-14	1607-1610	and	_	
11-15	1611-1618	putamen	_	
11-16	1619-1626	volumes	_	
11-17	1626-1627	,	_	
11-18	1628-1631	and	_	
11-19	1632-1641	rightward	_	
11-20	1642-1651	asymmetry	_	
11-21	1652-1655	for	_	
11-22	1656-1664	amygdala	_	
11-23	1665-1668	and	_	
11-24	1669-1680	hippocampal	_	
11-25	1681-1688	volumes	_	
11-26	1689-1691	in	_	
11-27	1692-1696	both	_	
11-28	1697-1705	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
11-29	1706-1709	and	_	
11-30	1710-1718	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
11-31	1719-1723	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
11-32	1724-1737	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
11-33	1737-1738	.	_	

#Text=Also, we demonstrated a schizophrenia-specific leftward asymmetry for pallidum volume.
12-1	1739-1743	Also	_	
12-2	1743-1744	,	_	
12-3	1745-1747	we	_	
12-4	1748-1760	demonstrated	_	
12-5	1761-1762	a	_	
12-6	1763-1785	schizophrenia-specific	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
12-7	1786-1794	leftward	_	
12-8	1795-1804	asymmetry	_	
12-9	1805-1808	for	_	
12-10	1809-1817	pallidum	_	
12-11	1818-1824	volume	_	
12-12	1824-1825	.	_	

#Text=These findings suggest the possibility of aberrant laterality in neural pathways and connectivity patterns related to the pallidum in schizophrenia.
13-1	1826-1831	These	_	
13-2	1832-1840	findings	_	
13-3	1841-1848	suggest	_	
13-4	1849-1852	the	_	
13-5	1853-1864	possibility	_	
13-6	1865-1867	of	_	
13-7	1868-1876	aberrant	_	
13-8	1877-1887	laterality	_	
13-9	1888-1890	in	_	
13-10	1891-1897	neural	_	
13-11	1898-1906	pathways	_	
13-12	1907-1910	and	_	
13-13	1911-1923	connectivity	_	
13-14	1924-1932	patterns	_	
13-15	1933-1940	related	_	
13-16	1941-1943	to	_	
13-17	1944-1947	the	_	
13-18	1948-1956	pallidum	_	
13-19	1957-1959	in	_	
13-20	1960-1973	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
13-21	1973-1974	.	_	

#Text=Introduction
#Text=Patients with schizophrenia have volumetric abnormalities in both cortical and subcortical brain regions, which are closely related to characteristic symptoms and behaviors.
14-1	1975-1987	Introduction	_	
14-2	1988-1996	Patients	_	
14-3	1997-2001	with	_	
14-4	2002-2015	schizophrenia	_	
14-5	2016-2020	have	_	
14-6	2021-2031	volumetric	_	
14-7	2032-2045	abnormalities	_	
14-8	2046-2048	in	_	
14-9	2049-2053	both	_	
14-10	2054-2062	cortical	_	
14-11	2063-2066	and	_	
14-12	2067-2078	subcortical	_	
14-13	2079-2084	brain	_	
14-14	2085-2092	regions	_	
14-15	2092-2093	,	_	
14-16	2094-2099	which	_	
14-17	2100-2103	are	_	
14-18	2104-2111	closely	_	
14-19	2112-2119	related	_	
14-20	2120-2122	to	_	
14-21	2123-2137	characteristic	_	
14-22	2138-2146	symptoms	_	
14-23	2147-2150	and	_	
14-24	2151-2160	behaviors	_	
14-25	2160-2161	.	_	

#Text=Patients with schizophrenia demonstrate both positive and negative symptoms as well as cognitive impairment, and many of these characteristic symptoms have been related to structural brain alterations and disrupted interregional connections.
15-1	2162-2170	Patients	_	
15-2	2171-2175	with	_	
15-3	2176-2189	schizophrenia	_	
15-4	2190-2201	demonstrate	_	
15-5	2202-2206	both	_	
15-6	2207-2215	positive	_	
15-7	2216-2219	and	_	
15-8	2220-2228	negative	_	
15-9	2229-2237	symptoms	_	
15-10	2238-2240	as	_	
15-11	2241-2245	well	_	
15-12	2246-2248	as	_	
15-13	2249-2258	cognitive	_	
15-14	2259-2269	impairment	_	
15-15	2269-2270	,	_	
15-16	2271-2274	and	_	
15-17	2275-2279	many	_	
15-18	2280-2282	of	_	
15-19	2283-2288	these	_	
15-20	2289-2303	characteristic	_	
15-21	2304-2312	symptoms	_	
15-22	2313-2317	have	_	
15-23	2318-2322	been	_	
15-24	2323-2330	related	_	
15-25	2331-2333	to	_	
15-26	2334-2344	structural	_	
15-27	2345-2350	brain	_	
15-28	2351-2362	alterations	_	
15-29	2363-2366	and	_	
15-30	2367-2376	disrupted	_	
15-31	2377-2390	interregional	_	
15-32	2391-2402	connections	_	
15-33	2402-2403	.	_	

#Text=Subcortical structures, which include the basal ganglia and parts of the limbic system, are integrally involved in learning and memory, as well as many primitive functions such as motor control, attention and emotion.
16-1	2404-2415	Subcortical	_	
16-2	2416-2426	structures	_	
16-3	2426-2427	,	_	
16-4	2428-2433	which	_	
16-5	2434-2441	include	_	
16-6	2442-2445	the	_	
16-7	2446-2451	basal	_	
16-8	2452-2459	ganglia	_	
16-9	2460-2463	and	_	
16-10	2464-2469	parts	_	
16-11	2470-2472	of	_	
16-12	2473-2476	the	_	
16-13	2477-2483	limbic	_	
16-14	2484-2490	system	_	
16-15	2490-2491	,	_	
16-16	2492-2495	are	_	
16-17	2496-2506	integrally	_	
16-18	2507-2515	involved	_	
16-19	2516-2518	in	_	
16-20	2519-2527	learning	_	
16-21	2528-2531	and	_	
16-22	2532-2538	memory	_	
16-23	2538-2539	,	_	
16-24	2540-2542	as	_	
16-25	2543-2547	well	_	
16-26	2548-2550	as	_	
16-27	2551-2555	many	_	
16-28	2556-2565	primitive	_	
16-29	2566-2575	functions	_	
16-30	2576-2580	such	_	
16-31	2581-2583	as	_	
16-32	2584-2589	motor	_	
16-33	2590-2597	control	_	
16-34	2597-2598	,	_	
16-35	2599-2608	attention	_	
16-36	2609-2612	and	_	
16-37	2613-2620	emotion	_	
16-38	2620-2621	.	_	

#Text=Further, they also have important roles in higher-order executive functions including inhibitory control and working memory through their structural and functional connectivity with prefrontal cortices.
17-1	2622-2629	Further	_	
17-2	2629-2630	,	_	
17-3	2631-2635	they	_	
17-4	2636-2640	also	_	
17-5	2641-2645	have	_	
17-6	2646-2655	important	_	
17-7	2656-2661	roles	_	
17-8	2662-2664	in	_	
17-9	2665-2677	higher-order	_	
17-10	2678-2687	executive	_	
17-11	2688-2697	functions	_	
17-12	2698-2707	including	_	
17-13	2708-2718	inhibitory	_	
17-14	2719-2726	control	_	
17-15	2727-2730	and	_	
17-16	2731-2738	working	_	
17-17	2739-2745	memory	_	
17-18	2746-2753	through	_	
17-19	2754-2759	their	_	
17-20	2760-2770	structural	_	
17-21	2771-2774	and	_	
17-22	2775-2785	functional	_	
17-23	2786-2798	connectivity	_	
17-24	2799-2803	with	_	
17-25	2804-2814	prefrontal	_	
17-26	2815-2823	cortices	_	
17-27	2823-2824	.	_	

#Text=Prior studies have revealed volumetric alterations in the subcortical regions in schizophrenia.
18-1	2825-2830	Prior	_	
18-2	2831-2838	studies	_	
18-3	2839-2843	have	_	
18-4	2844-2852	revealed	_	
18-5	2853-2863	volumetric	_	
18-6	2864-2875	alterations	_	
18-7	2876-2878	in	_	
18-8	2879-2882	the	_	
18-9	2883-2894	subcortical	_	
18-10	2895-2902	regions	_	
18-11	2903-2905	in	_	
18-12	2906-2919	schizophrenia	_	
18-13	2919-2920	.	_	

#Text=For example, many studies report bilateral hippocampal volume reductions in patients with schizophrenia.
19-1	2921-2924	For	_	
19-2	2925-2932	example	_	
19-3	2932-2933	,	_	
19-4	2934-2938	many	_	
19-5	2939-2946	studies	_	
19-6	2947-2953	report	_	
19-7	2954-2963	bilateral	_	
19-8	2964-2975	hippocampal	_	
19-9	2976-2982	volume	_	
19-10	2983-2993	reductions	_	
19-11	2994-2996	in	_	
19-12	2997-3005	patients	_	
19-13	3006-3010	with	_	
19-14	3011-3024	schizophrenia	_	
19-15	3024-3025	.	_	

#Text=Likewise, on average, individuals with schizophrenia demonstrate lower volumes in the left, right or both thalamic regions, and decreased left thalamic volume has even been reported in individuals experiencing first-episode psychosis.
20-1	3026-3034	Likewise	_	
20-2	3034-3035	,	_	
20-3	3036-3038	on	_	
20-4	3039-3046	average	_	
20-5	3046-3047	,	_	
20-6	3048-3059	individuals	_	
20-7	3060-3064	with	_	
20-8	3065-3078	schizophrenia	_	
20-9	3079-3090	demonstrate	_	
20-10	3091-3096	lower	_	
20-11	3097-3104	volumes	_	
20-12	3105-3107	in	_	
20-13	3108-3111	the	_	
20-14	3112-3116	left	_	
20-15	3116-3117	,	_	
20-16	3118-3123	right	_	
20-17	3124-3126	or	_	
20-18	3127-3131	both	_	
20-19	3132-3140	thalamic	_	
20-20	3141-3148	regions	_	
20-21	3148-3149	,	_	
20-22	3150-3153	and	_	
20-23	3154-3163	decreased	_	
20-24	3164-3168	left	_	
20-25	3169-3177	thalamic	_	
20-26	3178-3184	volume	_	
20-27	3185-3188	has	_	
20-28	3189-3193	even	_	
20-29	3194-3198	been	_	
20-30	3199-3207	reported	_	
20-31	3208-3210	in	_	
20-32	3211-3222	individuals	_	
20-33	3223-3235	experiencing	_	
20-34	3236-3249	first-episode	_	
20-35	3250-3259	psychosis	_	
20-36	3259-3260	.	_	

#Text=On the other hand, results of prior studies on basal ganglia volume in schizophrenia have been somewhat heterogeneous.
21-1	3261-3263	On	_	
21-2	3264-3267	the	_	
21-3	3268-3273	other	_	
21-4	3274-3278	hand	_	
21-5	3278-3279	,	_	
21-6	3280-3287	results	_	
21-7	3288-3290	of	_	
21-8	3291-3296	prior	_	
21-9	3297-3304	studies	_	
21-10	3305-3307	on	_	
21-11	3308-3313	basal	_	
21-12	3314-3321	ganglia	_	
21-13	3322-3328	volume	_	
21-14	3329-3331	in	_	
21-15	3332-3345	schizophrenia	_	
21-16	3346-3350	have	_	
21-17	3351-3355	been	_	
21-18	3356-3364	somewhat	_	
21-19	3365-3378	heterogeneous	_	
21-20	3378-3379	.	_	

#Text=Stegmayer et al. reported decreased gray matter density in the right ventral striatum in patients with schizophrenia having severe emotional dysregulation, while Ha et al. showed increased gray matter concentrations in the right striatum in schizophrenia.
22-1	3380-3389	Stegmayer	_	
22-2	3390-3392	et	_	
22-3	3393-3395	al	_	
22-4	3395-3396	.	_	
22-5	3397-3405	reported	_	
22-6	3406-3415	decreased	_	
22-7	3416-3420	gray	_	
22-8	3421-3427	matter	_	
22-9	3428-3435	density	_	
22-10	3436-3438	in	_	
22-11	3439-3442	the	_	
22-12	3443-3448	right	_	
22-13	3449-3456	ventral	_	
22-14	3457-3465	striatum	_	
22-15	3466-3468	in	_	
22-16	3469-3477	patients	_	
22-17	3478-3482	with	_	
22-18	3483-3496	schizophrenia	_	
22-19	3497-3503	having	_	
22-20	3504-3510	severe	_	
22-21	3511-3520	emotional	_	
22-22	3521-3534	dysregulation	_	
22-23	3534-3535	,	_	
22-24	3536-3541	while	_	
22-25	3542-3544	Ha	_	
22-26	3545-3547	et	_	
22-27	3548-3550	al	_	
22-28	3550-3551	.	_	
22-29	3552-3558	showed	_	
22-30	3559-3568	increased	_	
22-31	3569-3573	gray	_	
22-32	3574-3580	matter	_	
22-33	3581-3595	concentrations	_	
22-34	3596-3598	in	_	
22-35	3599-3602	the	_	
22-36	3603-3608	right	_	
22-37	3609-3617	striatum	_	
22-38	3618-3620	in	_	
22-39	3621-3634	schizophrenia	_	
22-40	3634-3635	.	_	

#Text=Perhaps owing to differences in antipsychotic medications or duration of illness, the right putamen volume has been reported as being increased in schizophrenia in one study, while another study demonstrated decreased gray matter volume in the left putamen in recurrently ill patients with schizophrenia.
23-1	3636-3643	Perhaps	_	
23-2	3644-3649	owing	_	
23-3	3650-3652	to	_	
23-4	3653-3664	differences	_	
23-5	3665-3667	in	_	
23-6	3668-3681	antipsychotic	_	
23-7	3682-3693	medications	_	
23-8	3694-3696	or	_	
23-9	3697-3705	duration	_	
23-10	3706-3708	of	_	
23-11	3709-3716	illness	_	
23-12	3716-3717	,	_	
23-13	3718-3721	the	_	
23-14	3722-3727	right	_	
23-15	3728-3735	putamen	_	
23-16	3736-3742	volume	_	
23-17	3743-3746	has	_	
23-18	3747-3751	been	_	
23-19	3752-3760	reported	_	
23-20	3761-3763	as	_	
23-21	3764-3769	being	_	
23-22	3770-3779	increased	_	
23-23	3780-3782	in	_	
23-24	3783-3796	schizophrenia	_	
23-25	3797-3799	in	_	
23-26	3800-3803	one	_	
23-27	3804-3809	study	_	
23-28	3809-3810	,	_	
23-29	3811-3816	while	_	
23-30	3817-3824	another	_	
23-31	3825-3830	study	_	
23-32	3831-3843	demonstrated	_	
23-33	3844-3853	decreased	_	
23-34	3854-3858	gray	_	
23-35	3859-3865	matter	_	
23-36	3866-3872	volume	_	
23-37	3873-3875	in	_	
23-38	3876-3879	the	_	
23-39	3880-3884	left	_	
23-40	3885-3892	putamen	_	
23-41	3893-3895	in	_	
23-42	3896-3907	recurrently	_	
23-43	3908-3911	ill	_	
23-44	3912-3920	patients	_	
23-45	3921-3925	with	_	
23-46	3926-3939	schizophrenia	_	
23-47	3939-3940	.	_	

#Text=Thus, individual studies may reach different conclusions, suggesting added value of multi-cohort meta-analyses.
24-1	3941-3945	Thus	_	
24-2	3945-3946	,	_	
24-3	3947-3957	individual	_	
24-4	3958-3965	studies	_	
24-5	3966-3969	may	_	
24-6	3970-3975	reach	_	
24-7	3976-3985	different	_	
24-8	3986-3997	conclusions	_	
24-9	3997-3998	,	_	
24-10	3999-4009	suggesting	_	
24-11	4010-4015	added	_	
24-12	4016-4021	value	_	
24-13	4022-4024	of	_	
24-14	4025-4037	multi-cohort	_	
24-15	4038-4051	meta-analyses	_	
24-16	4051-4052	.	_	

#Text=Brain lateralization is considered highly related to human psychological and behavioral characteristics.
25-1	4053-4058	Brain	_	
25-2	4059-4073	lateralization	_	
25-3	4074-4076	is	_	
25-4	4077-4087	considered	_	
25-5	4088-4094	highly	_	
25-6	4095-4102	related	_	
25-7	4103-4105	to	_	
25-8	4106-4111	human	_	
25-9	4112-4125	psychological	_	
25-10	4126-4129	and	_	
25-11	4130-4140	behavioral	_	
25-12	4141-4156	characteristics	_	
25-13	4156-4157	.	_	

#Text=Initially, it was widely believed that the left hemisphere supported language and logical thinking, while the right hemisphere was involved to a greater extent in creativity and intuition.
26-1	4158-4167	Initially	_	
26-2	4167-4168	,	_	
26-3	4169-4171	it	_	
26-4	4172-4175	was	_	
26-5	4176-4182	widely	_	
26-6	4183-4191	believed	_	
26-7	4192-4196	that	_	
26-8	4197-4200	the	_	
26-9	4201-4205	left	_	
26-10	4206-4216	hemisphere	_	
26-11	4217-4226	supported	_	
26-12	4227-4235	language	_	
26-13	4236-4239	and	_	
26-14	4240-4247	logical	_	
26-15	4248-4256	thinking	_	
26-16	4256-4257	,	_	
26-17	4258-4263	while	_	
26-18	4264-4267	the	_	
26-19	4268-4273	right	_	
26-20	4274-4284	hemisphere	_	
26-21	4285-4288	was	_	
26-22	4289-4297	involved	_	
26-23	4298-4300	to	_	
26-24	4301-4302	a	_	
26-25	4303-4310	greater	_	
26-26	4311-4317	extent	_	
26-27	4318-4320	in	_	
26-28	4321-4331	creativity	_	
26-29	4332-4335	and	_	
26-30	4336-4345	intuition	_	
26-31	4345-4346	.	_	

#Text=In recent years, anatomical and functional brain lateralization has been assessed using brain-mapping approaches, and various investigations have revealed the lateralization of subcortical regional volumes in healthy subjects.
27-1	4347-4349	In	_	
27-2	4350-4356	recent	_	
27-3	4357-4362	years	_	
27-4	4362-4363	,	_	
27-5	4364-4374	anatomical	_	
27-6	4375-4378	and	_	
27-7	4379-4389	functional	_	
27-8	4390-4395	brain	_	
27-9	4396-4410	lateralization	_	
27-10	4411-4414	has	_	
27-11	4415-4419	been	_	
27-12	4420-4428	assessed	_	
27-13	4429-4434	using	_	
27-14	4435-4448	brain-mapping	_	
27-15	4449-4459	approaches	_	
27-16	4459-4460	,	_	
27-17	4461-4464	and	_	
27-18	4465-4472	various	_	
27-19	4473-4487	investigations	_	
27-20	4488-4492	have	_	
27-21	4493-4501	revealed	_	
27-22	4502-4505	the	_	
27-23	4506-4520	lateralization	_	
27-24	4521-4523	of	_	
27-25	4524-4535	subcortical	_	
27-26	4536-4544	regional	_	
27-27	4545-4552	volumes	_	
27-28	4553-4555	in	_	
27-29	4556-4563	healthy	_	
27-30	4564-4572	subjects	_	
27-31	4572-4573	.	_	

#Text=For example, rightward asymmetry has been commonly reported for the hippocampus and amygdala.
28-1	4574-4577	For	_	
28-2	4578-4585	example	_	
28-3	4585-4586	,	_	
28-4	4587-4596	rightward	_	
28-5	4597-4606	asymmetry	_	
28-6	4607-4610	has	_	
28-7	4611-4615	been	_	
28-8	4616-4624	commonly	_	
28-9	4625-4633	reported	_	
28-10	4634-4637	for	_	
28-11	4638-4641	the	_	
28-12	4642-4653	hippocampus	_	
28-13	4654-4657	and	_	
28-14	4658-4666	amygdala	_	
28-15	4666-4667	.	_	

#Text=In contrast, results on lateralization of regional volumes for the thalamus, lateral ventricles, caudate nuclei, putamen, globus pallidus and nucleus accumbens are so far controversial and non-conclusive.
29-1	4668-4670	In	_	
29-2	4671-4679	contrast	_	
29-3	4679-4680	,	_	
29-4	4681-4688	results	_	
29-5	4689-4691	on	_	
29-6	4692-4706	lateralization	_	
29-7	4707-4709	of	_	
29-8	4710-4718	regional	_	
29-9	4719-4726	volumes	_	
29-10	4727-4730	for	_	
29-11	4731-4734	the	_	
29-12	4735-4743	thalamus	_	
29-13	4743-4744	,	_	
29-14	4745-4752	lateral	_	
29-15	4753-4763	ventricles	_	
29-16	4763-4764	,	_	
29-17	4765-4772	caudate	_	
29-18	4773-4779	nuclei	_	
29-19	4779-4780	,	_	
29-20	4781-4788	putamen	_	
29-21	4788-4789	,	_	
29-22	4790-4796	globus	_	
29-23	4797-4805	pallidus	_	
29-24	4806-4809	and	_	
29-25	4810-4817	nucleus	_	
29-26	4818-4827	accumbens	_	
29-27	4828-4831	are	_	
29-28	4832-4834	so	_	
29-29	4835-4838	far	_	
29-30	4839-4852	controversial	_	
29-31	4853-4856	and	_	
29-32	4857-4871	non-conclusive	_	
29-33	4871-4872	.	_	

#Text=Altered structural lateralization in schizophrenia has recently been investigated.
30-1	4873-4880	Altered	_	
30-2	4881-4891	structural	_	
30-3	4892-4906	lateralization	_	
30-4	4907-4909	in	_	
30-5	4910-4923	schizophrenia	_	
30-6	4924-4927	has	_	
30-7	4928-4936	recently	_	
30-8	4937-4941	been	_	
30-9	4942-4954	investigated	_	
30-10	4954-4955	.	_	

#Text=Many studies have shown differences in hemispheric asymmetries of cortical volume between patients with schizophrenia and controls.
31-1	4956-4960	Many	_	
31-2	4961-4968	studies	_	
31-3	4969-4973	have	_	
31-4	4974-4979	shown	_	
31-5	4980-4991	differences	_	
31-6	4992-4994	in	_	
31-7	4995-5006	hemispheric	_	
31-8	5007-5018	asymmetries	_	
31-9	5019-5021	of	_	
31-10	5022-5030	cortical	_	
31-11	5031-5037	volume	_	
31-12	5038-5045	between	_	
31-13	5046-5054	patients	_	
31-14	5055-5059	with	_	
31-15	5060-5073	schizophrenia	_	
31-16	5074-5077	and	_	
31-17	5078-5086	controls	_	
31-18	5086-5087	.	_	

#Text=In addition, changes in subcortical structural asymmetry in schizophrenia have also been demonstrated.
32-1	5088-5090	In	_	
32-2	5091-5099	addition	_	
32-3	5099-5100	,	_	
32-4	5101-5108	changes	_	
32-5	5109-5111	in	_	
32-6	5112-5123	subcortical	_	
32-7	5124-5134	structural	_	
32-8	5135-5144	asymmetry	_	
32-9	5145-5147	in	_	
32-10	5148-5161	schizophrenia	_	
32-11	5162-5166	have	_	
32-12	5167-5171	also	_	
32-13	5172-5176	been	_	
32-14	5177-5189	demonstrated	_	
32-15	5189-5190	.	_	

#Text=For example, exaggerated rightward asymmetry of the thalamus, similar but exaggerated rightward asymmetry of the hippocampus and reduced rightward asymmetry of the amygdala have been reported.
33-1	5191-5194	For	_	
33-2	5195-5202	example	_	
33-3	5202-5203	,	_	
33-4	5204-5215	exaggerated	_	
33-5	5216-5225	rightward	_	
33-6	5226-5235	asymmetry	_	
33-7	5236-5238	of	_	
33-8	5239-5242	the	_	
33-9	5243-5251	thalamus	_	
33-10	5251-5252	,	_	
33-11	5253-5260	similar	_	
33-12	5261-5264	but	_	
33-13	5265-5276	exaggerated	_	
33-14	5277-5286	rightward	_	
33-15	5287-5296	asymmetry	_	
33-16	5297-5299	of	_	
33-17	5300-5303	the	_	
33-18	5304-5315	hippocampus	_	
33-19	5316-5319	and	_	
33-20	5320-5327	reduced	_	
33-21	5328-5337	rightward	_	
33-22	5338-5347	asymmetry	_	
33-23	5348-5350	of	_	
33-24	5351-5354	the	_	
33-25	5355-5363	amygdala	_	
33-26	5364-5368	have	_	
33-27	5369-5373	been	_	
33-28	5374-5382	reported	_	
33-29	5382-5383	.	_	

#Text=However, few comprehensive studies have been conducted and little is known on the lateralization of subcortical structures in schizophrenia.
34-1	5384-5391	However	_	
34-2	5391-5392	,	_	
34-3	5393-5396	few	_	
34-4	5397-5410	comprehensive	_	
34-5	5411-5418	studies	_	
34-6	5419-5423	have	_	
34-7	5424-5428	been	_	
34-8	5429-5438	conducted	_	
34-9	5439-5442	and	_	
34-10	5443-5449	little	_	
34-11	5450-5452	is	_	
34-12	5453-5458	known	_	
34-13	5459-5461	on	_	
34-14	5462-5465	the	_	
34-15	5466-5480	lateralization	_	
34-16	5481-5483	of	_	
34-17	5484-5495	subcortical	_	
34-18	5496-5506	structures	_	
34-19	5507-5509	in	_	
34-20	5510-5523	schizophrenia	_	
34-21	5523-5524	.	_	

#Text=Conventional meta-analyses have been used to assess the overall evidence for structural alterations in schizophrenia.
35-1	5525-5537	Conventional	_	
35-2	5538-5551	meta-analyses	_	
35-3	5552-5556	have	_	
35-4	5557-5561	been	_	
35-5	5562-5566	used	_	
35-6	5567-5569	to	_	
35-7	5570-5576	assess	_	
35-8	5577-5580	the	_	
35-9	5581-5588	overall	_	
35-10	5589-5597	evidence	_	
35-11	5598-5601	for	_	
35-12	5602-5612	structural	_	
35-13	5613-5624	alterations	_	
35-14	5625-5627	in	_	
35-15	5628-5641	schizophrenia	_	
35-16	5641-5642	.	_	

#Text=However, this method has some disadvantages.
36-1	5643-5650	However	_	
36-2	5650-5651	,	_	
36-3	5652-5656	this	_	
36-4	5657-5663	method	_	
36-5	5664-5667	has	_	
36-6	5668-5672	some	_	
36-7	5673-5686	disadvantages	_	
36-8	5686-5687	.	_	

#Text=Studies included in a conventional meta-analysis have varying designs, and often have different populations, conditions and analysis methods.
37-1	5688-5695	Studies	_	
37-2	5696-5704	included	_	
37-3	5705-5707	in	_	
37-4	5708-5709	a	_	
37-5	5710-5722	conventional	_	
37-6	5723-5736	meta-analysis	_	
37-7	5737-5741	have	_	
37-8	5742-5749	varying	_	
37-9	5750-5757	designs	_	
37-10	5757-5758	,	_	
37-11	5759-5762	and	_	
37-12	5763-5768	often	_	
37-13	5769-5773	have	_	
37-14	5774-5783	different	_	
37-15	5784-5795	populations	_	
37-16	5795-5796	,	_	
37-17	5797-5807	conditions	_	
37-18	5808-5811	and	_	
37-19	5812-5820	analysis	_	
37-20	5821-5828	methods	_	
37-21	5828-5829	.	_	

#Text=Thus, the overall effects may be weakened.
38-1	5830-5834	Thus	_	
38-2	5834-5835	,	_	
38-3	5836-5839	the	_	
38-4	5840-5847	overall	_	
38-5	5848-5855	effects	_	
38-6	5856-5859	may	_	
38-7	5860-5862	be	_	
38-8	5863-5871	weakened	_	
38-9	5871-5872	.	_	

#Text=Multi-centered large-scale research is very important for elucidating the neural basis of psychiatric disorders such as schizophrenia, as some single studies may have only small effects, or the confidence interval on the magnitude of the effects may be wide in smaller cohorts.
39-1	5873-5887	Multi-centered	_	
39-2	5888-5899	large-scale	_	
39-3	5900-5908	research	_	
39-4	5909-5911	is	_	
39-5	5912-5916	very	_	
39-6	5917-5926	important	_	
39-7	5927-5930	for	_	
39-8	5931-5942	elucidating	_	
39-9	5943-5946	the	_	
39-10	5947-5953	neural	_	
39-11	5954-5959	basis	_	
39-12	5960-5962	of	_	
39-13	5963-5974	psychiatric	_	
39-14	5975-5984	disorders	_	
39-15	5985-5989	such	_	
39-16	5990-5992	as	_	
39-17	5993-6006	schizophrenia	_	
39-18	6006-6007	,	_	
39-19	6008-6010	as	_	
39-20	6011-6015	some	_	
39-21	6016-6022	single	_	
39-22	6023-6030	studies	_	
39-23	6031-6034	may	_	
39-24	6035-6039	have	_	
39-25	6040-6044	only	_	
39-26	6045-6050	small	_	
39-27	6051-6058	effects	_	
39-28	6058-6059	,	_	
39-29	6060-6062	or	_	
39-30	6063-6066	the	_	
39-31	6067-6077	confidence	_	
39-32	6078-6086	interval	_	
39-33	6087-6089	on	_	
39-34	6090-6093	the	_	
39-35	6094-6103	magnitude	_	
39-36	6104-6106	of	_	
39-37	6107-6110	the	_	
39-38	6111-6118	effects	_	
39-39	6119-6122	may	_	
39-40	6123-6125	be	_	
39-41	6126-6130	wide	_	
39-42	6131-6133	in	_	
39-43	6134-6141	smaller	_	
39-44	6142-6149	cohorts	_	
39-45	6149-6150	.	_	

#Text=In this context, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium was organized by neuroscience and genetics researchers from worldwide, to work together on imaging genetics research for psychiatric disorders.
40-1	6151-6153	In	_	
40-2	6154-6158	this	_	
40-3	6159-6166	context	_	
40-4	6166-6167	,	_	
40-5	6168-6171	the	_	
40-6	6172-6181	Enhancing	_	
40-7	6182-6187	Neuro	_	
40-8	6188-6195	Imaging	_	
40-9	6196-6204	Genetics	_	
40-10	6205-6212	through	_	
40-11	6213-6226	Meta-Analysis	_	
40-12	6227-6228	(	_	
40-13	6228-6234	ENIGMA	_	
40-14	6234-6235	)	_	
40-15	6236-6246	Consortium	_	
40-16	6247-6250	was	_	
40-17	6251-6260	organized	_	
40-18	6261-6263	by	_	
40-19	6264-6276	neuroscience	_	
40-20	6277-6280	and	_	
40-21	6281-6289	genetics	_	
40-22	6290-6301	researchers	_	
40-23	6302-6306	from	_	
40-24	6307-6316	worldwide	_	
40-25	6316-6317	,	_	
40-26	6318-6320	to	_	
40-27	6321-6325	work	_	
40-28	6326-6334	together	_	
40-29	6335-6337	on	_	
40-30	6338-6345	imaging	_	
40-31	6346-6354	genetics	_	
40-32	6355-6363	research	_	
40-33	6364-6367	for	_	
40-34	6368-6379	psychiatric	_	
40-35	6380-6389	disorders	_	
40-36	6389-6390	.	_	

#Text=Several reports have already been published by the consortium.
41-1	6391-6398	Several	_	
41-2	6399-6406	reports	_	
41-3	6407-6411	have	_	
41-4	6412-6419	already	_	
41-5	6420-6424	been	_	
41-6	6425-6434	published	_	
41-7	6435-6437	by	_	
41-8	6438-6441	the	_	
41-9	6442-6452	consortium	_	
41-10	6452-6453	.	_	

#Text=Recently, van Erp et al. published an original article about the analysis of brain morphology in schizophrenia.
42-1	6454-6462	Recently	_	
42-2	6462-6463	,	_	
42-3	6464-6467	van	_	
42-4	6468-6471	Erp	_	
42-5	6472-6474	et	_	
42-6	6475-6477	al	_	
42-7	6477-6478	.	_	
42-8	6479-6488	published	_	
42-9	6489-6491	an	_	
42-10	6492-6500	original	_	
42-11	6501-6508	article	_	
42-12	6509-6514	about	_	
42-13	6515-6518	the	_	
42-14	6519-6527	analysis	_	
42-15	6528-6530	of	_	
42-16	6531-6536	brain	_	
42-17	6537-6547	morphology	_	
42-18	6548-6550	in	_	
42-19	6551-6564	schizophrenia	_	
42-20	6564-6565	.	_	

#Text=They identified subcortical regional volumes that are different between patients with schizophrenia and controls, across 15 cohorts, and ordered them by effect sizes.
43-1	6566-6570	They	_	
43-2	6571-6581	identified	_	
43-3	6582-6593	subcortical	_	
43-4	6594-6602	regional	_	
43-5	6603-6610	volumes	_	
43-6	6611-6615	that	_	
43-7	6616-6619	are	_	
43-8	6620-6629	different	_	
43-9	6630-6637	between	_	
43-10	6638-6646	patients	_	
43-11	6647-6651	with	_	
43-12	6652-6665	schizophrenia	_	
43-13	6666-6669	and	_	
43-14	6670-6678	controls	_	
43-15	6678-6679	,	_	
43-16	6680-6686	across	_	
43-17	6687-6689	15	_	
43-18	6690-6697	cohorts	_	
43-19	6697-6698	,	_	
43-20	6699-6702	and	_	
43-21	6703-6710	ordered	_	
43-22	6711-6715	them	_	
43-23	6716-6718	by	_	
43-24	6719-6725	effect	_	
43-25	6726-6731	sizes	_	
43-26	6731-6732	.	_	

#Text=Patients with schizophrenia showed smaller-than-normal volumes in the hippocampus, amygdala, thalamus and accumbens as well as smaller-than-normal intracranial volume (ICV).
44-1	6733-6741	Patients	_	
44-2	6742-6746	with	_	
44-3	6747-6760	schizophrenia	_	
44-4	6761-6767	showed	_	
44-5	6768-6787	smaller-than-normal	_	
44-6	6788-6795	volumes	_	
44-7	6796-6798	in	_	
44-8	6799-6802	the	_	
44-9	6803-6814	hippocampus	_	
44-10	6814-6815	,	_	
44-11	6816-6824	amygdala	_	
44-12	6824-6825	,	_	
44-13	6826-6834	thalamus	_	
44-14	6835-6838	and	_	
44-15	6839-6848	accumbens	_	
44-16	6849-6851	as	_	
44-17	6852-6856	well	_	
44-18	6857-6859	as	_	
44-19	6860-6879	smaller-than-normal	_	
44-20	6880-6892	intracranial	_	
44-21	6893-6899	volume	_	
44-22	6900-6901	(	_	
44-23	6901-6904	ICV	_	
44-24	6904-6905	)	_	
44-25	6905-6906	.	_	

#Text=On the other hand, these patients showed larger-than-normal pallidum and lateral ventricle volumes.
45-1	6907-6909	On	_	
45-2	6910-6913	the	_	
45-3	6914-6919	other	_	
45-4	6920-6924	hand	_	
45-5	6924-6925	,	_	
45-6	6926-6931	these	_	
45-7	6932-6940	patients	_	
45-8	6941-6947	showed	_	
45-9	6948-6966	larger-than-normal	_	
45-10	6967-6975	pallidum	_	
45-11	6976-6979	and	_	
45-12	6980-6987	lateral	_	
45-13	6988-6997	ventricle	_	
45-14	6998-7005	volumes	_	
45-15	7005-7006	.	_	

#Text=In our current study, as a research project by a Japanese consortium, the COCORO (Cognitive Genetics Collaborative Research Organization), we conducted a multisite large-scale cross-sectional investigation of subcortical regional volumetric differences between patients with schizophrenia and healthy subjects by using meta-analytic methods similar to those of the van Erp et al. study.
46-1	7007-7009	In	_	
46-2	7010-7013	our	_	
46-3	7014-7021	current	_	
46-4	7022-7027	study	_	
46-5	7027-7028	,	_	
46-6	7029-7031	as	_	
46-7	7032-7033	a	_	
46-8	7034-7042	research	_	
46-9	7043-7050	project	_	
46-10	7051-7053	by	_	
46-11	7054-7055	a	_	
46-12	7056-7064	Japanese	_	
46-13	7065-7075	consortium	_	
46-14	7075-7076	,	_	
46-15	7077-7080	the	_	
46-16	7081-7087	COCORO	_	
46-17	7088-7089	(	_	
46-18	7089-7098	Cognitive	_	
46-19	7099-7107	Genetics	_	
46-20	7108-7121	Collaborative	_	
46-21	7122-7130	Research	_	
46-22	7131-7143	Organization	_	
46-23	7143-7144	)	_	
46-24	7144-7145	,	_	
46-25	7146-7148	we	_	
46-26	7149-7158	conducted	_	
46-27	7159-7160	a	_	
46-28	7161-7170	multisite	_	
46-29	7171-7182	large-scale	_	
46-30	7183-7198	cross-sectional	_	
46-31	7199-7212	investigation	_	
46-32	7213-7215	of	_	
46-33	7216-7227	subcortical	_	
46-34	7228-7236	regional	_	
46-35	7237-7247	volumetric	_	
46-36	7248-7259	differences	_	
46-37	7260-7267	between	_	
46-38	7268-7276	patients	_	
46-39	7277-7281	with	_	
46-40	7282-7295	schizophrenia	_	
46-41	7296-7299	and	_	
46-42	7300-7307	healthy	_	
46-43	7308-7316	subjects	_	
46-44	7317-7319	by	_	
46-45	7320-7325	using	_	
46-46	7326-7339	meta-analytic	_	
46-47	7340-7347	methods	_	
46-48	7348-7355	similar	_	
46-49	7356-7358	to	_	
46-50	7359-7364	those	_	
46-51	7365-7367	of	_	
46-52	7368-7371	the	_	
46-53	7372-7375	van	_	
46-54	7376-7379	Erp	_	
46-55	7380-7382	et	_	
46-56	7383-7385	al	_	
46-57	7385-7386	.	_	
46-58	7387-7392	study	_	
46-59	7392-7393	.	_	

#Text=As a new line of work, we also separately assessed group differences in each hemispheric regional volume.
47-1	7394-7396	As	_	
47-2	7397-7398	a	_	
47-3	7399-7402	new	_	
47-4	7403-7407	line	_	
47-5	7408-7410	of	_	
47-6	7411-7415	work	_	
47-7	7415-7416	,	_	
47-8	7417-7419	we	_	
47-9	7420-7424	also	_	
47-10	7425-7435	separately	_	
47-11	7436-7444	assessed	_	
47-12	7445-7450	group	_	
47-13	7451-7462	differences	_	
47-14	7463-7465	in	_	
47-15	7466-7470	each	_	
47-16	7471-7482	hemispheric	_	
47-17	7483-7491	regional	_	
47-18	7492-7498	volume	_	
47-19	7498-7499	.	_	

#Text=Further, we explored the asymmetry of subcortical regional volumes both in healthy subjects and in patients with schizophrenia, and investigated possible alterations of subcortical asymmetry in schizophrenia.
48-1	7500-7507	Further	_	
48-2	7507-7508	,	_	
48-3	7509-7511	we	_	
48-4	7512-7520	explored	_	
48-5	7521-7524	the	_	
48-6	7525-7534	asymmetry	_	
48-7	7535-7537	of	_	
48-8	7538-7549	subcortical	_	
48-9	7550-7558	regional	_	
48-10	7559-7566	volumes	_	
48-11	7567-7571	both	_	
48-12	7572-7574	in	_	
48-13	7575-7582	healthy	_	
48-14	7583-7591	subjects	_	
48-15	7592-7595	and	_	
48-16	7596-7598	in	_	
48-17	7599-7607	patients	_	
48-18	7608-7612	with	_	
48-19	7613-7626	schizophrenia	_	
48-20	7626-7627	,	_	
48-21	7628-7631	and	_	
48-22	7632-7644	investigated	_	
48-23	7645-7653	possible	_	
48-24	7654-7665	alterations	_	
48-25	7666-7668	of	_	
48-26	7669-7680	subcortical	_	
48-27	7681-7690	asymmetry	_	
48-28	7691-7693	in	_	
48-29	7694-7707	schizophrenia	_	
48-30	7707-7708	.	_	

#Text=The first aim of our study was to investigate whether the results of the work by van Erp et al. could be replicated.
49-1	7709-7712	The	_	
49-2	7713-7718	first	_	
49-3	7719-7722	aim	_	
49-4	7723-7725	of	_	
49-5	7726-7729	our	_	
49-6	7730-7735	study	_	
49-7	7736-7739	was	_	
49-8	7740-7742	to	_	
49-9	7743-7754	investigate	_	
49-10	7755-7762	whether	_	
49-11	7763-7766	the	_	
49-12	7767-7774	results	_	
49-13	7775-7777	of	_	
49-14	7778-7781	the	_	
49-15	7782-7786	work	_	
49-16	7787-7789	by	_	
49-17	7790-7793	van	_	
49-18	7794-7797	Erp	_	
49-19	7798-7800	et	_	
49-20	7801-7803	al	_	
49-21	7803-7804	.	_	
49-22	7805-7810	could	_	
49-23	7811-7813	be	_	
49-24	7814-7824	replicated	_	
49-25	7824-7825	.	_	

#Text=The second aim was to elucidate characteristic similarities and differences in subcortical volumetric lateralization between patients with schizophrenia and healthy individuals.
50-1	7826-7829	The	_	
50-2	7830-7836	second	_	
50-3	7837-7840	aim	_	
50-4	7841-7844	was	_	
50-5	7845-7847	to	_	
50-6	7848-7857	elucidate	_	
50-7	7858-7872	characteristic	_	
50-8	7873-7885	similarities	_	
50-9	7886-7889	and	_	
50-10	7890-7901	differences	_	
50-11	7902-7904	in	_	
50-12	7905-7916	subcortical	_	
50-13	7917-7927	volumetric	_	
50-14	7928-7942	lateralization	_	
50-15	7943-7950	between	_	
50-16	7951-7959	patients	_	
50-17	7960-7964	with	_	
50-18	7965-7978	schizophrenia	_	
50-19	7979-7982	and	_	
50-20	7983-7990	healthy	_	
50-21	7991-8002	individuals	_	
50-22	8002-8003	.	_	

#Text=Materials and methods
#Text=Sample subjects and imaging
#Text=A total of 3208 individuals took part in the current large-scale cross-sectional cohort project—the overall cohort consisted of 2091 healthy controls and 1117 patients with schizophrenia from 11 sites in COCORO.
51-1	8004-8013	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
51-2	8014-8017	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
51-3	8018-8025	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
51-4	8026-8032	Sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-5	8033-8041	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-6	8042-8045	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-7	8046-8053	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-8	8054-8055	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-9	8056-8061	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-10	8062-8064	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-11	8065-8069	3208	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-12	8070-8081	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-13	8082-8086	took	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-14	8087-8091	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-15	8092-8094	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-16	8095-8098	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-17	8099-8106	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-18	8107-8118	large-scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-19	8119-8134	cross-sectional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-20	8135-8141	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
51-21	8142-8153	project—the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-22	8154-8161	overall	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-23	8162-8168	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-24	8169-8178	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-25	8179-8181	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-26	8182-8186	2091	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-27	8187-8194	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
51-28	8195-8203	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
51-29	8204-8207	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-30	8208-8212	1117	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-31	8213-8221	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
51-32	8222-8226	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
51-33	8227-8240	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
51-34	8241-8245	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-35	8246-8248	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-36	8249-8254	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-37	8255-8257	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-38	8258-8264	COCORO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-39	8264-8265	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Participants did not overlap between the van Erp et al. study and our current study.
52-1	8266-8278	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-2	8279-8282	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-3	8283-8286	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-4	8287-8294	overlap	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-5	8295-8302	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-6	8303-8306	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-7	8307-8310	van	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-8	8311-8314	Erp	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-9	8315-8317	et	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-10	8318-8320	al	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-11	8320-8321	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-12	8322-8327	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-13	8328-8331	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-14	8332-8335	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-15	8336-8343	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-16	8344-8349	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-17	8349-8350	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Subject inclusion and exclusion criteria by site are described in Supplementary Method 1.
53-1	8351-8358	Subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-2	8359-8368	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-3	8369-8372	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-4	8373-8382	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-5	8383-8391	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-6	8392-8394	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-7	8395-8399	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-8	8400-8403	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-9	8404-8413	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-10	8414-8416	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-11	8417-8430	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-12	8431-8437	Method	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-13	8438-8439	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
53-14	8439-8440	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Written informed consent was obtained from each subject before participation.
54-1	8441-8448	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-2	8449-8457	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-3	8458-8465	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-4	8466-8469	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-5	8470-8478	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-6	8479-8483	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-7	8484-8488	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-8	8489-8496	subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-9	8497-8503	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-10	8504-8517	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-11	8517-8518	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=This procedure was approved by each local institutional review board.
55-1	8519-8523	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-2	8524-8533	procedure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-3	8534-8537	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-4	8538-8546	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-5	8547-8549	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-6	8550-8554	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-7	8555-8560	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-8	8561-8574	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-9	8575-8581	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-10	8582-8587	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
55-11	8587-8588	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Each participating site conducted magnetic resonance imaging (MRI) scanning and obtained T1-weighted images with one or more scanner(s) and imaging protocol(s).
56-1	8589-8593	Each	_	
56-2	8594-8607	participating	_	
56-3	8608-8612	site	_	
56-4	8613-8622	conducted	_	
56-5	8623-8631	magnetic	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-6	8632-8641	resonance	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-7	8642-8649	imaging	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-8	8650-8651	(	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-9	8651-8654	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-10	8654-8655	)	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-11	8656-8664	scanning	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
56-12	8665-8668	and	_	
56-13	8669-8677	obtained	_	
56-14	8678-8680	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
56-15	8680-8681	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
56-16	8681-8689	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
56-17	8690-8696	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[16]	
56-18	8697-8701	with	_	
56-19	8702-8705	one	_	
56-20	8706-8708	or	_	
56-21	8709-8713	more	_	
56-22	8714-8721	scanner	_	
56-23	8721-8722	(	_	
56-24	8722-8723	s	_	
56-25	8723-8724	)	_	
56-26	8725-8728	and	_	
56-27	8729-8736	imaging	_	
56-28	8737-8745	protocol	_	
56-29	8745-8746	(	_	
56-30	8746-8747	s	_	
56-31	8747-8748	)	_	
56-32	8748-8749	.	_	

#Text=A combination of one scanner and one imaging protocol was defined as one ‘protocol', and 26 protocols were registered in the current study.
57-1	8750-8751	A	_	
57-2	8752-8763	combination	_	
57-3	8764-8766	of	_	
57-4	8767-8770	one	_	
57-5	8771-8778	scanner	_	
57-6	8779-8782	and	_	
57-7	8783-8786	one	_	
57-8	8787-8794	imaging	_	
57-9	8795-8803	protocol	_	
57-10	8804-8807	was	_	
57-11	8808-8815	defined	_	
57-12	8816-8818	as	_	
57-13	8819-8822	one	_	
57-14	8823-8824	‘	_	
57-15	8824-8832	protocol	_	
57-16	8832-8833	'	_	
57-17	8833-8834	,	_	
57-18	8835-8838	and	_	
57-19	8839-8841	26	_	
57-20	8842-8851	protocols	_	
57-21	8852-8856	were	_	
57-22	8857-8867	registered	_	
57-23	8868-8870	in	_	
57-24	8871-8874	the	_	
57-25	8875-8882	current	_	
57-26	8883-8888	study	_	
57-27	8888-8889	.	_	

#Text=Detailed imaging parameters for each protocol are shown in Supplementary Table 1.
58-1	8890-8898	Detailed	_	
58-2	8899-8906	imaging	_	
58-3	8907-8917	parameters	_	
58-4	8918-8921	for	_	
58-5	8922-8926	each	_	
58-6	8927-8935	protocol	_	
58-7	8936-8939	are	_	
58-8	8940-8945	shown	_	
58-9	8946-8948	in	_	
58-10	8949-8962	Supplementary	_	
58-11	8963-8968	Table	_	
58-12	8969-8970	1	_	
58-13	8970-8971	.	_	

#Text=For accurate exploration of brain hemispheric characteristics including lateralization, we investigated the possibility of left–right errors derived from MRI data format conversion.
59-1	8972-8975	For	_	
59-2	8976-8984	accurate	_	
59-3	8985-8996	exploration	_	
59-4	8997-8999	of	_	
59-5	9000-9005	brain	_	
59-6	9006-9017	hemispheric	_	
59-7	9018-9033	characteristics	_	
59-8	9034-9043	including	_	
59-9	9044-9058	lateralization	_	
59-10	9058-9059	,	_	
59-11	9060-9062	we	_	
59-12	9063-9075	investigated	_	
59-13	9076-9079	the	_	
59-14	9080-9091	possibility	_	
59-15	9092-9094	of	_	
59-16	9095-9105	left–right	_	
59-17	9106-9112	errors	_	
59-18	9113-9120	derived	_	
59-19	9121-9125	from	_	
59-20	9126-9129	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
59-21	9130-9134	data	_	
59-22	9135-9141	format	_	
59-23	9142-9152	conversion	_	
59-24	9152-9153	.	_	

#Text=The details are described in Supplementary Method 2.
60-1	9154-9157	The	_	
60-2	9158-9165	details	_	
60-3	9166-9169	are	_	
60-4	9170-9179	described	_	
60-5	9180-9182	in	_	
60-6	9183-9196	Supplementary	_	
60-7	9197-9203	Method	_	
60-8	9204-9205	2	_	
60-9	9205-9206	.	_	

#Text=Imaging processing, quality control and protocol selection
#Text=The procedures described in this section are summarized in Figure 1.
61-1	9207-9214	Imaging	_	
61-2	9215-9225	processing	_	
61-3	9225-9226	,	_	
61-4	9227-9234	quality	_	
61-5	9235-9242	control	_	
61-6	9243-9246	and	_	
61-7	9247-9255	protocol	_	
61-8	9256-9265	selection	_	
61-9	9266-9269	The	_	
61-10	9270-9280	procedures	_	
61-11	9281-9290	described	_	
61-12	9291-9293	in	_	
61-13	9294-9298	this	_	
61-14	9299-9306	section	_	
61-15	9307-9310	are	_	
61-16	9311-9321	summarized	_	
61-17	9322-9324	in	_	
61-18	9325-9331	Figure	_	
61-19	9332-9333	1	_	
61-20	9333-9334	.	_	

#Text=In the first quality control step, original T1-weighted images were checked by visual inspection.
62-1	9335-9337	In	_	
62-2	9338-9341	the	_	
62-3	9342-9347	first	_	
62-4	9348-9355	quality	_	
62-5	9356-9363	control	_	
62-6	9364-9368	step	_	
62-7	9368-9369	,	_	
62-8	9370-9378	original	_	
62-9	9379-9381	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[17]	
62-10	9381-9382	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[17]	
62-11	9382-9390	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[17]	
62-12	9391-9397	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[17]	
62-13	9398-9402	were	_	
62-14	9403-9410	checked	_	
62-15	9411-9413	by	_	
62-16	9414-9420	visual	_	
62-17	9421-9431	inspection	_	
62-18	9431-9432	.	_	

#Text=We excluded images with insufficient brain coverage (field-of-view problem), those with low signal-to-noise ratios or any artifacts (for example, motion artifacts and magnetic susceptibility artifacts) and those with any abnormal organic findings (for example, large cerebellar cysts and cavum septum pellucidum).
63-1	9433-9435	We	_	
63-2	9436-9444	excluded	_	
63-3	9445-9451	images	_	
63-4	9452-9456	with	_	
63-5	9457-9469	insufficient	_	
63-6	9470-9475	brain	_	
63-7	9476-9484	coverage	_	
63-8	9485-9486	(	_	
63-9	9486-9499	field-of-view	_	
63-10	9500-9507	problem	_	
63-11	9507-9508	)	_	
63-12	9508-9509	,	_	
63-13	9510-9515	those	_	
63-14	9516-9520	with	_	
63-15	9521-9524	low	_	
63-16	9525-9540	signal-to-noise	_	
63-17	9541-9547	ratios	_	
63-18	9548-9550	or	_	
63-19	9551-9554	any	_	
63-20	9555-9564	artifacts	_	
63-21	9565-9566	(	_	
63-22	9566-9569	for	_	
63-23	9570-9577	example	_	
63-24	9577-9578	,	_	
63-25	9579-9585	motion	_	
63-26	9586-9595	artifacts	_	
63-27	9596-9599	and	_	
63-28	9600-9608	magnetic	_	
63-29	9609-9623	susceptibility	_	
63-30	9624-9633	artifacts	_	
63-31	9633-9634	)	_	
63-32	9635-9638	and	_	
63-33	9639-9644	those	_	
63-34	9645-9649	with	_	
63-35	9650-9653	any	_	
63-36	9654-9662	abnormal	_	
63-37	9663-9670	organic	_	
63-38	9671-9679	findings	_	
63-39	9680-9681	(	_	
63-40	9681-9684	for	_	
63-41	9685-9692	example	_	
63-42	9692-9693	,	_	
63-43	9694-9699	large	_	
63-44	9700-9710	cerebellar	_	
63-45	9711-9716	cysts	_	
63-46	9717-9720	and	_	
63-47	9721-9726	cavum	_	
63-48	9727-9733	septum	_	
63-49	9734-9744	pellucidum	_	
63-50	9744-9745	)	_	
63-51	9745-9746	.	_	

#Text=Through this process, 306 healthy subjects and 167 patients with schizophrenia were excluded.
64-1	9747-9754	Through	_	
64-2	9755-9759	this	_	
64-3	9760-9767	process	_	
64-4	9767-9768	,	_	
64-5	9769-9772	306	_	
64-6	9773-9780	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]	
64-7	9781-9789	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]	
64-8	9790-9793	and	_	
64-9	9794-9797	167	_	
64-10	9798-9806	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
64-11	9807-9811	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
64-12	9812-9825	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
64-13	9826-9830	were	_	
64-14	9831-9839	excluded	_	
64-15	9839-9840	.	_	

#Text=Next, T1-weighted imaging data that had passed the first quality control step were processed with FreeSurfer software version 5.3 (http://surfer.nmr.mgh.harvard.edu), as described previously.
65-1	9841-9845	Next	_	
65-2	9845-9846	,	_	
65-3	9847-9849	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
65-4	9849-9850	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
65-5	9850-9858	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
65-6	9859-9866	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
65-7	9867-9871	data	_	
65-8	9872-9876	that	_	
65-9	9877-9880	had	_	
65-10	9881-9887	passed	_	
65-11	9888-9891	the	_	
65-12	9892-9897	first	_	
65-13	9898-9905	quality	_	
65-14	9906-9913	control	_	
65-15	9914-9918	step	_	
65-16	9919-9923	were	_	
65-17	9924-9933	processed	_	
65-18	9934-9938	with	_	
65-19	9939-9949	FreeSurfer	_	
65-20	9950-9958	software	_	
65-21	9959-9966	version	_	
65-22	9967-9970	5.3	_	
65-23	9971-9972	(	_	
65-24	9972-9976	http	_	
65-25	9976-9977	:	_	
65-26	9977-9978	/	_	
65-27	9978-9979	/	_	
65-28	9979-10005	surfer.nmr.mgh.harvard.edu	_	
65-29	10005-10006	)	_	
65-30	10006-10007	,	_	
65-31	10008-10010	as	_	
65-32	10011-10020	described	_	
65-33	10021-10031	previously	_	
65-34	10031-10032	.	_	

#Text=Through this procedure, we obtained images of subcortical segmentation and regional volumes (for the bilateral lateral ventricles, thalamus, caudate, putamen, globus pallidus, hippocampus, amygdala, accumbens and the ICV).
66-1	10033-10040	Through	_	
66-2	10041-10045	this	_	
66-3	10046-10055	procedure	_	
66-4	10055-10056	,	_	
66-5	10057-10059	we	_	
66-6	10060-10068	obtained	_	
66-7	10069-10075	images	_	
66-8	10076-10078	of	_	
66-9	10079-10090	subcortical	_	
66-10	10091-10103	segmentation	_	
66-11	10104-10107	and	_	
66-12	10108-10116	regional	_	
66-13	10117-10124	volumes	_	
66-14	10125-10126	(	_	
66-15	10126-10129	for	_	
66-16	10130-10133	the	_	
66-17	10134-10143	bilateral	_	
66-18	10144-10151	lateral	_	
66-19	10152-10162	ventricles	_	
66-20	10162-10163	,	_	
66-21	10164-10172	thalamus	_	
66-22	10172-10173	,	_	
66-23	10174-10181	caudate	_	
66-24	10181-10182	,	_	
66-25	10183-10190	putamen	_	
66-26	10190-10191	,	_	
66-27	10192-10198	globus	_	
66-28	10199-10207	pallidus	_	
66-29	10207-10208	,	_	
66-30	10209-10220	hippocampus	_	
66-31	10220-10221	,	_	
66-32	10222-10230	amygdala	_	
66-33	10230-10231	,	_	
66-34	10232-10241	accumbens	_	
66-35	10242-10245	and	_	
66-36	10246-10249	the	_	
66-37	10250-10253	ICV	_	
66-38	10253-10254	)	_	
66-39	10254-10255	.	_	

#Text=Fourteen healthy controls and three patients with schizophrenia were rejected owing to the failure of FreeSurfer processing.
67-1	10256-10264	Fourteen	_	
67-2	10265-10272	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
67-3	10273-10281	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
67-4	10282-10285	and	_	
67-5	10286-10291	three	_	
67-6	10292-10300	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[22]	
67-7	10301-10305	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[22]	
67-8	10306-10319	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[22]	
67-9	10320-10324	were	_	
67-10	10325-10333	rejected	_	
67-11	10334-10339	owing	_	
67-12	10340-10342	to	_	
67-13	10343-10346	the	_	
67-14	10347-10354	failure	_	
67-15	10355-10357	of	_	
67-16	10358-10368	FreeSurfer	_	
67-17	10369-10379	processing	_	
67-18	10379-10380	.	_	

#Text=After that, two independent researchers visually inspected each segmentation image to exclude images with poor parcellation.
68-1	10381-10386	After	_	
68-2	10387-10391	that	_	
68-3	10391-10392	,	_	
68-4	10393-10396	two	_	
68-5	10397-10408	independent	_	
68-6	10409-10420	researchers	_	
68-7	10421-10429	visually	_	
68-8	10430-10439	inspected	_	
68-9	10440-10444	each	_	
68-10	10445-10457	segmentation	_	
68-11	10458-10463	image	_	
68-12	10464-10466	to	_	
68-13	10467-10474	exclude	_	
68-14	10475-10481	images	_	
68-15	10482-10486	with	_	
68-16	10487-10491	poor	_	
68-17	10492-10504	parcellation	_	
68-18	10504-10505	.	_	

#Text=One patient with schizophrenia was excluded by this approach.
69-1	10506-10509	One	_	
69-2	10510-10517	patient	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
69-3	10518-10522	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
69-4	10523-10536	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
69-5	10537-10540	was	_	
69-6	10541-10549	excluded	_	
69-7	10550-10552	by	_	
69-8	10553-10557	this	_	
69-9	10558-10566	approach	_	
69-10	10566-10567	.	_	

#Text=A total of 14 healthy controls and four patients with schizophrenia were excluded in the second quality control step (the quality control of FreeSurfer analysis).
70-1	10568-10569	A	_	
70-2	10570-10575	total	_	
70-3	10576-10578	of	_	
70-4	10579-10581	14	_	
70-5	10582-10589	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]	
70-6	10590-10598	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]	
70-7	10599-10602	and	_	
70-8	10603-10607	four	_	
70-9	10608-10616	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[25]	
70-10	10617-10621	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[25]	
70-11	10622-10635	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[25]	
70-12	10636-10640	were	_	
70-13	10641-10649	excluded	_	
70-14	10650-10652	in	_	
70-15	10653-10656	the	_	
70-16	10657-10663	second	_	
70-17	10664-10671	quality	_	
70-18	10672-10679	control	_	
70-19	10680-10684	step	_	
70-20	10685-10686	(	_	
70-21	10686-10689	the	_	
70-22	10690-10697	quality	_	
70-23	10698-10705	control	_	
70-24	10706-10708	of	_	
70-25	10709-10719	FreeSurfer	_	
70-26	10720-10728	analysis	_	
70-27	10728-10729	)	_	
70-28	10729-10730	.	_	

#Text=After the two quality control steps (inspection of original MRI data and screening for successful FreeSurfer processing), 1771 healthy subjects and 946 patients with schizophrenia remained for possible analysis in the study (available data remained as shown in Supplementary Table 2).
71-1	10731-10736	After	_	
71-2	10737-10740	the	_	
71-3	10741-10744	two	_	
71-4	10745-10752	quality	_	
71-5	10753-10760	control	_	
71-6	10761-10766	steps	_	
71-7	10767-10768	(	_	
71-8	10768-10778	inspection	_	
71-9	10779-10781	of	_	
71-10	10782-10790	original	_	
71-11	10791-10794	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
71-12	10795-10799	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[26]	
71-13	10800-10803	and	_	
71-14	10804-10813	screening	_	
71-15	10814-10817	for	_	
71-16	10818-10828	successful	_	
71-17	10829-10839	FreeSurfer	_	
71-18	10840-10850	processing	_	
71-19	10850-10851	)	_	
71-20	10851-10852	,	_	
71-21	10853-10857	1771	_	
71-22	10858-10865	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[27]	
71-23	10866-10874	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[27]	
71-24	10875-10878	and	_	
71-25	10879-10882	946	_	
71-26	10883-10891	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[28]	
71-27	10892-10896	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[28]	
71-28	10897-10910	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[28]	
71-29	10911-10919	remained	_	
71-30	10920-10923	for	_	
71-31	10924-10932	possible	_	
71-32	10933-10941	analysis	_	
71-33	10942-10944	in	_	
71-34	10945-10948	the	_	
71-35	10949-10954	study	_	
71-36	10955-10956	(	_	
71-37	10956-10965	available	_	
71-38	10966-10970	data	_	
71-39	10971-10979	remained	_	
71-40	10980-10982	as	_	
71-41	10983-10988	shown	_	
71-42	10989-10991	in	_	
71-43	10992-11005	Supplementary	_	
71-44	11006-11011	Table	_	
71-45	11012-11013	2	_	
71-46	11013-11014	)	_	
71-47	11014-11015	.	_	

#Text=Among potential candidates, protocols with less than 50 total participants and those with less than 10 participants in either diagnostic group were excluded before the following meta-analysis, to minimize undue effects of very small groups.
72-1	11016-11021	Among	_	
72-2	11022-11031	potential	_	
72-3	11032-11042	candidates	_	
72-4	11042-11043	,	_	
72-5	11044-11053	protocols	_	
72-6	11054-11058	with	_	
72-7	11059-11063	less	_	
72-8	11064-11068	than	_	
72-9	11069-11071	50	_	
72-10	11072-11077	total	_	
72-11	11078-11090	participants	_	
72-12	11091-11094	and	_	
72-13	11095-11100	those	_	
72-14	11101-11105	with	_	
72-15	11106-11110	less	_	
72-16	11111-11115	than	_	
72-17	11116-11118	10	_	
72-18	11119-11131	participants	_	
72-19	11132-11134	in	_	
72-20	11135-11141	either	_	
72-21	11142-11152	diagnostic	_	
72-22	11153-11158	group	_	
72-23	11159-11163	were	_	
72-24	11164-11172	excluded	_	
72-25	11173-11179	before	_	
72-26	11180-11183	the	_	
72-27	11184-11193	following	_	
72-28	11194-11207	meta-analysis	_	
72-29	11207-11208	,	_	
72-30	11209-11211	to	_	
72-31	11212-11220	minimize	_	
72-32	11221-11226	undue	_	
72-33	11227-11234	effects	_	
72-34	11235-11237	of	_	
72-35	11238-11242	very	_	
72-36	11243-11248	small	_	
72-37	11249-11255	groups	_	
72-38	11255-11256	.	_	

#Text=Finally, 1680 healthy individuals and 884 patients with schizophrenia from 15 protocols remained for inclusion (Table 1).
73-1	11257-11264	Finally	_	
73-2	11264-11265	,	_	
73-3	11266-11270	1680	_	
73-4	11271-11278	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
73-5	11279-11290	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
73-6	11291-11294	and	_	
73-7	11295-11298	884	_	
73-8	11299-11307	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[30]	
73-9	11308-11312	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[30]	
73-10	11313-11326	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[30]	
73-11	11327-11331	from	_	
73-12	11332-11334	15	_	
73-13	11335-11344	protocols	_	
73-14	11345-11353	remained	_	
73-15	11354-11357	for	_	
73-16	11358-11367	inclusion	_	
73-17	11368-11369	(	_	
73-18	11369-11374	Table	_	
73-19	11375-11376	1	_	
73-20	11376-11377	)	_	
73-21	11377-11378	.	_	

#Text=The mean and standard deviation of age across protocols for healthy controls were 34.5±12.7 and for patients were 34.8±11.7 years.
74-1	11379-11382	The	_	
74-2	11383-11387	mean	_	
74-3	11388-11391	and	_	
74-4	11392-11400	standard	_	
74-5	11401-11410	deviation	_	
74-6	11411-11413	of	_	
74-7	11414-11417	age	_	
74-8	11418-11424	across	_	
74-9	11425-11434	protocols	_	
74-10	11435-11438	for	_	
74-11	11439-11446	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[31]	
74-12	11447-11455	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[31]	
74-13	11456-11460	were	_	
74-14	11461-11465	34.5	_	
74-15	11465-11466	±	_	
74-16	11466-11470	12.7	_	
74-17	11471-11474	and	_	
74-18	11475-11478	for	_	
74-19	11479-11487	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
74-20	11488-11492	were	_	
74-21	11493-11497	34.8	_	
74-22	11497-11498	±	_	
74-23	11498-11502	11.7	_	
74-24	11503-11508	years	_	
74-25	11508-11509	.	_	

#Text=As for sex ratio, 52% of the controls and 50% of the patients were male.
75-1	11510-11512	As	_	
75-2	11513-11516	for	_	
75-3	11517-11520	sex	_	
75-4	11521-11526	ratio	_	
75-5	11526-11527	,	_	
75-6	11528-11531	52%	_	
75-7	11532-11534	of	_	
75-8	11535-11538	the	_	
75-9	11539-11547	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
75-10	11548-11551	and	_	
75-11	11552-11555	50%	_	
75-12	11556-11558	of	_	
75-13	11559-11562	the	_	
75-14	11563-11571	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
75-15	11572-11576	were	_	
75-16	11577-11581	male	_	
75-17	11581-11582	.	_	

#Text=Supplementary Figures 1a–q and 2a–q demonstrate regional volume histograms by site in healthy subjects and in patients with schizophrenia, respectively.
76-1	11583-11596	Supplementary	_	
76-2	11597-11604	Figures	_	
76-3	11605-11609	1a–q	_	
76-4	11610-11613	and	_	
76-5	11614-11618	2a–q	_	
76-6	11619-11630	demonstrate	_	
76-7	11631-11639	regional	_	
76-8	11640-11646	volume	_	
76-9	11647-11657	histograms	_	
76-10	11658-11660	by	_	
76-11	11661-11665	site	_	
76-12	11666-11668	in	_	
76-13	11669-11676	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[32]	
76-14	11677-11685	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[32]	
76-15	11686-11689	and	_	
76-16	11690-11692	in	_	
76-17	11693-11701	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[33]	
76-18	11702-11706	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[33]	
76-19	11707-11720	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[33]	
76-20	11720-11721	,	_	
76-21	11722-11734	respectively	_	
76-22	11734-11735	.	_	

#Text=Subgroup sample sizes of the van Erp et al. study and the current study are compared in Supplementary Table 3.
77-1	11736-11744	Subgroup	_	
77-2	11745-11751	sample	_	
77-3	11752-11757	sizes	_	
77-4	11758-11760	of	_	
77-5	11761-11764	the	_	
77-6	11765-11768	van	_	
77-7	11769-11772	Erp	_	
77-8	11773-11775	et	_	
77-9	11776-11778	al	_	
77-10	11778-11779	.	_	
77-11	11780-11785	study	_	
77-12	11786-11789	and	_	
77-13	11790-11793	the	_	
77-14	11794-11801	current	_	
77-15	11802-11807	study	_	
77-16	11808-11811	are	_	
77-17	11812-11820	compared	_	
77-18	11821-11823	in	_	
77-19	11824-11837	Supplementary	_	
77-20	11838-11843	Table	_	
77-21	11844-11845	3	_	
77-22	11845-11846	.	_	

#Text=Alterations of subcortical regional volumes in schizophrenia
#Text=All linear regression analyses were conducted using SPSS version 19.0.0 (SPSS, Chicago, IL, USA), and all meta-analyses were performed using Review Manager version 5.3 (The Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) and Metasoft software.
78-1	11847-11858	Alterations	_	
78-2	11859-11861	of	_	
78-3	11862-11873	subcortical	_	
78-4	11874-11882	regional	_	
78-5	11883-11890	volumes	_	
78-6	11891-11893	in	_	
78-7	11894-11907	schizophrenia	_	
78-8	11908-11911	All	_	
78-9	11912-11918	linear	_	
78-10	11919-11929	regression	_	
78-11	11930-11938	analyses	_	
78-12	11939-11943	were	_	
78-13	11944-11953	conducted	_	
78-14	11954-11959	using	_	
78-15	11960-11964	SPSS	_	
78-16	11965-11972	version	_	
78-17	11973-11979	19.0.0	_	
78-18	11980-11981	(	_	
78-19	11981-11985	SPSS	_	
78-20	11985-11986	,	_	
78-21	11987-11994	Chicago	_	
78-22	11994-11995	,	_	
78-23	11996-11998	IL	_	
78-24	11998-11999	,	_	
78-25	12000-12003	USA	_	
78-26	12003-12004	)	_	
78-27	12004-12005	,	_	
78-28	12006-12009	and	_	
78-29	12010-12013	all	_	
78-30	12014-12027	meta-analyses	_	
78-31	12028-12032	were	_	
78-32	12033-12042	performed	_	
78-33	12043-12048	using	_	
78-34	12049-12055	Review	_	
78-35	12056-12063	Manager	_	
78-36	12064-12071	version	_	
78-37	12072-12075	5.3	_	
78-38	12076-12077	(	_	
78-39	12077-12080	The	_	
78-40	12081-12087	Nordic	_	
78-41	12088-12096	Cochrane	_	
78-42	12097-12103	Centre	_	
78-43	12103-12104	,	_	
78-44	12105-12113	Cochrane	_	
78-45	12114-12127	Collaboration	_	
78-46	12127-12128	,	_	
78-47	12129-12139	Copenhagen	_	
78-48	12139-12140	,	_	
78-49	12141-12148	Denmark	_	
78-50	12148-12149	)	_	
78-51	12150-12153	and	_	
78-52	12154-12162	Metasoft	_	
78-53	12163-12171	software	_	
78-54	12171-12172	.	_	

#Text=For definition of statistical significance, we set the type-I error rate (P-value) at 0.05.
79-1	12173-12176	For	_	
79-2	12177-12187	definition	_	
79-3	12188-12190	of	_	
79-4	12191-12202	statistical	_	
79-5	12203-12215	significance	_	
79-6	12215-12216	,	_	
79-7	12217-12219	we	_	
79-8	12220-12223	set	_	
79-9	12224-12227	the	_	
79-10	12228-12234	type-I	_	
79-11	12235-12240	error	_	
79-12	12241-12245	rate	_	
79-13	12246-12247	(	_	
79-14	12247-12254	P-value	_	
79-15	12254-12255	)	_	
79-16	12256-12258	at	_	
79-17	12259-12263	0.05	_	
79-18	12263-12264	.	_	

#Text=Moreover, a Bonferroni correction was applied to the statistical results to reduce type-I errors generated by multiple comparisons.
80-1	12265-12273	Moreover	_	
80-2	12273-12274	,	_	
80-3	12275-12276	a	_	
80-4	12277-12287	Bonferroni	_	
80-5	12288-12298	correction	_	
80-6	12299-12302	was	_	
80-7	12303-12310	applied	_	
80-8	12311-12313	to	_	
80-9	12314-12317	the	_	
80-10	12318-12329	statistical	_	
80-11	12330-12337	results	_	
80-12	12338-12340	to	_	
80-13	12341-12347	reduce	_	
80-14	12348-12354	type-I	_	
80-15	12355-12361	errors	_	
80-16	12362-12371	generated	_	
80-17	12372-12374	by	_	
80-18	12375-12383	multiple	_	
80-19	12384-12395	comparisons	_	
80-20	12395-12396	.	_	

#Text=First, means and standard deviations of subcortical regional volumes and ICV were calculated for each protocol for each diagnostic group.
81-1	12397-12402	First	_	
81-2	12402-12403	,	_	
81-3	12404-12409	means	_	
81-4	12410-12413	and	_	
81-5	12414-12422	standard	_	
81-6	12423-12433	deviations	_	
81-7	12434-12436	of	_	
81-8	12437-12448	subcortical	_	
81-9	12449-12457	regional	_	
81-10	12458-12465	volumes	_	
81-11	12466-12469	and	_	
81-12	12470-12473	ICV	_	
81-13	12474-12478	were	_	
81-14	12479-12489	calculated	_	
81-15	12490-12493	for	_	
81-16	12494-12498	each	_	
81-17	12499-12507	protocol	_	
81-18	12508-12511	for	_	
81-19	12512-12516	each	_	
81-20	12517-12527	diagnostic	_	
81-21	12528-12533	group	_	
81-22	12533-12534	.	_	

#Text=Second, we examined group differences in regional volumes within each protocol.
82-1	12535-12541	Second	_	
82-2	12541-12542	,	_	
82-3	12543-12545	we	_	
82-4	12546-12554	examined	_	
82-5	12555-12560	group	_	
82-6	12561-12572	differences	_	
82-7	12573-12575	in	_	
82-8	12576-12584	regional	_	
82-9	12585-12592	volumes	_	
82-10	12593-12599	within	_	
82-11	12600-12604	each	_	
82-12	12605-12613	protocol	_	
82-13	12613-12614	.	_	

#Text=Group differences in subcortical regional volumes were investigated using a univariate linear regression analysis including sex, age and ICV as nuisance covariates.
83-1	12615-12620	Group	_	
83-2	12621-12632	differences	_	
83-3	12633-12635	in	_	
83-4	12636-12647	subcortical	_	
83-5	12648-12656	regional	_	
83-6	12657-12664	volumes	_	
83-7	12665-12669	were	_	
83-8	12670-12682	investigated	_	
83-9	12683-12688	using	_	
83-10	12689-12690	a	_	
83-11	12691-12701	univariate	_	
83-12	12702-12708	linear	_	
83-13	12709-12719	regression	_	
83-14	12720-12728	analysis	_	
83-15	12729-12738	including	_	
83-16	12739-12742	sex	_	
83-17	12742-12743	,	_	
83-18	12744-12747	age	_	
83-19	12748-12751	and	_	
83-20	12752-12755	ICV	_	
83-21	12756-12758	as	_	
83-22	12759-12767	nuisance	_	
83-23	12768-12778	covariates	_	
83-24	12778-12779	.	_	

#Text=For group differences in ICV, only sex and age were included as nuisance covariates in the regression analysis.
84-1	12780-12783	For	_	
84-2	12784-12789	group	_	
84-3	12790-12801	differences	_	
84-4	12802-12804	in	_	
84-5	12805-12808	ICV	_	
84-6	12808-12809	,	_	
84-7	12810-12814	only	_	
84-8	12815-12818	sex	_	
84-9	12819-12822	and	_	
84-10	12823-12826	age	_	
84-11	12827-12831	were	_	
84-12	12832-12840	included	_	
84-13	12841-12843	as	_	
84-14	12844-12852	nuisance	_	
84-15	12853-12863	covariates	_	
84-16	12864-12866	in	_	
84-17	12867-12870	the	_	
84-18	12871-12881	regression	_	
84-19	12882-12890	analysis	_	
84-20	12890-12891	.	_	

#Text=Finally, we performed meta-analysis of group differences in each regional volume.
85-1	12892-12899	Finally	_	
85-2	12899-12900	,	_	
85-3	12901-12903	we	_	
85-4	12904-12913	performed	_	
85-5	12914-12927	meta-analysis	_	
85-6	12928-12930	of	_	
85-7	12931-12936	group	_	
85-8	12937-12948	differences	_	
85-9	12949-12951	in	_	
85-10	12952-12956	each	_	
85-11	12957-12965	regional	_	
85-12	12966-12972	volume	_	
85-13	12972-12973	.	_	

#Text=The group differences and standard errors for each protocol were entered into a random-effect model meta-analysis, and overall group differences and standard errors were obtained.
86-1	12974-12977	The	_	
86-2	12978-12983	group	_	
86-3	12984-12995	differences	_	
86-4	12996-12999	and	_	
86-5	13000-13008	standard	_	
86-6	13009-13015	errors	_	
86-7	13016-13019	for	_	
86-8	13020-13024	each	_	
86-9	13025-13033	protocol	_	
86-10	13034-13038	were	_	
86-11	13039-13046	entered	_	
86-12	13047-13051	into	_	
86-13	13052-13053	a	_	
86-14	13054-13067	random-effect	_	
86-15	13068-13073	model	_	
86-16	13074-13087	meta-analysis	_	
86-17	13087-13088	,	_	
86-18	13089-13092	and	_	
86-19	13093-13100	overall	_	
86-20	13101-13106	group	_	
86-21	13107-13118	differences	_	
86-22	13119-13122	and	_	
86-23	13123-13131	standard	_	
86-24	13132-13138	errors	_	
86-25	13139-13143	were	_	
86-26	13144-13152	obtained	_	
86-27	13152-13153	.	_	

#Text=For each brain region, Cohen's d effect sizes were calculated from the overall group contrast.
87-1	13154-13157	For	_	
87-2	13158-13162	each	_	
87-3	13163-13168	brain	_	
87-4	13169-13175	region	_	
87-5	13175-13176	,	_	
87-6	13177-13184	Cohen's	_	
87-7	13185-13186	d	_	
87-8	13187-13193	effect	_	
87-9	13194-13199	sizes	_	
87-10	13200-13204	were	_	
87-11	13205-13215	calculated	_	
87-12	13216-13220	from	_	
87-13	13221-13224	the	_	
87-14	13225-13232	overall	_	
87-15	13233-13238	group	_	
87-16	13239-13247	contrast	_	
87-17	13247-13248	.	_	

#Text=The analytical methods used in the van Erp et al. study from the ENIGMA Schizophrenia Working Group (ENIGMA-SZ) were followed in this analysis.
88-1	13249-13252	The	_	
88-2	13253-13263	analytical	_	
88-3	13264-13271	methods	_	
88-4	13272-13276	used	_	
88-5	13277-13279	in	_	
88-6	13280-13283	the	_	
88-7	13284-13287	van	_	
88-8	13288-13291	Erp	_	
88-9	13292-13294	et	_	
88-10	13295-13297	al	_	
88-11	13297-13298	.	_	
88-12	13299-13304	study	_	
88-13	13305-13309	from	_	
88-14	13310-13313	the	_	
88-15	13314-13320	ENIGMA	_	
88-16	13321-13334	Schizophrenia	_	
88-17	13335-13342	Working	_	
88-18	13343-13348	Group	_	
88-19	13349-13350	(	_	
88-20	13350-13359	ENIGMA-SZ	_	
88-21	13359-13360	)	_	
88-22	13361-13365	were	_	
88-23	13366-13374	followed	_	
88-24	13375-13377	in	_	
88-25	13378-13382	this	_	
88-26	13383-13391	analysis	_	
88-27	13391-13392	.	_	

#Text=Laterality of subcortical regional volumes
#Text=To assess laterality for each regional volume, we used a laterality index (LI), defined as the ratio [(left−right)/(left+right)] this is commonly used to evaluate brain structural asymmetry.
89-1	13393-13403	Laterality	_	
89-2	13404-13406	of	_	
89-3	13407-13418	subcortical	_	
89-4	13419-13427	regional	_	
89-5	13428-13435	volumes	_	
89-6	13436-13438	To	_	
89-7	13439-13445	assess	_	
89-8	13446-13456	laterality	_	
89-9	13457-13460	for	_	
89-10	13461-13465	each	_	
89-11	13466-13474	regional	_	
89-12	13475-13481	volume	_	
89-13	13481-13482	,	_	
89-14	13483-13485	we	_	
89-15	13486-13490	used	_	
89-16	13491-13492	a	_	
89-17	13493-13503	laterality	_	
89-18	13504-13509	index	_	
89-19	13510-13511	(	_	
89-20	13511-13513	LI	_	
89-21	13513-13514	)	_	
89-22	13514-13515	,	_	
89-23	13516-13523	defined	_	
89-24	13524-13526	as	_	
89-25	13527-13530	the	_	
89-26	13531-13536	ratio	_	
89-27	13537-13538	[	_	
89-28	13538-13539	(	_	
89-29	13539-13543	left	_	
89-30	13543-13544	−	_	
89-31	13544-13549	right	_	
89-32	13549-13550	)	_	
89-33	13550-13551	/	_	
89-34	13551-13552	(	_	
89-35	13552-13556	left	_	
89-36	13556-13557	+	_	
89-37	13557-13562	right	_	
89-38	13562-13563	)	_	
89-39	13563-13564	]	_	
89-40	13565-13569	this	_	
89-41	13570-13572	is	_	
89-42	13573-13581	commonly	_	
89-43	13582-13586	used	_	
89-44	13587-13589	to	_	
89-45	13590-13598	evaluate	_	
89-46	13599-13604	brain	_	
89-47	13605-13615	structural	_	
89-48	13616-13625	asymmetry	_	
89-49	13625-13626	.	_	

#Text=LIs can range from −1 to 1 and a positive LI means a leftward asymmetry.
90-1	13627-13630	LIs	_	
90-2	13631-13634	can	_	
90-3	13635-13640	range	_	
90-4	13641-13645	from	_	
90-5	13646-13647	−	_	
90-6	13647-13648	1	_	
90-7	13649-13651	to	_	
90-8	13652-13653	1	_	
90-9	13654-13657	and	_	
90-10	13658-13659	a	_	
90-11	13660-13668	positive	_	
90-12	13669-13671	LI	_	
90-13	13672-13677	means	_	
90-14	13678-13679	a	_	
90-15	13680-13688	leftward	_	
90-16	13689-13698	asymmetry	_	
90-17	13698-13699	.	_	

#Text=First, the means and standard deviations of LIs of subcortical regional volumes were calculated for each protocol for each diagnostic group.
91-1	13700-13705	First	_	
91-2	13705-13706	,	_	
91-3	13707-13710	the	_	
91-4	13711-13716	means	_	
91-5	13717-13720	and	_	
91-6	13721-13729	standard	_	
91-7	13730-13740	deviations	_	
91-8	13741-13743	of	_	
91-9	13744-13747	LIs	_	
91-10	13748-13750	of	_	
91-11	13751-13762	subcortical	_	
91-12	13763-13771	regional	_	
91-13	13772-13779	volumes	_	
91-14	13780-13784	were	_	
91-15	13785-13795	calculated	_	
91-16	13796-13799	for	_	
91-17	13800-13804	each	_	
91-18	13805-13813	protocol	_	
91-19	13814-13817	for	_	
91-20	13818-13822	each	_	
91-21	13823-13833	diagnostic	_	
91-22	13834-13839	group	_	
91-23	13839-13840	.	_	

#Text=One-sample tests were conducted to evaluate whether mean LIs were significantly different from zero.
92-1	13841-13851	One-sample	_	
92-2	13852-13857	tests	_	
92-3	13858-13862	were	_	
92-4	13863-13872	conducted	_	
92-5	13873-13875	to	_	
92-6	13876-13884	evaluate	_	
92-7	13885-13892	whether	_	
92-8	13893-13897	mean	_	
92-9	13898-13901	LIs	_	
92-10	13902-13906	were	_	
92-11	13907-13920	significantly	_	
92-12	13921-13930	different	_	
92-13	13931-13935	from	_	
92-14	13936-13940	zero	_	
92-15	13940-13941	.	_	

#Text=Second, we performed a separate meta-analysis for LIs in each group.
93-1	13942-13948	Second	_	
93-2	13948-13949	,	_	
93-3	13950-13952	we	_	
93-4	13953-13962	performed	_	
93-5	13963-13964	a	_	
93-6	13965-13973	separate	_	
93-7	13974-13987	meta-analysis	_	
93-8	13988-13991	for	_	
93-9	13992-13995	LIs	_	
93-10	13996-13998	in	_	
93-11	13999-14003	each	_	
93-12	14004-14009	group	_	
93-13	14009-14010	.	_	

#Text=Mean LIs and standard errors in each protocol were entered into a random-effect model meta-analysis, and overall mean LIs in each group were obtained.
94-1	14011-14015	Mean	_	
94-2	14016-14019	LIs	_	
94-3	14020-14023	and	_	
94-4	14024-14032	standard	_	
94-5	14033-14039	errors	_	
94-6	14040-14042	in	_	
94-7	14043-14047	each	_	
94-8	14048-14056	protocol	_	
94-9	14057-14061	were	_	
94-10	14062-14069	entered	_	
94-11	14070-14074	into	_	
94-12	14075-14076	a	_	
94-13	14077-14090	random-effect	_	
94-14	14091-14096	model	_	
94-15	14097-14110	meta-analysis	_	
94-16	14110-14111	,	_	
94-17	14112-14115	and	_	
94-18	14116-14123	overall	_	
94-19	14124-14128	mean	_	
94-20	14129-14132	LIs	_	
94-21	14133-14135	in	_	
94-22	14136-14140	each	_	
94-23	14141-14146	group	_	
94-24	14147-14151	were	_	
94-25	14152-14160	obtained	_	
94-26	14160-14161	.	_	

#Text=LIs have similar characteristics to effect sizes; that is, both of them are referenced and indexed to zero (thus, LIs themselves can be meta-analyzed).
95-1	14162-14165	LIs	_	
95-2	14166-14170	have	_	
95-3	14171-14178	similar	_	
95-4	14179-14194	characteristics	_	
95-5	14195-14197	to	_	
95-6	14198-14204	effect	_	
95-7	14205-14210	sizes	_	
95-8	14210-14211	;	_	
95-9	14212-14216	that	_	
95-10	14217-14219	is	_	
95-11	14219-14220	,	_	
95-12	14221-14225	both	_	
95-13	14226-14228	of	_	
95-14	14229-14233	them	_	
95-15	14234-14237	are	_	
95-16	14238-14248	referenced	_	
95-17	14249-14252	and	_	
95-18	14253-14260	indexed	_	
95-19	14261-14263	to	_	
95-20	14264-14268	zero	_	
95-21	14269-14270	(	_	
95-22	14270-14274	thus	_	
95-23	14274-14275	,	_	
95-24	14276-14279	LIs	_	
95-25	14280-14290	themselves	_	
95-26	14291-14294	can	_	
95-27	14295-14297	be	_	
95-28	14298-14311	meta-analyzed	_	
95-29	14311-14312	)	_	
95-30	14312-14313	.	_	

#Text=For each group and each brain region, Cohen's d effect sizes for LIs were calculated from the overall average.
96-1	14314-14317	For	_	
96-2	14318-14322	each	_	
96-3	14323-14328	group	_	
96-4	14329-14332	and	_	
96-5	14333-14337	each	_	
96-6	14338-14343	brain	_	
96-7	14344-14350	region	_	
96-8	14350-14351	,	_	
96-9	14352-14359	Cohen's	_	
96-10	14360-14361	d	_	
96-11	14362-14368	effect	_	
96-12	14369-14374	sizes	_	
96-13	14375-14378	for	_	
96-14	14379-14382	LIs	_	
96-15	14383-14387	were	_	
96-16	14388-14398	calculated	_	
96-17	14399-14403	from	_	
96-18	14404-14407	the	_	
96-19	14408-14415	overall	_	
96-20	14416-14423	average	_	
96-21	14423-14424	.	_	

#Text=Third, group differences in LIs within each protocol were examined using a univariate linear regression, which included sex and age as nuisance covariates, as LIs may not distribute normally.
97-1	14425-14430	Third	_	
97-2	14430-14431	,	_	
97-3	14432-14437	group	_	
97-4	14438-14449	differences	_	
97-5	14450-14452	in	_	
97-6	14453-14456	LIs	_	
97-7	14457-14463	within	_	
97-8	14464-14468	each	_	
97-9	14469-14477	protocol	_	
97-10	14478-14482	were	_	
97-11	14483-14491	examined	_	
97-12	14492-14497	using	_	
97-13	14498-14499	a	_	
97-14	14500-14510	univariate	_	
97-15	14511-14517	linear	_	
97-16	14518-14528	regression	_	
97-17	14528-14529	,	_	
97-18	14530-14535	which	_	
97-19	14536-14544	included	_	
97-20	14545-14548	sex	_	
97-21	14549-14552	and	_	
97-22	14553-14556	age	_	
97-23	14557-14559	as	_	
97-24	14560-14568	nuisance	_	
97-25	14569-14579	covariates	_	
97-26	14579-14580	,	_	
97-27	14581-14583	as	_	
97-28	14584-14587	LIs	_	
97-29	14588-14591	may	_	
97-30	14592-14595	not	_	
97-31	14596-14606	distribute	_	
97-32	14607-14615	normally	_	
97-33	14615-14616	.	_	

#Text=Fourth, we performed a meta-analysis of group differences in LIs.
98-1	14617-14623	Fourth	_	
98-2	14623-14624	,	_	
98-3	14625-14627	we	_	
98-4	14628-14637	performed	_	
98-5	14638-14639	a	_	
98-6	14640-14653	meta-analysis	_	
98-7	14654-14656	of	_	
98-8	14657-14662	group	_	
98-9	14663-14674	differences	_	
98-10	14675-14677	in	_	
98-11	14678-14681	LIs	_	
98-12	14681-14682	.	_	

#Text=Group differences in LIs and standard errors in each protocol were included into a random-effect model meta-analysis, and overall group differences in LIs were obtained.
99-1	14683-14688	Group	_	
99-2	14689-14700	differences	_	
99-3	14701-14703	in	_	
99-4	14704-14707	LIs	_	
99-5	14708-14711	and	_	
99-6	14712-14720	standard	_	
99-7	14721-14727	errors	_	
99-8	14728-14730	in	_	
99-9	14731-14735	each	_	
99-10	14736-14744	protocol	_	
99-11	14745-14749	were	_	
99-12	14750-14758	included	_	
99-13	14759-14763	into	_	
99-14	14764-14765	a	_	
99-15	14766-14779	random-effect	_	
99-16	14780-14785	model	_	
99-17	14786-14799	meta-analysis	_	
99-18	14799-14800	,	_	
99-19	14801-14804	and	_	
99-20	14805-14812	overall	_	
99-21	14813-14818	group	_	
99-22	14819-14830	differences	_	
99-23	14831-14833	in	_	
99-24	14834-14837	LIs	_	
99-25	14838-14842	were	_	
99-26	14843-14851	obtained	_	
99-27	14851-14852	.	_	

#Text=Cohen's d effect sizes for differences in LIs between groups were calculated from the overall group contrast.
100-1	14853-14860	Cohen's	_	
100-2	14861-14862	d	_	
100-3	14863-14869	effect	_	
100-4	14870-14875	sizes	_	
100-5	14876-14879	for	_	
100-6	14880-14891	differences	_	
100-7	14892-14894	in	_	
100-8	14895-14898	LIs	_	
100-9	14899-14906	between	_	
100-10	14907-14913	groups	_	
100-11	14914-14918	were	_	
100-12	14919-14929	calculated	_	
100-13	14930-14934	from	_	
100-14	14935-14938	the	_	
100-15	14939-14946	overall	_	
100-16	14947-14952	group	_	
100-17	14953-14961	contrast	_	
100-18	14961-14962	.	_	

#Text=Using a similar method as used in the van Erp et al. study, we also conducted a power analysis to estimate the sample sizes required to detect the given effect sizes at a power of 0.80 and a one-tailed significance level of 0.05, with G*Power version 3.1.9.2.
101-1	14963-14968	Using	_	
101-2	14969-14970	a	_	
101-3	14971-14978	similar	_	
101-4	14979-14985	method	_	
101-5	14986-14988	as	_	
101-6	14989-14993	used	_	
101-7	14994-14996	in	_	
101-8	14997-15000	the	_	
101-9	15001-15004	van	_	
101-10	15005-15008	Erp	_	
101-11	15009-15011	et	_	
101-12	15012-15014	al	_	
101-13	15014-15015	.	_	
101-14	15016-15021	study	_	
101-15	15021-15022	,	_	
101-16	15023-15025	we	_	
101-17	15026-15030	also	_	
101-18	15031-15040	conducted	_	
101-19	15041-15042	a	_	
101-20	15043-15048	power	_	
101-21	15049-15057	analysis	_	
101-22	15058-15060	to	_	
101-23	15061-15069	estimate	_	
101-24	15070-15073	the	_	
101-25	15074-15080	sample	_	
101-26	15081-15086	sizes	_	
101-27	15087-15095	required	_	
101-28	15096-15098	to	_	
101-29	15099-15105	detect	_	
101-30	15106-15109	the	_	
101-31	15110-15115	given	_	
101-32	15116-15122	effect	_	
101-33	15123-15128	sizes	_	
101-34	15129-15131	at	_	
101-35	15132-15133	a	_	
101-36	15134-15139	power	_	
101-37	15140-15142	of	_	
101-38	15143-15147	0.80	_	
101-39	15148-15151	and	_	
101-40	15152-15153	a	_	
101-41	15154-15164	one-tailed	_	
101-42	15165-15177	significance	_	
101-43	15178-15183	level	_	
101-44	15184-15186	of	_	
101-45	15187-15191	0.05	_	
101-46	15191-15192	,	_	
101-47	15193-15197	with	_	
101-48	15198-15199	G	_	
101-49	15199-15200	*	_	
101-50	15200-15205	Power	_	
101-51	15206-15213	version	_	
101-52	15214-15221	3.1.9.2	_	
101-53	15221-15222	.	_	

#Text=Finally, as an additional analysis, we performed a meta-analysis of group differences in LIs using FMRIB's Integrated Registration and Segmentation Tool (FIRST) in the FMRIB Software Library (FSL) version 5.0.8 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST), as LIs for subcortical volumes calculated with FreeSurfer can be different from those calculated using FSL.
102-1	15223-15230	Finally	_	
102-2	15230-15231	,	_	
102-3	15232-15234	as	_	
102-4	15235-15237	an	_	
102-5	15238-15248	additional	_	
102-6	15249-15257	analysis	_	
102-7	15257-15258	,	_	
102-8	15259-15261	we	_	
102-9	15262-15271	performed	_	
102-10	15272-15273	a	_	
102-11	15274-15287	meta-analysis	_	
102-12	15288-15290	of	_	
102-13	15291-15296	group	_	
102-14	15297-15308	differences	_	
102-15	15309-15311	in	_	
102-16	15312-15315	LIs	_	
102-17	15316-15321	using	_	
102-18	15322-15329	FMRIB's	_	
102-19	15330-15340	Integrated	_	
102-20	15341-15353	Registration	_	
102-21	15354-15357	and	_	
102-22	15358-15370	Segmentation	_	
102-23	15371-15375	Tool	_	
102-24	15376-15377	(	_	
102-25	15377-15382	FIRST	_	
102-26	15382-15383	)	_	
102-27	15384-15386	in	_	
102-28	15387-15390	the	_	
102-29	15391-15396	FMRIB	_	
102-30	15397-15405	Software	_	
102-31	15406-15413	Library	_	
102-32	15414-15415	(	_	
102-33	15415-15418	FSL	_	
102-34	15418-15419	)	_	
102-35	15420-15427	version	_	
102-36	15428-15433	5.0.8	_	
102-37	15434-15435	(	_	
102-38	15435-15439	http	_	
102-39	15439-15440	:	_	
102-40	15440-15441	/	_	
102-41	15441-15442	/	_	
102-42	15442-15460	fsl.fmrib.ox.ac.uk	_	
102-43	15460-15461	/	_	
102-44	15461-15464	fsl	_	
102-45	15464-15465	/	_	
102-46	15465-15472	fslwiki	_	
102-47	15472-15473	/	_	
102-48	15473-15478	FIRST	_	
102-49	15478-15479	)	_	
102-50	15479-15480	,	_	
102-51	15481-15483	as	_	
102-52	15484-15487	LIs	_	
102-53	15488-15491	for	_	
102-54	15492-15503	subcortical	_	
102-55	15504-15511	volumes	_	
102-56	15512-15522	calculated	_	
102-57	15523-15527	with	_	
102-58	15528-15538	FreeSurfer	_	
102-59	15539-15542	can	_	
102-60	15543-15545	be	_	
102-61	15546-15555	different	_	
102-62	15556-15560	from	_	
102-63	15561-15566	those	_	
102-64	15567-15577	calculated	_	
102-65	15578-15583	using	_	
102-66	15584-15587	FSL	_	
102-67	15587-15588	.	_	

#Text=Of the 2564 participants (1680 healthy controls and 884 patients with schizophrenia) included in the main analyses, 29 subjects (18 controls and 11 patients) failed to be processed with FSL.
103-1	15589-15591	Of	_	
103-2	15592-15595	the	_	
103-3	15596-15600	2564	_	
103-4	15601-15613	participants	_	
103-5	15614-15615	(	_	
103-6	15615-15619	1680	_	
103-7	15620-15627	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[34]	
103-8	15628-15636	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[34]	
103-9	15637-15640	and	_	
103-10	15641-15644	884	_	
103-11	15645-15653	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[35]	
103-12	15654-15658	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[35]	
103-13	15659-15672	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[35]	
103-14	15672-15673	)	_	
103-15	15674-15682	included	_	
103-16	15683-15685	in	_	
103-17	15686-15689	the	_	
103-18	15690-15694	main	_	
103-19	15695-15703	analyses	_	
103-20	15703-15704	,	_	
103-21	15705-15707	29	_	
103-22	15708-15716	subjects	_	
103-23	15717-15718	(	_	
103-24	15718-15720	18	_	
103-25	15721-15729	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
103-26	15730-15733	and	_	
103-27	15734-15736	11	_	
103-28	15737-15745	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
103-29	15745-15746	)	_	
103-30	15747-15753	failed	_	
103-31	15754-15756	to	_	
103-32	15757-15759	be	_	
103-33	15760-15769	processed	_	
103-34	15770-15774	with	_	
103-35	15775-15778	FSL	_	
103-36	15778-15779	.	_	

#Text=After that, each segmentation image was visually checked for exclusion of poor parcellation.
104-1	15780-15785	After	_	
104-2	15786-15790	that	_	
104-3	15790-15791	,	_	
104-4	15792-15796	each	_	
104-5	15797-15809	segmentation	_	
104-6	15810-15815	image	_	
104-7	15816-15819	was	_	
104-8	15820-15828	visually	_	
104-9	15829-15836	checked	_	
104-10	15837-15840	for	_	
104-11	15841-15850	exclusion	_	
104-12	15851-15853	of	_	
104-13	15854-15858	poor	_	
104-14	15859-15871	parcellation	_	
104-15	15871-15872	.	_	

#Text=Fifty-eight subjects (35 controls and 23 patients) were excluded by this approach.
105-1	15873-15884	Fifty-eight	_	
105-2	15885-15893	subjects	_	
105-3	15894-15895	(	_	
105-4	15895-15897	35	_	
105-5	15898-15906	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
105-6	15907-15910	and	_	
105-7	15911-15913	23	_	
105-8	15914-15922	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
105-9	15922-15923	)	_	
105-10	15924-15928	were	_	
105-11	15929-15937	excluded	_	
105-12	15938-15940	by	_	
105-13	15941-15945	this	_	
105-14	15946-15954	approach	_	
105-15	15954-15955	.	_	

#Text=Thus, a total of 2477 participants (1627 controls and 850 patients) were entered into the additional analysis.
106-1	15956-15960	Thus	_	
106-2	15960-15961	,	_	
106-3	15962-15963	a	_	
106-4	15964-15969	total	_	
106-5	15970-15972	of	_	
106-6	15973-15977	2477	_	
106-7	15978-15990	participants	_	
106-8	15991-15992	(	_	
106-9	15992-15996	1627	_	
106-10	15997-16005	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
106-11	16006-16009	and	_	
106-12	16010-16013	850	_	
106-13	16014-16022	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
106-14	16022-16023	)	_	
106-15	16024-16028	were	_	
106-16	16029-16036	entered	_	
106-17	16037-16041	into	_	
106-18	16042-16045	the	_	
106-19	16046-16056	additional	_	
106-20	16057-16065	analysis	_	
106-21	16065-16066	.	_	

#Text=Results
#Text=Alterations of subcortical regional volumes in schizophrenia
#Text=Means and standard deviations of regional volumes for each protocol for each diagnostic group can be found in Supplementary Table 4.
107-1	16067-16074	Results	_	
107-2	16075-16086	Alterations	_	
107-3	16087-16089	of	_	
107-4	16090-16101	subcortical	_	
107-5	16102-16110	regional	_	
107-6	16111-16118	volumes	_	
107-7	16119-16121	in	_	
107-8	16122-16135	schizophrenia	_	
107-9	16136-16141	Means	_	
107-10	16142-16145	and	_	
107-11	16146-16154	standard	_	
107-12	16155-16165	deviations	_	
107-13	16166-16168	of	_	
107-14	16169-16177	regional	_	
107-15	16178-16185	volumes	_	
107-16	16186-16189	for	_	
107-17	16190-16194	each	_	
107-18	16195-16203	protocol	_	
107-19	16204-16207	for	_	
107-20	16208-16212	each	_	
107-21	16213-16223	diagnostic	_	
107-22	16224-16229	group	_	
107-23	16230-16233	can	_	
107-24	16234-16236	be	_	
107-25	16237-16242	found	_	
107-26	16243-16245	in	_	
107-27	16246-16259	Supplementary	_	
107-28	16260-16265	Table	_	
107-29	16266-16267	4	_	
107-30	16267-16268	.	_	

#Text=Group differences in regional volumes within each protocol were examined and listed in Supplementary Table 5.
108-1	16269-16274	Group	_	
108-2	16275-16286	differences	_	
108-3	16287-16289	in	_	
108-4	16290-16298	regional	_	
108-5	16299-16306	volumes	_	
108-6	16307-16313	within	_	
108-7	16314-16318	each	_	
108-8	16319-16327	protocol	_	
108-9	16328-16332	were	_	
108-10	16333-16341	examined	_	
108-11	16342-16345	and	_	
108-12	16346-16352	listed	_	
108-13	16353-16355	in	_	
108-14	16356-16369	Supplementary	_	
108-15	16370-16375	Table	_	
108-16	16376-16377	5	_	
108-17	16377-16378	.	_	

#Text=We performed a meta-analysis of group differences in regional volumes.
109-1	16379-16381	We	_	
109-2	16382-16391	performed	_	
109-3	16392-16393	a	_	
109-4	16394-16407	meta-analysis	_	
109-5	16408-16410	of	_	
109-6	16411-16416	group	_	
109-7	16417-16428	differences	_	
109-8	16429-16431	in	_	
109-9	16432-16440	regional	_	
109-10	16441-16448	volumes	_	
109-11	16448-16449	.	_	

#Text=Compared with controls, patients with schizophrenia demonstrated significantly smaller bilateral hippocampus, amygdala, thalamus and accumbens volumes as well as smaller ICVs; however, patients exhibited larger bilateral caudate, putamen, pallidum and lateral ventricle volumes (Supplementary Table 6).
110-1	16450-16458	Compared	_	
110-2	16459-16463	with	_	
110-3	16464-16472	controls	_	
110-4	16472-16473	,	_	
110-5	16474-16482	patients	_	
110-6	16483-16487	with	_	
110-7	16488-16501	schizophrenia	_	
110-8	16502-16514	demonstrated	_	
110-9	16515-16528	significantly	_	
110-10	16529-16536	smaller	_	
110-11	16537-16546	bilateral	_	
110-12	16547-16558	hippocampus	_	
110-13	16558-16559	,	_	
110-14	16560-16568	amygdala	_	
110-15	16568-16569	,	_	
110-16	16570-16578	thalamus	_	
110-17	16579-16582	and	_	
110-18	16583-16592	accumbens	_	
110-19	16593-16600	volumes	_	
110-20	16601-16603	as	_	
110-21	16604-16608	well	_	
110-22	16609-16611	as	_	
110-23	16612-16619	smaller	_	
110-24	16620-16624	ICVs	_	
110-25	16624-16625	;	_	
110-26	16626-16633	however	_	
110-27	16633-16634	,	_	
110-28	16635-16643	patients	_	
110-29	16644-16653	exhibited	_	
110-30	16654-16660	larger	_	
110-31	16661-16670	bilateral	_	
110-32	16671-16678	caudate	_	
110-33	16678-16679	,	_	
110-34	16680-16687	putamen	_	
110-35	16687-16688	,	_	
110-36	16689-16697	pallidum	_	
110-37	16698-16701	and	_	
110-38	16702-16709	lateral	_	
110-39	16710-16719	ventricle	_	
110-40	16720-16727	volumes	_	
110-41	16728-16729	(	_	
110-42	16729-16742	Supplementary	_	
110-43	16743-16748	Table	_	
110-44	16749-16750	6	_	
110-45	16750-16751	)	_	
110-46	16751-16752	.	_	

#Text=The largest decreasing patient–control effect size was found for left hippocampal volume (d=−0.49, P=7.2 × 10−25) and the largest increase was seen for left lateral ventricle volume (d=0.52, P=2.1 × 10−18).
111-1	16753-16756	The	_	
111-2	16757-16764	largest	_	
111-3	16765-16775	decreasing	_	
111-4	16776-16791	patient–control	_	
111-5	16792-16798	effect	_	
111-6	16799-16803	size	_	
111-7	16804-16807	was	_	
111-8	16808-16813	found	_	
111-9	16814-16817	for	_	
111-10	16818-16822	left	_	
111-11	16823-16834	hippocampal	_	
111-12	16835-16841	volume	_	
111-13	16842-16843	(	_	
111-14	16843-16844	d	_	
111-15	16844-16845	=	_	
111-16	16845-16846	−	_	
111-17	16846-16850	0.49	_	
111-18	16850-16851	,	_	
111-19	16852-16853	P	_	
111-20	16853-16854	=	_	
111-21	16854-16857	7.2	_	
111-22	16858-16859	×	_	
111-23	16860-16862	10	_	
111-24	16862-16863	−	_	
111-25	16863-16865	25	_	
111-26	16865-16866	)	_	
111-27	16867-16870	and	_	
111-28	16871-16874	the	_	
111-29	16875-16882	largest	_	
111-30	16883-16891	increase	_	
111-31	16892-16895	was	_	
111-32	16896-16900	seen	_	
111-33	16901-16904	for	_	
111-34	16905-16909	left	_	
111-35	16910-16917	lateral	_	
111-36	16918-16927	ventricle	_	
111-37	16928-16934	volume	_	
111-38	16935-16936	(	_	
111-39	16936-16937	d	_	
111-40	16937-16938	=	_	
111-41	16938-16942	0.52	_	
111-42	16942-16943	,	_	
111-43	16944-16945	P	_	
111-44	16945-16946	=	_	
111-45	16946-16949	2.1	_	
111-46	16950-16951	×	_	
111-47	16952-16954	10	_	
111-48	16954-16955	−	_	
111-49	16955-16957	18	_	
111-50	16957-16958	)	_	
111-51	16958-16959	.	_	

#Text=Each of these brain structures studied, excluding the left caudate volume (d=0.09, P=8.5 × 10−3) and right caudate volume (d=0.13, P=3.0 × 10−3), had significant group differences even at a conservative Bonferroni-corrected threshold of P<2.9 × 10−3 (0.05/17).
112-1	16960-16964	Each	_	
112-2	16965-16967	of	_	
112-3	16968-16973	these	_	
112-4	16974-16979	brain	_	
112-5	16980-16990	structures	_	
112-6	16991-16998	studied	_	
112-7	16998-16999	,	_	
112-8	17000-17009	excluding	_	
112-9	17010-17013	the	_	
112-10	17014-17018	left	_	
112-11	17019-17026	caudate	_	
112-12	17027-17033	volume	_	
112-13	17034-17035	(	_	
112-14	17035-17036	d	_	
112-15	17036-17037	=	_	
112-16	17037-17041	0.09	_	
112-17	17041-17042	,	_	
112-18	17043-17044	P	_	
112-19	17044-17045	=	_	
112-20	17045-17048	8.5	_	
112-21	17049-17050	×	_	
112-22	17051-17053	10	_	
112-23	17053-17054	−	_	
112-24	17054-17055	3	_	
112-25	17055-17056	)	_	
112-26	17057-17060	and	_	
112-27	17061-17066	right	_	
112-28	17067-17074	caudate	_	
112-29	17075-17081	volume	_	
112-30	17082-17083	(	_	
112-31	17083-17084	d	_	
112-32	17084-17085	=	_	
112-33	17085-17089	0.13	_	
112-34	17089-17090	,	_	
112-35	17091-17092	P	_	
112-36	17092-17093	=	_	
112-37	17093-17096	3.0	_	
112-38	17097-17098	×	_	
112-39	17099-17101	10	_	
112-40	17101-17102	−	_	
112-41	17102-17103	3	_	
112-42	17103-17104	)	_	
112-43	17104-17105	,	_	
112-44	17106-17109	had	_	
112-45	17110-17121	significant	_	
112-46	17122-17127	group	_	
112-47	17128-17139	differences	_	
112-48	17140-17144	even	_	
112-49	17145-17147	at	_	
112-50	17148-17149	a	_	
112-51	17150-17162	conservative	_	
112-52	17163-17183	Bonferroni-corrected	_	
112-53	17184-17193	threshold	_	
112-54	17194-17196	of	_	
112-55	17197-17198	P	_	
112-56	17198-17199	<	_	
112-57	17199-17202	2.9	_	
112-58	17203-17204	×	_	
112-59	17205-17207	10	_	
112-60	17207-17208	−	_	
112-61	17208-17209	3	_	
112-62	17210-17211	(	_	
112-63	17211-17215	0.05	_	
112-64	17215-17216	/	_	
112-65	17216-17218	17	_	
112-66	17218-17219	)	_	
112-67	17219-17220	.	_	

#Text=Results for left and right hemispheric volumes of each region demonstrated similar tendencies.
113-1	17221-17228	Results	_	
113-2	17229-17232	for	_	
113-3	17233-17237	left	_	
113-4	17238-17241	and	_	
113-5	17242-17247	right	_	
113-6	17248-17259	hemispheric	_	
113-7	17260-17267	volumes	_	
113-8	17268-17270	of	_	
113-9	17271-17275	each	_	
113-10	17276-17282	region	_	
113-11	17283-17295	demonstrated	_	
113-12	17296-17303	similar	_	
113-13	17304-17314	tendencies	_	
113-14	17314-17315	.	_	

#Text=The effect sizes and standard errors for subcortical regional volume differences are depicted in Figure 2, where the results of the van Erp et al. study from ENIGMA-SZ and those of the current study from COCORO are merged.
114-1	17316-17319	The	_	
114-2	17320-17326	effect	_	
114-3	17327-17332	sizes	_	
114-4	17333-17336	and	_	
114-5	17337-17345	standard	_	
114-6	17346-17352	errors	_	
114-7	17353-17356	for	_	
114-8	17357-17368	subcortical	_	
114-9	17369-17377	regional	_	
114-10	17378-17384	volume	_	
114-11	17385-17396	differences	_	
114-12	17397-17400	are	_	
114-13	17401-17409	depicted	_	
114-14	17410-17412	in	_	
114-15	17413-17419	Figure	_	
114-16	17420-17421	2	_	
114-17	17421-17422	,	_	
114-18	17423-17428	where	_	
114-19	17429-17432	the	_	
114-20	17433-17440	results	_	
114-21	17441-17443	of	_	
114-22	17444-17447	the	_	
114-23	17448-17451	van	_	
114-24	17452-17455	Erp	_	
114-25	17456-17458	et	_	
114-26	17459-17461	al	_	
114-27	17461-17462	.	_	
114-28	17463-17468	study	_	
114-29	17469-17473	from	_	
114-30	17474-17483	ENIGMA-SZ	_	
114-31	17484-17487	and	_	
114-32	17488-17493	those	_	
114-33	17494-17496	of	_	
114-34	17497-17500	the	_	
114-35	17501-17508	current	_	
114-36	17509-17514	study	_	
114-37	17515-17519	from	_	
114-38	17520-17526	COCORO	_	
114-39	17527-17530	are	_	
114-40	17531-17537	merged	_	
114-41	17537-17538	.	_	

#Text=The I2 index, which represented the heterogeneity of effect sizes, varied from zero to moderate (range: 0–56%).
115-1	17539-17542	The	_	
115-2	17543-17545	I2	_	
115-3	17546-17551	index	_	
115-4	17551-17552	,	_	
115-5	17553-17558	which	_	
115-6	17559-17570	represented	_	
115-7	17571-17574	the	_	
115-8	17575-17588	heterogeneity	_	
115-9	17589-17591	of	_	
115-10	17592-17598	effect	_	
115-11	17599-17604	sizes	_	
115-12	17604-17605	,	_	
115-13	17606-17612	varied	_	
115-14	17613-17617	from	_	
115-15	17618-17622	zero	_	
115-16	17623-17625	to	_	
115-17	17626-17634	moderate	_	
115-18	17635-17636	(	_	
115-19	17636-17641	range	_	
115-20	17641-17642	:	_	
115-21	17643-17644	0	_	
115-22	17644-17645	–	_	
115-23	17645-17648	56%	_	
115-24	17648-17649	)	_	
115-25	17649-17650	.	_	

#Text=Group differences for each protocol are provided in Supplementary Figures 3a–q.
116-1	17651-17656	Group	_	
116-2	17657-17668	differences	_	
116-3	17669-17672	for	_	
116-4	17673-17677	each	_	
116-5	17678-17686	protocol	_	
116-6	17687-17690	are	_	
116-7	17691-17699	provided	_	
116-8	17700-17702	in	_	
116-9	17703-17716	Supplementary	_	
116-10	17717-17724	Figures	_	
116-11	17725-17729	3a–q	_	
116-12	17729-17730	.	_	

#Text=Laterality of subcortical regional volumes
#Text=Means and standard deviations of LIs of regional volumes for each protocol for each group are listed in Supplementary Table 7.
117-1	17731-17741	Laterality	_	
117-2	17742-17744	of	_	
117-3	17745-17756	subcortical	_	
117-4	17757-17765	regional	_	
117-5	17766-17773	volumes	_	
117-6	17774-17779	Means	_	
117-7	17780-17783	and	_	
117-8	17784-17792	standard	_	
117-9	17793-17803	deviations	_	
117-10	17804-17806	of	_	
117-11	17807-17810	LIs	_	
117-12	17811-17813	of	_	
117-13	17814-17822	regional	_	
117-14	17823-17830	volumes	_	
117-15	17831-17834	for	_	
117-16	17835-17839	each	_	
117-17	17840-17848	protocol	_	
117-18	17849-17852	for	_	
117-19	17853-17857	each	_	
117-20	17858-17863	group	_	
117-21	17864-17867	are	_	
117-22	17868-17874	listed	_	
117-23	17875-17877	in	_	
117-24	17878-17891	Supplementary	_	
117-25	17892-17897	Table	_	
117-26	17898-17899	7	_	
117-27	17899-17900	.	_	

#Text=We performed a meta-analysis of LIs in each group (Figure 3 and Supplementary Table 8).
118-1	17901-17903	We	_	
118-2	17904-17913	performed	_	
118-3	17914-17915	a	_	
118-4	17916-17929	meta-analysis	_	
118-5	17930-17932	of	_	
118-6	17933-17936	LIs	_	
118-7	17937-17939	in	_	
118-8	17940-17944	each	_	
118-9	17945-17950	group	_	
118-10	17951-17952	(	_	
118-11	17952-17958	Figure	_	
118-12	17959-17960	3	_	
118-13	17961-17964	and	_	
118-14	17965-17978	Supplementary	_	
118-15	17979-17984	Table	_	
118-16	17985-17986	8	_	
118-17	17986-17987	)	_	
118-18	17987-17988	.	_	

#Text=Healthy controls and patients with schizophrenia showed significantly positive LIs in the thalamus (d=1.32, d=1.26, respectively), lateral ventricles (d=0.59, d=0.62, respectively), caudate (d=0.57, d=0.53, respectively) and putamen (d=0.55, d=0.52, respectively), as well as significantly negative LIs in the hippocampus (d=−0.42, d=−0.41, respectively) and amygdala (d=−0.25, d=−0.36, respectively).
119-1	17989-17996	Healthy	_	
119-2	17997-18005	controls	_	
119-3	18006-18009	and	_	
119-4	18010-18018	patients	_	
119-5	18019-18023	with	_	
119-6	18024-18037	schizophrenia	_	
119-7	18038-18044	showed	_	
119-8	18045-18058	significantly	_	
119-9	18059-18067	positive	_	
119-10	18068-18071	LIs	_	
119-11	18072-18074	in	_	
119-12	18075-18078	the	_	
119-13	18079-18087	thalamus	_	
119-14	18088-18089	(	_	
119-15	18089-18090	d	_	
119-16	18090-18091	=	_	
119-17	18091-18095	1.32	_	
119-18	18095-18096	,	_	
119-19	18097-18098	d	_	
119-20	18098-18099	=	_	
119-21	18099-18103	1.26	_	
119-22	18103-18104	,	_	
119-23	18105-18117	respectively	_	
119-24	18117-18118	)	_	
119-25	18118-18119	,	_	
119-26	18120-18127	lateral	_	
119-27	18128-18138	ventricles	_	
119-28	18139-18140	(	_	
119-29	18140-18141	d	_	
119-30	18141-18142	=	_	
119-31	18142-18146	0.59	_	
119-32	18146-18147	,	_	
119-33	18148-18149	d	_	
119-34	18149-18150	=	_	
119-35	18150-18154	0.62	_	
119-36	18154-18155	,	_	
119-37	18156-18168	respectively	_	
119-38	18168-18169	)	_	
119-39	18169-18170	,	_	
119-40	18171-18178	caudate	_	
119-41	18179-18180	(	_	
119-42	18180-18181	d	_	
119-43	18181-18182	=	_	
119-44	18182-18186	0.57	_	
119-45	18186-18187	,	_	
119-46	18188-18189	d	_	
119-47	18189-18190	=	_	
119-48	18190-18194	0.53	_	
119-49	18194-18195	,	_	
119-50	18196-18208	respectively	_	
119-51	18208-18209	)	_	
119-52	18210-18213	and	_	
119-53	18214-18221	putamen	_	
119-54	18222-18223	(	_	
119-55	18223-18224	d	_	
119-56	18224-18225	=	_	
119-57	18225-18229	0.55	_	
119-58	18229-18230	,	_	
119-59	18231-18232	d	_	
119-60	18232-18233	=	_	
119-61	18233-18237	0.52	_	
119-62	18237-18238	,	_	
119-63	18239-18251	respectively	_	
119-64	18251-18252	)	_	
119-65	18252-18253	,	_	
119-66	18254-18256	as	_	
119-67	18257-18261	well	_	
119-68	18262-18264	as	_	
119-69	18265-18278	significantly	_	
119-70	18279-18287	negative	_	
119-71	18288-18291	LIs	_	
119-72	18292-18294	in	_	
119-73	18295-18298	the	_	
119-74	18299-18310	hippocampus	_	
119-75	18311-18312	(	_	
119-76	18312-18313	d	_	
119-77	18313-18314	=	_	
119-78	18314-18315	−	_	
119-79	18315-18319	0.42	_	
119-80	18319-18320	,	_	
119-81	18321-18322	d	_	
119-82	18322-18323	=	_	
119-83	18323-18324	−	_	
119-84	18324-18328	0.41	_	
119-85	18328-18329	,	_	
119-86	18330-18342	respectively	_	
119-87	18342-18343	)	_	
119-88	18344-18347	and	_	
119-89	18348-18356	amygdala	_	
119-90	18357-18358	(	_	
119-91	18358-18359	d	_	
119-92	18359-18360	=	_	
119-93	18360-18361	−	_	
119-94	18361-18365	0.25	_	
119-95	18365-18366	,	_	
119-96	18367-18368	d	_	
119-97	18368-18369	=	_	
119-98	18369-18370	−	_	
119-99	18370-18374	0.36	_	
119-100	18374-18375	,	_	
119-101	18376-18388	respectively	_	
119-102	18388-18389	)	_	
119-103	18389-18390	.	_	

#Text=LIs of these regions in both groups survived a Bonferroni correction with a threshold of P<6.3 × 10−3 (0.05/8), except that of the amygdala in healthy subjects.
120-1	18391-18394	LIs	_	
120-2	18395-18397	of	_	
120-3	18398-18403	these	_	
120-4	18404-18411	regions	_	
120-5	18412-18414	in	_	
120-6	18415-18419	both	_	
120-7	18420-18426	groups	_	
120-8	18427-18435	survived	_	
120-9	18436-18437	a	_	
120-10	18438-18448	Bonferroni	_	
120-11	18449-18459	correction	_	
120-12	18460-18464	with	_	
120-13	18465-18466	a	_	
120-14	18467-18476	threshold	_	
120-15	18477-18479	of	_	
120-16	18480-18481	P	_	
120-17	18481-18482	<	_	
120-18	18482-18485	6.3	_	
120-19	18486-18487	×	_	
120-20	18488-18490	10	_	
120-21	18490-18491	−	_	
120-22	18491-18492	3	_	
120-23	18493-18494	(	_	
120-24	18494-18498	0.05	_	
120-25	18498-18499	/	_	
120-26	18499-18500	8	_	
120-27	18500-18501	)	_	
120-28	18501-18502	,	_	
120-29	18503-18509	except	_	
120-30	18510-18514	that	_	
120-31	18515-18517	of	_	
120-32	18518-18521	the	_	
120-33	18522-18530	amygdala	_	
120-34	18531-18533	in	_	
120-35	18534-18541	healthy	_	
120-36	18542-18550	subjects	_	
120-37	18550-18551	.	_	

#Text=LIs of the nucleus accumbens in both groups were not significantly different from zero (d=−0.08, d=0.00, respectively).
121-1	18552-18555	LIs	_	
121-2	18556-18558	of	_	
121-3	18559-18562	the	_	
121-4	18563-18570	nucleus	_	
121-5	18571-18580	accumbens	_	
121-6	18581-18583	in	_	
121-7	18584-18588	both	_	
121-8	18589-18595	groups	_	
121-9	18596-18600	were	_	
121-10	18601-18604	not	_	
121-11	18605-18618	significantly	_	
121-12	18619-18628	different	_	
121-13	18629-18633	from	_	
121-14	18634-18638	zero	_	
121-15	18639-18640	(	_	
121-16	18640-18641	d	_	
121-17	18641-18642	=	_	
121-18	18642-18643	−	_	
121-19	18643-18647	0.08	_	
121-20	18647-18648	,	_	
121-21	18649-18650	d	_	
121-22	18650-18651	=	_	
121-23	18651-18655	0.00	_	
121-24	18655-18656	,	_	
121-25	18657-18669	respectively	_	
121-26	18669-18670	)	_	
121-27	18670-18671	.	_	

#Text=The LI of the globus pallidus in controls did not differ from zero (d=−0.02, P=0.90), while in patients with schizophrenia it was positive with a trend towards significance (d=0.31, P=1.0 × 10−2).
122-1	18672-18675	The	_	
122-2	18676-18678	LI	_	
122-3	18679-18681	of	_	
122-4	18682-18685	the	_	
122-5	18686-18692	globus	_	
122-6	18693-18701	pallidus	_	
122-7	18702-18704	in	_	
122-8	18705-18713	controls	_	
122-9	18714-18717	did	_	
122-10	18718-18721	not	_	
122-11	18722-18728	differ	_	
122-12	18729-18733	from	_	
122-13	18734-18738	zero	_	
122-14	18739-18740	(	_	
122-15	18740-18741	d	_	
122-16	18741-18742	=	_	
122-17	18742-18743	−	_	
122-18	18743-18747	0.02	_	
122-19	18747-18748	,	_	
122-20	18749-18750	P	_	
122-21	18750-18751	=	_	
122-22	18751-18755	0.90	_	
122-23	18755-18756	)	_	
122-24	18756-18757	,	_	
122-25	18758-18763	while	_	
122-26	18764-18766	in	_	
122-27	18767-18775	patients	_	
122-28	18776-18780	with	_	
122-29	18781-18794	schizophrenia	_	
122-30	18795-18797	it	_	
122-31	18798-18801	was	_	
122-32	18802-18810	positive	_	
122-33	18811-18815	with	_	
122-34	18816-18817	a	_	
122-35	18818-18823	trend	_	
122-36	18824-18831	towards	_	
122-37	18832-18844	significance	_	
122-38	18845-18846	(	_	
122-39	18846-18847	d	_	
122-40	18847-18848	=	_	
122-41	18848-18852	0.31	_	
122-42	18852-18853	,	_	
122-43	18854-18855	P	_	
122-44	18855-18856	=	_	
122-45	18856-18859	1.0	_	
122-46	18860-18861	×	_	
122-47	18862-18864	10	_	
122-48	18864-18865	−	_	
122-49	18865-18866	2	_	
122-50	18866-18867	)	_	
122-51	18867-18868	.	_	

#Text=LIs for each protocol in controls and in patients with schizophrenia are provided in Supplementary Figures 4a–h and 5a–h, respectively.
123-1	18869-18872	LIs	_	
123-2	18873-18876	for	_	
123-3	18877-18881	each	_	
123-4	18882-18890	protocol	_	
123-5	18891-18893	in	_	
123-6	18894-18902	controls	_	
123-7	18903-18906	and	_	
123-8	18907-18909	in	_	
123-9	18910-18918	patients	_	
123-10	18919-18923	with	_	
123-11	18924-18937	schizophrenia	_	
123-12	18938-18941	are	_	
123-13	18942-18950	provided	_	
123-14	18951-18953	in	_	
123-15	18954-18967	Supplementary	_	
123-16	18968-18975	Figures	_	
123-17	18976-18980	4a–h	_	
123-18	18981-18984	and	_	
123-19	18985-18989	5a–h	_	
123-20	18989-18990	,	_	
123-21	18991-19003	respectively	_	
123-22	19003-19004	.	_	

#Text=Group differences in LIs within each protocol were examined (Supplementary Table 9).
124-1	19005-19010	Group	_	
124-2	19011-19022	differences	_	
124-3	19023-19025	in	_	
124-4	19026-19029	LIs	_	
124-5	19030-19036	within	_	
124-6	19037-19041	each	_	
124-7	19042-19050	protocol	_	
124-8	19051-19055	were	_	
124-9	19056-19064	examined	_	
124-10	19065-19066	(	_	
124-11	19066-19079	Supplementary	_	
124-12	19080-19085	Table	_	
124-13	19086-19087	9	_	
124-14	19087-19088	)	_	
124-15	19088-19089	.	_	

#Text=We performed a meta-analysis of group differences in LIs (Supplementary Figure 6 and Supplementary Table 10).
125-1	19090-19092	We	_	
125-2	19093-19102	performed	_	
125-3	19103-19104	a	_	
125-4	19105-19118	meta-analysis	_	
125-5	19119-19121	of	_	
125-6	19122-19127	group	_	
125-7	19128-19139	differences	_	
125-8	19140-19142	in	_	
125-9	19143-19146	LIs	_	
125-10	19147-19148	(	_	
125-11	19148-19161	Supplementary	_	
125-12	19162-19168	Figure	_	
125-13	19169-19170	6	_	
125-14	19171-19174	and	_	
125-15	19175-19188	Supplementary	_	
125-16	19189-19194	Table	_	
125-17	19195-19197	10	_	
125-18	19197-19198	)	_	
125-19	19198-19199	.	_	

#Text=The LI of the globus pallidus in patients with schizophrenia was significantly higher than in the healthy controls (mean difference=0.021, d=0.30, P=2.8 × 10−11).
126-1	19200-19203	The	_	
126-2	19204-19206	LI	_	
126-3	19207-19209	of	_	
126-4	19210-19213	the	_	
126-5	19214-19220	globus	_	
126-6	19221-19229	pallidus	_	
126-7	19230-19232	in	_	
126-8	19233-19241	patients	_	
126-9	19242-19246	with	_	
126-10	19247-19260	schizophrenia	_	
126-11	19261-19264	was	_	
126-12	19265-19278	significantly	_	
126-13	19279-19285	higher	_	
126-14	19286-19290	than	_	
126-15	19291-19293	in	_	
126-16	19294-19297	the	_	
126-17	19298-19305	healthy	_	
126-18	19306-19314	controls	_	
126-19	19315-19316	(	_	
126-20	19316-19320	mean	_	
126-21	19321-19331	difference	_	
126-22	19331-19332	=	_	
126-23	19332-19337	0.021	_	
126-24	19337-19338	,	_	
126-25	19339-19340	d	_	
126-26	19340-19341	=	_	
126-27	19341-19345	0.30	_	
126-28	19345-19346	,	_	
126-29	19347-19348	P	_	
126-30	19348-19349	=	_	
126-31	19349-19352	2.8	_	
126-32	19353-19354	×	_	
126-33	19355-19357	10	_	
126-34	19357-19358	−	_	
126-35	19358-19360	11	_	
126-36	19360-19361	)	_	
126-37	19361-19362	.	_	

#Text=However, LIs of the other regions were not significantly different between groups.
127-1	19363-19370	However	_	
127-2	19370-19371	,	_	
127-3	19372-19375	LIs	_	
127-4	19376-19378	of	_	
127-5	19379-19382	the	_	
127-6	19383-19388	other	_	
127-7	19389-19396	regions	_	
127-8	19397-19401	were	_	
127-9	19402-19405	not	_	
127-10	19406-19419	significantly	_	
127-11	19420-19429	different	_	
127-12	19430-19437	between	_	
127-13	19438-19444	groups	_	
127-14	19444-19445	.	_	

#Text=Group differences in LIs for each protocol are provided in Supplementary Figures 7a–h.
128-1	19446-19451	Group	_	
128-2	19452-19463	differences	_	
128-3	19464-19466	in	_	
128-4	19467-19470	LIs	_	
128-5	19471-19474	for	_	
128-6	19475-19479	each	_	
128-7	19480-19488	protocol	_	
128-8	19489-19492	are	_	
128-9	19493-19501	provided	_	
128-10	19502-19504	in	_	
128-11	19505-19518	Supplementary	_	
128-12	19519-19526	Figures	_	
128-13	19527-19531	7a–h	_	
128-14	19531-19532	.	_	

#Text=According to a power analysis, the estimated sample sizes required for each group to reach a power of 0.80 (P<0.05, one-tailed) across regions ranged from 141 to 1 016 462.
129-1	19533-19542	According	_	
129-2	19543-19545	to	_	
129-3	19546-19547	a	_	
129-4	19548-19553	power	_	
129-5	19554-19562	analysis	_	
129-6	19562-19563	,	_	
129-7	19564-19567	the	_	
129-8	19568-19577	estimated	_	
129-9	19578-19584	sample	_	
129-10	19585-19590	sizes	_	
129-11	19591-19599	required	_	
129-12	19600-19603	for	_	
129-13	19604-19608	each	_	
129-14	19609-19614	group	_	
129-15	19615-19617	to	_	
129-16	19618-19623	reach	_	
129-17	19624-19625	a	_	
129-18	19626-19631	power	_	
129-19	19632-19634	of	_	
129-20	19635-19639	0.80	_	
129-21	19640-19641	(	_	
129-22	19641-19642	P	_	
129-23	19642-19643	<	_	
129-24	19643-19647	0.05	_	
129-25	19647-19648	,	_	
129-26	19649-19659	one-tailed	_	
129-27	19659-19660	)	_	
129-28	19661-19667	across	_	
129-29	19668-19675	regions	_	
129-30	19676-19682	ranged	_	
129-31	19683-19687	from	_	
129-32	19688-19691	141	_	
129-33	19692-19694	to	_	
129-34	19695-19696	1	_	
129-35	19697-19700	016	_	
129-36	19701-19704	462	_	
129-37	19704-19705	.	_	

#Text=As an additional analysis, we performed a meta-analysis of group differences in LIs using FSL (Supplementary Figure 8).
130-1	19706-19708	As	_	
130-2	19709-19711	an	_	
130-3	19712-19722	additional	_	
130-4	19723-19731	analysis	_	
130-5	19731-19732	,	_	
130-6	19733-19735	we	_	
130-7	19736-19745	performed	_	
130-8	19746-19747	a	_	
130-9	19748-19761	meta-analysis	_	
130-10	19762-19764	of	_	
130-11	19765-19770	group	_	
130-12	19771-19782	differences	_	
130-13	19783-19785	in	_	
130-14	19786-19789	LIs	_	
130-15	19790-19795	using	_	
130-16	19796-19799	FSL	_	
130-17	19800-19801	(	_	
130-18	19801-19814	Supplementary	_	
130-19	19815-19821	Figure	_	
130-20	19822-19823	8	_	
130-21	19823-19824	)	_	
130-22	19824-19825	.	_	

#Text=The LI of the globus pallidus in patients with schizophrenia was significantly higher than in the healthy controls (mean difference=0.009, d=0.20, P=1.3 × 10−8).
131-1	19826-19829	The	_	
131-2	19830-19832	LI	_	
131-3	19833-19835	of	_	
131-4	19836-19839	the	_	
131-5	19840-19846	globus	_	
131-6	19847-19855	pallidus	_	
131-7	19856-19858	in	_	
131-8	19859-19867	patients	_	
131-9	19868-19872	with	_	
131-10	19873-19886	schizophrenia	_	
131-11	19887-19890	was	_	
131-12	19891-19904	significantly	_	
131-13	19905-19911	higher	_	
131-14	19912-19916	than	_	
131-15	19917-19919	in	_	
131-16	19920-19923	the	_	
131-17	19924-19931	healthy	_	
131-18	19932-19940	controls	_	
131-19	19941-19942	(	_	
131-20	19942-19946	mean	_	
131-21	19947-19957	difference	_	
131-22	19957-19958	=	_	
131-23	19958-19963	0.009	_	
131-24	19963-19964	,	_	
131-25	19965-19966	d	_	
131-26	19966-19967	=	_	
131-27	19967-19971	0.20	_	
131-28	19971-19972	,	_	
131-29	19973-19974	P	_	
131-30	19974-19975	=	_	
131-31	19975-19978	1.3	_	
131-32	19979-19980	×	_	
131-33	19981-19983	10	_	
131-34	19983-19984	−	_	
131-35	19984-19985	8	_	
131-36	19985-19986	)	_	
131-37	19986-19987	.	_	

#Text=For the other regions, LIs were not significantly different between groups.
132-1	19988-19991	For	_	
132-2	19992-19995	the	_	
132-3	19996-20001	other	_	
132-4	20002-20009	regions	_	
132-5	20009-20010	,	_	
132-6	20011-20014	LIs	_	
132-7	20015-20019	were	_	
132-8	20020-20023	not	_	
132-9	20024-20037	significantly	_	
132-10	20038-20047	different	_	
132-11	20048-20055	between	_	
132-12	20056-20062	groups	_	
132-13	20062-20063	.	_	

#Text=Discussion
#Text=In the current study, we showed smaller-than-normal volumes in the bilateral hippocampi, amygdala, accumbens and ICV, and larger-than-normal volumes in the bilateral caudate, putamen, pallidum and lateral ventricle in patients with schizophrenia.
133-1	20064-20074	Discussion	_	
133-2	20075-20077	In	_	
133-3	20078-20081	the	_	
133-4	20082-20089	current	_	
133-5	20090-20095	study	_	
133-6	20095-20096	,	_	
133-7	20097-20099	we	_	
133-8	20100-20106	showed	_	
133-9	20107-20126	smaller-than-normal	_	
133-10	20127-20134	volumes	_	
133-11	20135-20137	in	_	
133-12	20138-20141	the	_	
133-13	20142-20151	bilateral	_	
133-14	20152-20162	hippocampi	_	
133-15	20162-20163	,	_	
133-16	20164-20172	amygdala	_	
133-17	20172-20173	,	_	
133-18	20174-20183	accumbens	_	
133-19	20184-20187	and	_	
133-20	20188-20191	ICV	_	
133-21	20191-20192	,	_	
133-22	20193-20196	and	_	
133-23	20197-20215	larger-than-normal	_	
133-24	20216-20223	volumes	_	
133-25	20224-20226	in	_	
133-26	20227-20230	the	_	
133-27	20231-20240	bilateral	_	
133-28	20241-20248	caudate	_	
133-29	20248-20249	,	_	
133-30	20250-20257	putamen	_	
133-31	20257-20258	,	_	
133-32	20259-20267	pallidum	_	
133-33	20268-20271	and	_	
133-34	20272-20279	lateral	_	
133-35	20280-20289	ventricle	_	
133-36	20290-20292	in	_	
133-37	20293-20301	patients	_	
133-38	20302-20306	with	_	
133-39	20307-20320	schizophrenia	_	
133-40	20320-20321	.	_	

#Text=Supplementary Table 11 demonstrates sample sizes and results on subcortical volume alterations in schizophrenia both in previous studies and in the current study.
134-1	20322-20335	Supplementary	_	
134-2	20336-20341	Table	_	
134-3	20342-20344	11	_	
134-4	20345-20357	demonstrates	_	
134-5	20358-20364	sample	_	
134-6	20365-20370	sizes	_	
134-7	20371-20374	and	_	
134-8	20375-20382	results	_	
134-9	20383-20385	on	_	
134-10	20386-20397	subcortical	_	
134-11	20398-20404	volume	_	
134-12	20405-20416	alterations	_	
134-13	20417-20419	in	_	
134-14	20420-20433	schizophrenia	_	
134-15	20434-20438	both	_	
134-16	20439-20441	in	_	
134-17	20442-20450	previous	_	
134-18	20451-20458	studies	_	
134-19	20459-20462	and	_	
134-20	20463-20465	in	_	
134-21	20466-20469	the	_	
134-22	20470-20477	current	_	
134-23	20478-20483	study	_	
134-24	20483-20484	.	_	

#Text=We successfully replicated the previous study from the ENIGMA consortium and another large-scale meta-analytic study conducted by Haijma et al., both of which showed smaller-than-normal volumes in the hippocampus, amygdala, thalamus and nucleus accumbens and ICV, as well as larger-than-normal volumes in the globus pallidus and lateral ventricles.
135-1	20485-20487	We	_	
135-2	20488-20500	successfully	_	
135-3	20501-20511	replicated	_	
135-4	20512-20515	the	_	
135-5	20516-20524	previous	_	
135-6	20525-20530	study	_	
135-7	20531-20535	from	_	
135-8	20536-20539	the	_	
135-9	20540-20546	ENIGMA	_	
135-10	20547-20557	consortium	_	
135-11	20558-20561	and	_	
135-12	20562-20569	another	_	
135-13	20570-20581	large-scale	_	
135-14	20582-20595	meta-analytic	_	
135-15	20596-20601	study	_	
135-16	20602-20611	conducted	_	
135-17	20612-20614	by	_	
135-18	20615-20621	Haijma	_	
135-19	20622-20624	et	_	
135-20	20625-20627	al	_	
135-21	20627-20628	.	_	
135-22	20628-20629	,	_	
135-23	20630-20634	both	_	
135-24	20635-20637	of	_	
135-25	20638-20643	which	_	
135-26	20644-20650	showed	_	
135-27	20651-20670	smaller-than-normal	_	
135-28	20671-20678	volumes	_	
135-29	20679-20681	in	_	
135-30	20682-20685	the	_	
135-31	20686-20697	hippocampus	_	
135-32	20697-20698	,	_	
135-33	20699-20707	amygdala	_	
135-34	20707-20708	,	_	
135-35	20709-20717	thalamus	_	
135-36	20718-20721	and	_	
135-37	20722-20729	nucleus	_	
135-38	20730-20739	accumbens	_	
135-39	20740-20743	and	_	
135-40	20744-20747	ICV	_	
135-41	20747-20748	,	_	
135-42	20749-20751	as	_	
135-43	20752-20756	well	_	
135-44	20757-20759	as	_	
135-45	20760-20778	larger-than-normal	_	
135-46	20779-20786	volumes	_	
135-47	20787-20789	in	_	
135-48	20790-20793	the	_	
135-49	20794-20800	globus	_	
135-50	20801-20809	pallidus	_	
135-51	20810-20813	and	_	
135-52	20814-20821	lateral	_	
135-53	20822-20832	ventricles	_	
135-54	20832-20833	.	_	

#Text=In addition, as demonstrated in Figure 2, the rank order of effect sizes for group differences in the current study was similar to that in the van Erp et al. study.
136-1	20834-20836	In	_	
136-2	20837-20845	addition	_	
136-3	20845-20846	,	_	
136-4	20847-20849	as	_	
136-5	20850-20862	demonstrated	_	
136-6	20863-20865	in	_	
136-7	20866-20872	Figure	_	
136-8	20873-20874	2	_	
136-9	20874-20875	,	_	
136-10	20876-20879	the	_	
136-11	20880-20884	rank	_	
136-12	20885-20890	order	_	
136-13	20891-20893	of	_	
136-14	20894-20900	effect	_	
136-15	20901-20906	sizes	_	
136-16	20907-20910	for	_	
136-17	20911-20916	group	_	
136-18	20917-20928	differences	_	
136-19	20929-20931	in	_	
136-20	20932-20935	the	_	
136-21	20936-20943	current	_	
136-22	20944-20949	study	_	
136-23	20950-20953	was	_	
136-24	20954-20961	similar	_	
136-25	20962-20964	to	_	
136-26	20965-20969	that	_	
136-27	20970-20972	in	_	
136-28	20973-20976	the	_	
136-29	20977-20980	van	_	
136-30	20981-20984	Erp	_	
136-31	20985-20987	et	_	
136-32	20988-20990	al	_	
136-33	20990-20991	.	_	
136-34	20992-20997	study	_	
136-35	20997-20998	.	_	

#Text=Our results revealing larger-than-normal volumes of the caudate and putamen in patients with schizophrenia were not in line with the two previous studies.
137-1	20999-21002	Our	_	
137-2	21003-21010	results	_	
137-3	21011-21020	revealing	_	
137-4	21021-21039	larger-than-normal	_	
137-5	21040-21047	volumes	_	
137-6	21048-21050	of	_	
137-7	21051-21054	the	_	
137-8	21055-21062	caudate	_	
137-9	21063-21066	and	_	
137-10	21067-21074	putamen	_	
137-11	21075-21077	in	_	
137-12	21078-21086	patients	_	
137-13	21087-21091	with	_	
137-14	21092-21105	schizophrenia	_	
137-15	21106-21110	were	_	
137-16	21111-21114	not	_	
137-17	21115-21117	in	_	
137-18	21118-21122	line	_	
137-19	21123-21127	with	_	
137-20	21128-21131	the	_	
137-21	21132-21135	two	_	
137-22	21136-21144	previous	_	
137-23	21145-21152	studies	_	
137-24	21152-21153	.	_	

#Text=This discrepancy might partly be because the samples included in the current study were relatively ethnically homogeneous, namely, most of the participants were Japanese people.
138-1	21154-21158	This	_	
138-2	21159-21170	discrepancy	_	
138-3	21171-21176	might	_	
138-4	21177-21183	partly	_	
138-5	21184-21186	be	_	
138-6	21187-21194	because	_	
138-7	21195-21198	the	_	
138-8	21199-21206	samples	_	
138-9	21207-21215	included	_	
138-10	21216-21218	in	_	
138-11	21219-21222	the	_	
138-12	21223-21230	current	_	
138-13	21231-21236	study	_	
138-14	21237-21241	were	_	
138-15	21242-21252	relatively	_	
138-16	21253-21263	ethnically	_	
138-17	21264-21275	homogeneous	_	
138-18	21275-21276	,	_	
138-19	21277-21283	namely	_	
138-20	21283-21284	,	_	
138-21	21285-21289	most	_	
138-22	21290-21292	of	_	
138-23	21293-21296	the	_	
138-24	21297-21309	participants	_	
138-25	21310-21314	were	_	
138-26	21315-21323	Japanese	_	
138-27	21324-21330	people	_	
138-28	21330-21331	.	_	

#Text=The discrepancy might also be owing to the use of a single pipeline for preparation before the statistical analysis of the MRI data, which included quality control and preprocessing with FreeSurfer.
139-1	21332-21335	The	_	
139-2	21336-21347	discrepancy	_	
139-3	21348-21353	might	_	
139-4	21354-21358	also	_	
139-5	21359-21361	be	_	
139-6	21362-21367	owing	_	
139-7	21368-21370	to	_	
139-8	21371-21374	the	_	
139-9	21375-21378	use	_	
139-10	21379-21381	of	_	
139-11	21382-21383	a	_	
139-12	21384-21390	single	_	
139-13	21391-21399	pipeline	_	
139-14	21400-21403	for	_	
139-15	21404-21415	preparation	_	
139-16	21416-21422	before	_	
139-17	21423-21426	the	_	
139-18	21427-21438	statistical	_	
139-19	21439-21447	analysis	_	
139-20	21448-21450	of	_	
139-21	21451-21454	the	_	
139-22	21455-21458	MRI	_	
139-23	21459-21463	data	_	
139-24	21463-21464	,	_	
139-25	21465-21470	which	_	
139-26	21471-21479	included	_	
139-27	21480-21487	quality	_	
139-28	21488-21495	control	_	
139-29	21496-21499	and	_	
139-30	21500-21513	preprocessing	_	
139-31	21514-21518	with	_	
139-32	21519-21529	FreeSurfer	_	
139-33	21529-21530	.	_	

#Text=In contrast to the two above-mentioned studies, our results of enlarged caudate and putamen volumes in patients with schizophrenia were consistent with a number of previous studies.
140-1	21531-21533	In	_	
140-2	21534-21542	contrast	_	
140-3	21543-21545	to	_	
140-4	21546-21549	the	_	
140-5	21550-21553	two	_	
140-6	21554-21569	above-mentioned	_	
140-7	21570-21577	studies	_	
140-8	21577-21578	,	_	
140-9	21579-21582	our	_	
140-10	21583-21590	results	_	
140-11	21591-21593	of	_	
140-12	21594-21602	enlarged	_	
140-13	21603-21610	caudate	_	
140-14	21611-21614	and	_	
140-15	21615-21622	putamen	_	
140-16	21623-21630	volumes	_	
140-17	21631-21633	in	_	
140-18	21634-21642	patients	_	
140-19	21643-21647	with	_	
140-20	21648-21661	schizophrenia	_	
140-21	21662-21666	were	_	
140-22	21667-21677	consistent	_	
140-23	21678-21682	with	_	
140-24	21683-21684	a	_	
140-25	21685-21691	number	_	
140-26	21692-21694	of	_	
140-27	21695-21703	previous	_	
140-28	21704-21711	studies	_	
140-29	21711-21712	.	_	

#Text=For example, Hokama et al. reported enlarged volumes of the globus pallidus, putamen and caudate.
141-1	21713-21716	For	_	
141-2	21717-21724	example	_	
141-3	21724-21725	,	_	
141-4	21726-21732	Hokama	_	
141-5	21733-21735	et	_	
141-6	21736-21738	al	_	
141-7	21738-21739	.	_	
141-8	21740-21748	reported	_	
141-9	21749-21757	enlarged	_	
141-10	21758-21765	volumes	_	
141-11	21766-21768	of	_	
141-12	21769-21772	the	_	
141-13	21773-21779	globus	_	
141-14	21780-21788	pallidus	_	
141-15	21788-21789	,	_	
141-16	21790-21797	putamen	_	
141-17	21798-21801	and	_	
141-18	21802-21809	caudate	_	
141-19	21809-21810	.	_	

#Text=Moreover, Glahn et al. reported enlarged volumes in the bilateral putamen and right head of the caudate.
142-1	21811-21819	Moreover	_	
142-2	21819-21820	,	_	
142-3	21821-21826	Glahn	_	
142-4	21827-21829	et	_	
142-5	21830-21832	al	_	
142-6	21832-21833	.	_	
142-7	21834-21842	reported	_	
142-8	21843-21851	enlarged	_	
142-9	21852-21859	volumes	_	
142-10	21860-21862	in	_	
142-11	21863-21866	the	_	
142-12	21867-21876	bilateral	_	
142-13	21877-21884	putamen	_	
142-14	21885-21888	and	_	
142-15	21889-21894	right	_	
142-16	21895-21899	head	_	
142-17	21900-21902	of	_	
142-18	21903-21906	the	_	
142-19	21907-21914	caudate	_	
142-20	21914-21915	.	_	

#Text=Another study reported an association between caudate volume and working memory, as well as putamen volume and verbal learning, vigilance and executive function in schizophrenia.
143-1	21916-21923	Another	_	
143-2	21924-21929	study	_	
143-3	21930-21938	reported	_	
143-4	21939-21941	an	_	
143-5	21942-21953	association	_	
143-6	21954-21961	between	_	
143-7	21962-21969	caudate	_	
143-8	21970-21976	volume	_	
143-9	21977-21980	and	_	
143-10	21981-21988	working	_	
143-11	21989-21995	memory	_	
143-12	21995-21996	,	_	
143-13	21997-21999	as	_	
143-14	22000-22004	well	_	
143-15	22005-22007	as	_	
143-16	22008-22015	putamen	_	
143-17	22016-22022	volume	_	
143-18	22023-22026	and	_	
143-19	22027-22033	verbal	_	
143-20	22034-22042	learning	_	
143-21	22042-22043	,	_	
143-22	22044-22053	vigilance	_	
143-23	22054-22057	and	_	
143-24	22058-22067	executive	_	
143-25	22068-22076	function	_	
143-26	22077-22079	in	_	
143-27	22080-22093	schizophrenia	_	
143-28	22093-22094	.	_	

#Text=Mamah et al. reported increased volume in the bilateral caudate and putamen and a positive correlation between attention/vigilance performance with caudate and putamen volume in schizophrenia.
144-1	22095-22100	Mamah	_	
144-2	22101-22103	et	_	
144-3	22104-22106	al	_	
144-4	22106-22107	.	_	
144-5	22108-22116	reported	_	
144-6	22117-22126	increased	_	
144-7	22127-22133	volume	_	
144-8	22134-22136	in	_	
144-9	22137-22140	the	_	
144-10	22141-22150	bilateral	_	
144-11	22151-22158	caudate	_	
144-12	22159-22162	and	_	
144-13	22163-22170	putamen	_	
144-14	22171-22174	and	_	
144-15	22175-22176	a	_	
144-16	22177-22185	positive	_	
144-17	22186-22197	correlation	_	
144-18	22198-22205	between	_	
144-19	22206-22215	attention	_	
144-20	22215-22216	/	_	
144-21	22216-22225	vigilance	_	
144-22	22226-22237	performance	_	
144-23	22238-22242	with	_	
144-24	22243-22250	caudate	_	
144-25	22251-22254	and	_	
144-26	22255-22262	putamen	_	
144-27	22263-22269	volume	_	
144-28	22270-22272	in	_	
144-29	22273-22286	schizophrenia	_	
144-30	22286-22287	.	_	

#Text=Finally, a review by Brandt and Bonelli demonstrated a decreased caudate volume in first-episode schizophrenia and increased caudate and putamen volume in chronic schizophrenia.
145-1	22288-22295	Finally	_	
145-2	22295-22296	,	_	
145-3	22297-22298	a	_	
145-4	22299-22305	review	_	
145-5	22306-22308	by	_	
145-6	22309-22315	Brandt	_	
145-7	22316-22319	and	_	
145-8	22320-22327	Bonelli	_	
145-9	22328-22340	demonstrated	_	
145-10	22341-22342	a	_	
145-11	22343-22352	decreased	_	
145-12	22353-22360	caudate	_	
145-13	22361-22367	volume	_	
145-14	22368-22370	in	_	
145-15	22371-22384	first-episode	_	
145-16	22385-22398	schizophrenia	_	
145-17	22399-22402	and	_	
145-18	22403-22412	increased	_	
145-19	22413-22420	caudate	_	
145-20	22421-22424	and	_	
145-21	22425-22432	putamen	_	
145-22	22433-22439	volume	_	
145-23	22440-22442	in	_	
145-24	22443-22450	chronic	_	
145-25	22451-22464	schizophrenia	_	
145-26	22464-22465	.	_	

#Text=Further research is needed to elucidate volumetric alterations of caudate and putamen in schizophrenia.
146-1	22466-22473	Further	_	
146-2	22474-22482	research	_	
146-3	22483-22485	is	_	
146-4	22486-22492	needed	_	
146-5	22493-22495	to	_	
146-6	22496-22505	elucidate	_	
146-7	22506-22516	volumetric	_	
146-8	22517-22528	alterations	_	
146-9	22529-22531	of	_	
146-10	22532-22539	caudate	_	
146-11	22540-22543	and	_	
146-12	22544-22551	putamen	_	
146-13	22552-22554	in	_	
146-14	22555-22568	schizophrenia	_	
146-15	22568-22569	.	_	

#Text=The current study revealed asymmetry in several subcortical structures.
147-1	22570-22573	The	_	
147-2	22574-22581	current	_	
147-3	22582-22587	study	_	
147-4	22588-22596	revealed	_	
147-5	22597-22606	asymmetry	_	
147-6	22607-22609	in	_	
147-7	22610-22617	several	_	
147-8	22618-22629	subcortical	_	
147-9	22630-22640	structures	_	
147-10	22640-22641	.	_	

#Text=First, healthy controls demonstrated leftward asymmetry in the lateral ventricles, thalamus, caudate and putamen, while rightward asymmetry was found in the hippocampus and amygdala.
148-1	22642-22647	First	_	
148-2	22647-22648	,	_	
148-3	22649-22656	healthy	_	
148-4	22657-22665	controls	_	
148-5	22666-22678	demonstrated	_	
148-6	22679-22687	leftward	_	
148-7	22688-22697	asymmetry	_	
148-8	22698-22700	in	_	
148-9	22701-22704	the	_	
148-10	22705-22712	lateral	_	
148-11	22713-22723	ventricles	_	
148-12	22723-22724	,	_	
148-13	22725-22733	thalamus	_	
148-14	22733-22734	,	_	
148-15	22735-22742	caudate	_	
148-16	22743-22746	and	_	
148-17	22747-22754	putamen	_	
148-18	22754-22755	,	_	
148-19	22756-22761	while	_	
148-20	22762-22771	rightward	_	
148-21	22772-22781	asymmetry	_	
148-22	22782-22785	was	_	
148-23	22786-22791	found	_	
148-24	22792-22794	in	_	
148-25	22795-22798	the	_	
148-26	22799-22810	hippocampus	_	
148-27	22811-22814	and	_	
148-28	22815-22823	amygdala	_	
148-29	22823-22824	.	_	

#Text=For hippocampus and amygdala volumes, our results are consistent with previous studies, one of which was a meta-analytic review.
149-1	22825-22828	For	_	
149-2	22829-22840	hippocampus	_	
149-3	22841-22844	and	_	
149-4	22845-22853	amygdala	_	
149-5	22854-22861	volumes	_	
149-6	22861-22862	,	_	
149-7	22863-22866	our	_	
149-8	22867-22874	results	_	
149-9	22875-22878	are	_	
149-10	22879-22889	consistent	_	
149-11	22890-22894	with	_	
149-12	22895-22903	previous	_	
149-13	22904-22911	studies	_	
149-14	22911-22912	,	_	
149-15	22913-22916	one	_	
149-16	22917-22919	of	_	
149-17	22920-22925	which	_	
149-18	22926-22929	was	_	
149-19	22930-22931	a	_	
149-20	22932-22945	meta-analytic	_	
149-21	22946-22952	review	_	
149-22	22952-22953	.	_	

#Text=Although our results are discordant with those of some previous studies on volumetric lateralization for the thalamus, caudate and putamen, the current study is in accordance with other previous reports on volumetric lateralization of the lateral ventricle, putamen, globus pallidus and nucleus accumbens.
150-1	22954-22962	Although	_	
150-2	22963-22966	our	_	
150-3	22967-22974	results	_	
150-4	22975-22978	are	_	
150-5	22979-22989	discordant	_	
150-6	22990-22994	with	_	
150-7	22995-23000	those	_	
150-8	23001-23003	of	_	
150-9	23004-23008	some	_	
150-10	23009-23017	previous	_	
150-11	23018-23025	studies	_	
150-12	23026-23028	on	_	
150-13	23029-23039	volumetric	_	
150-14	23040-23054	lateralization	_	
150-15	23055-23058	for	_	
150-16	23059-23062	the	_	
150-17	23063-23071	thalamus	_	
150-18	23071-23072	,	_	
150-19	23073-23080	caudate	_	
150-20	23081-23084	and	_	
150-21	23085-23092	putamen	_	
150-22	23092-23093	,	_	
150-23	23094-23097	the	_	
150-24	23098-23105	current	_	
150-25	23106-23111	study	_	
150-26	23112-23114	is	_	
150-27	23115-23117	in	_	
150-28	23118-23128	accordance	_	
150-29	23129-23133	with	_	
150-30	23134-23139	other	_	
150-31	23140-23148	previous	_	
150-32	23149-23156	reports	_	
150-33	23157-23159	on	_	
150-34	23160-23170	volumetric	_	
150-35	23171-23185	lateralization	_	
150-36	23186-23188	of	_	
150-37	23189-23192	the	_	
150-38	23193-23200	lateral	_	
150-39	23201-23210	ventricle	_	
150-40	23210-23211	,	_	
150-41	23212-23219	putamen	_	
150-42	23219-23220	,	_	
150-43	23221-23227	globus	_	
150-44	23228-23236	pallidus	_	
150-45	23237-23240	and	_	
150-46	23241-23248	nucleus	_	
150-47	23249-23258	accumbens	_	
150-48	23258-23259	.	_	

#Text=Except for Pedraza et al., these previous studies had at most 150 participants, and may have been driven by sampling bias.
151-1	23260-23266	Except	_	
151-2	23267-23270	for	_	
151-3	23271-23278	Pedraza	_	
151-4	23279-23281	et	_	
151-5	23282-23284	al	_	
151-6	23284-23285	.	_	
151-7	23285-23286	,	_	
151-8	23287-23292	these	_	
151-9	23293-23301	previous	_	
151-10	23302-23309	studies	_	
151-11	23310-23313	had	_	
151-12	23314-23316	at	_	
151-13	23317-23321	most	_	
151-14	23322-23325	150	_	
151-15	23326-23338	participants	_	
151-16	23338-23339	,	_	
151-17	23340-23343	and	_	
151-18	23344-23347	may	_	
151-19	23348-23352	have	_	
151-20	23353-23357	been	_	
151-21	23358-23364	driven	_	
151-22	23365-23367	by	_	
151-23	23368-23376	sampling	_	
151-24	23377-23381	bias	_	
151-25	23381-23382	.	_	

#Text=Further, scanner differences (for example, vendor, model and magnetic field strength) and image processing biases may have also possibly influenced findings across the studies.
152-1	23383-23390	Further	_	
152-2	23390-23391	,	_	
152-3	23392-23399	scanner	_	
152-4	23400-23411	differences	_	
152-5	23412-23413	(	_	
152-6	23413-23416	for	_	
152-7	23417-23424	example	_	
152-8	23424-23425	,	_	
152-9	23426-23432	vendor	_	
152-10	23432-23433	,	_	
152-11	23434-23439	model	_	
152-12	23440-23443	and	_	
152-13	23444-23452	magnetic	_	
152-14	23453-23458	field	_	
152-15	23459-23467	strength	_	
152-16	23467-23468	)	_	
152-17	23469-23472	and	_	
152-18	23473-23478	image	_	
152-19	23479-23489	processing	_	
152-20	23490-23496	biases	_	
152-21	23497-23500	may	_	
152-22	23501-23505	have	_	
152-23	23506-23510	also	_	
152-24	23511-23519	possibly	_	
152-25	23520-23530	influenced	_	
152-26	23531-23539	findings	_	
152-27	23540-23546	across	_	
152-28	23547-23550	the	_	
152-29	23551-23558	studies	_	
152-30	23558-23559	.	_	

#Text=Meta-analytic methods, such as the ones used in this study, could overcome such drawbacks.
153-1	23560-23573	Meta-analytic	_	
153-2	23574-23581	methods	_	
153-3	23581-23582	,	_	
153-4	23583-23587	such	_	
153-5	23588-23590	as	_	
153-6	23591-23594	the	_	
153-7	23595-23599	ones	_	
153-8	23600-23604	used	_	
153-9	23605-23607	in	_	
153-10	23608-23612	this	_	
153-11	23613-23618	study	_	
153-12	23618-23619	,	_	
153-13	23620-23625	could	_	
153-14	23626-23634	overcome	_	
153-15	23635-23639	such	_	
153-16	23640-23649	drawbacks	_	
153-17	23649-23650	.	_	

#Text=Second, with the exception of the globus pallidus, volumetric asymmetries in the subcortical regions were not significantly different between controls and patients with schizophrenia.
154-1	23651-23657	Second	_	
154-2	23657-23658	,	_	
154-3	23659-23663	with	_	
154-4	23664-23667	the	_	
154-5	23668-23677	exception	_	
154-6	23678-23680	of	_	
154-7	23681-23684	the	_	
154-8	23685-23691	globus	_	
154-9	23692-23700	pallidus	_	
154-10	23700-23701	,	_	
154-11	23702-23712	volumetric	_	
154-12	23713-23724	asymmetries	_	
154-13	23725-23727	in	_	
154-14	23728-23731	the	_	
154-15	23732-23743	subcortical	_	
154-16	23744-23751	regions	_	
154-17	23752-23756	were	_	
154-18	23757-23760	not	_	
154-19	23761-23774	significantly	_	
154-20	23775-23784	different	_	
154-21	23785-23792	between	_	
154-22	23793-23801	controls	_	
154-23	23802-23805	and	_	
154-24	23806-23814	patients	_	
154-25	23815-23819	with	_	
154-26	23820-23833	schizophrenia	_	
154-27	23833-23834	.	_	

#Text=The current study is consistent with a prior study demonstrating similar patterns of rightward hippocampal asymmetry in both schizophrenia and control groups.
155-1	23835-23838	The	_	
155-2	23839-23846	current	_	
155-3	23847-23852	study	_	
155-4	23853-23855	is	_	
155-5	23856-23866	consistent	_	
155-6	23867-23871	with	_	
155-7	23872-23873	a	_	
155-8	23874-23879	prior	_	
155-9	23880-23885	study	_	
155-10	23886-23899	demonstrating	_	
155-11	23900-23907	similar	_	
155-12	23908-23916	patterns	_	
155-13	23917-23919	of	_	
155-14	23920-23929	rightward	_	
155-15	23930-23941	hippocampal	_	
155-16	23942-23951	asymmetry	_	
155-17	23952-23954	in	_	
155-18	23955-23959	both	_	
155-19	23960-23973	schizophrenia	_	
155-20	23974-23977	and	_	
155-21	23978-23985	control	_	
155-22	23986-23992	groups	_	
155-23	23992-23993	.	_	

#Text=However, it should be noted that our results are discordant with some previous reports.
156-1	23994-24001	However	_	
156-2	24001-24002	,	_	
156-3	24003-24005	it	_	
156-4	24006-24012	should	_	
156-5	24013-24015	be	_	
156-6	24016-24021	noted	_	
156-7	24022-24026	that	_	
156-8	24027-24030	our	_	
156-9	24031-24038	results	_	
156-10	24039-24042	are	_	
156-11	24043-24053	discordant	_	
156-12	24054-24058	with	_	
156-13	24059-24063	some	_	
156-14	24064-24072	previous	_	
156-15	24073-24080	reports	_	
156-16	24080-24081	.	_	

#Text=Csernansky et al. showed increased rightward asymmetry of the thalamus in patients with schizophrenia compared with healthy controls.
157-1	24082-24092	Csernansky	_	
157-2	24093-24095	et	_	
157-3	24096-24098	al	_	
157-4	24098-24099	.	_	
157-5	24100-24106	showed	_	
157-6	24107-24116	increased	_	
157-7	24117-24126	rightward	_	
157-8	24127-24136	asymmetry	_	
157-9	24137-24139	of	_	
157-10	24140-24143	the	_	
157-11	24144-24152	thalamus	_	
157-12	24153-24155	in	_	
157-13	24156-24164	patients	_	
157-14	24165-24169	with	_	
157-15	24170-24183	schizophrenia	_	
157-16	24184-24192	compared	_	
157-17	24193-24197	with	_	
157-18	24198-24205	healthy	_	
157-19	24206-24214	controls	_	
157-20	24214-24215	.	_	

#Text=Moreover, Qiu et al. revealed rightward amygdala asymmetry in controls and a reduction of this asymmetry in patients with schizophrenia.
158-1	24216-24224	Moreover	_	
158-2	24224-24225	,	_	
158-3	24226-24229	Qiu	_	
158-4	24230-24232	et	_	
158-5	24233-24235	al	_	
158-6	24235-24236	.	_	
158-7	24237-24245	revealed	_	
158-8	24246-24255	rightward	_	
158-9	24256-24264	amygdala	_	
158-10	24265-24274	asymmetry	_	
158-11	24275-24277	in	_	
158-12	24278-24286	controls	_	
158-13	24287-24290	and	_	
158-14	24291-24292	a	_	
158-15	24293-24302	reduction	_	
158-16	24303-24305	of	_	
158-17	24306-24310	this	_	
158-18	24311-24320	asymmetry	_	
158-19	24321-24323	in	_	
158-20	24324-24332	patients	_	
158-21	24333-24337	with	_	
158-22	24338-24351	schizophrenia	_	
158-23	24351-24352	.	_	

#Text=We assume that the differences in results across studies can be ascribed to scanner differences, imaging processing biases, different sample sizes and various ethnicities.
159-1	24353-24355	We	_	
159-2	24356-24362	assume	_	
159-3	24363-24367	that	_	
159-4	24368-24371	the	_	
159-5	24372-24383	differences	_	
159-6	24384-24386	in	_	
159-7	24387-24394	results	_	
159-8	24395-24401	across	_	
159-9	24402-24409	studies	_	
159-10	24410-24413	can	_	
159-11	24414-24416	be	_	
159-12	24417-24425	ascribed	_	
159-13	24426-24428	to	_	
159-14	24429-24436	scanner	_	
159-15	24437-24448	differences	_	
159-16	24448-24449	,	_	
159-17	24450-24457	imaging	_	
159-18	24458-24468	processing	_	
159-19	24469-24475	biases	_	
159-20	24475-24476	,	_	
159-21	24477-24486	different	_	
159-22	24487-24493	sample	_	
159-23	24494-24499	sizes	_	
159-24	24500-24503	and	_	
159-25	24504-24511	various	_	
159-26	24512-24523	ethnicities	_	
159-27	24523-24524	.	_	

#Text=Collectively, to our knowledge, our results are the first to comprehensively characterize laterality of brain subcortical regional volumes in schizophrenia.
160-1	24525-24537	Collectively	_	
160-2	24537-24538	,	_	
160-3	24539-24541	to	_	
160-4	24542-24545	our	_	
160-5	24546-24555	knowledge	_	
160-6	24555-24556	,	_	
160-7	24557-24560	our	_	
160-8	24561-24568	results	_	
160-9	24569-24572	are	_	
160-10	24573-24576	the	_	
160-11	24577-24582	first	_	
160-12	24583-24585	to	_	
160-13	24586-24601	comprehensively	_	
160-14	24602-24614	characterize	_	
160-15	24615-24625	laterality	_	
160-16	24626-24628	of	_	
160-17	24629-24634	brain	_	
160-18	24635-24646	subcortical	_	
160-19	24647-24655	regional	_	
160-20	24656-24663	volumes	_	
160-21	24664-24666	in	_	
160-22	24667-24680	schizophrenia	_	
160-23	24680-24681	.	_	

#Text=Third, we revealed significant alterations of hemispheric asymmetry for globus pallidus volume in patients with schizophrenia when compared with controls.
161-1	24682-24687	Third	_	
161-2	24687-24688	,	_	
161-3	24689-24691	we	_	
161-4	24692-24700	revealed	_	
161-5	24701-24712	significant	_	
161-6	24713-24724	alterations	_	
161-7	24725-24727	of	_	
161-8	24728-24739	hemispheric	_	
161-9	24740-24749	asymmetry	_	
161-10	24750-24753	for	_	
161-11	24754-24760	globus	_	
161-12	24761-24769	pallidus	_	
161-13	24770-24776	volume	_	
161-14	24777-24779	in	_	
161-15	24780-24788	patients	_	
161-16	24789-24793	with	_	
161-17	24794-24807	schizophrenia	_	
161-18	24808-24812	when	_	
161-19	24813-24821	compared	_	
161-20	24822-24826	with	_	
161-21	24827-24835	controls	_	
161-22	24835-24836	.	_	

#Text=For this region, healthy subjects showed no asymmetry, while patients with schizophrenia demonstrated leftward asymmetry.
162-1	24837-24840	For	_	
162-2	24841-24845	this	_	
162-3	24846-24852	region	_	
162-4	24852-24853	,	_	
162-5	24854-24861	healthy	_	
162-6	24862-24870	subjects	_	
162-7	24871-24877	showed	_	
162-8	24878-24880	no	_	
162-9	24881-24890	asymmetry	_	
162-10	24890-24891	,	_	
162-11	24892-24897	while	_	
162-12	24898-24906	patients	_	
162-13	24907-24911	with	_	
162-14	24912-24925	schizophrenia	_	
162-15	24926-24938	demonstrated	_	
162-16	24939-24947	leftward	_	
162-17	24948-24957	asymmetry	_	
162-18	24957-24958	.	_	

#Text=Few previous studies have addressed globus pallidus volume laterality or made a direct comparison of left- and right-side volumes, although, contradictory to our results, some previous studies have reported enlarged globus pallidus volumes only on the right side in schizophrenia. van Erp et al. demonstrated a bilaterally increased volume of the globus pallidus in schizophrenia with similar effect sizes for both left and right regions, while not investigating the volume lateralization of this region.
163-1	24959-24962	Few	_	
163-2	24963-24971	previous	_	
163-3	24972-24979	studies	_	
163-4	24980-24984	have	_	
163-5	24985-24994	addressed	_	
163-6	24995-25001	globus	_	
163-7	25002-25010	pallidus	_	
163-8	25011-25017	volume	_	
163-9	25018-25028	laterality	_	
163-10	25029-25031	or	_	
163-11	25032-25036	made	_	
163-12	25037-25038	a	_	
163-13	25039-25045	direct	_	
163-14	25046-25056	comparison	_	
163-15	25057-25059	of	_	
163-16	25060-25064	left	_	
163-17	25064-25065	-	_	
163-18	25066-25069	and	_	
163-19	25070-25080	right-side	_	
163-20	25081-25088	volumes	_	
163-21	25088-25089	,	_	
163-22	25090-25098	although	_	
163-23	25098-25099	,	_	
163-24	25100-25113	contradictory	_	
163-25	25114-25116	to	_	
163-26	25117-25120	our	_	
163-27	25121-25128	results	_	
163-28	25128-25129	,	_	
163-29	25130-25134	some	_	
163-30	25135-25143	previous	_	
163-31	25144-25151	studies	_	
163-32	25152-25156	have	_	
163-33	25157-25165	reported	_	
163-34	25166-25174	enlarged	_	
163-35	25175-25181	globus	_	
163-36	25182-25190	pallidus	_	
163-37	25191-25198	volumes	_	
163-38	25199-25203	only	_	
163-39	25204-25206	on	_	
163-40	25207-25210	the	_	
163-41	25211-25216	right	_	
163-42	25217-25221	side	_	
163-43	25222-25224	in	_	
163-44	25225-25238	schizophrenia	_	
163-45	25238-25239	.	_	
163-46	25240-25243	van	_	
163-47	25244-25247	Erp	_	
163-48	25248-25250	et	_	
163-49	25251-25253	al	_	
163-50	25253-25254	.	_	
163-51	25255-25267	demonstrated	_	
163-52	25268-25269	a	_	
163-53	25270-25281	bilaterally	_	
163-54	25282-25291	increased	_	
163-55	25292-25298	volume	_	
163-56	25299-25301	of	_	
163-57	25302-25305	the	_	
163-58	25306-25312	globus	_	
163-59	25313-25321	pallidus	_	
163-60	25322-25324	in	_	
163-61	25325-25338	schizophrenia	_	
163-62	25339-25343	with	_	
163-63	25344-25351	similar	_	
163-64	25352-25358	effect	_	
163-65	25359-25364	sizes	_	
163-66	25365-25368	for	_	
163-67	25369-25373	both	_	
163-68	25374-25378	left	_	
163-69	25379-25382	and	_	
163-70	25383-25388	right	_	
163-71	25389-25396	regions	_	
163-72	25396-25397	,	_	
163-73	25398-25403	while	_	
163-74	25404-25407	not	_	
163-75	25408-25421	investigating	_	
163-76	25422-25425	the	_	
163-77	25426-25432	volume	_	
163-78	25433-25447	lateralization	_	
163-79	25448-25450	of	_	
163-80	25451-25455	this	_	
163-81	25456-25462	region	_	
163-82	25462-25463	.	_	

#Text=We presume no lateralization differences between groups in their data set.
164-1	25464-25466	We	_	
164-2	25467-25474	presume	_	
164-3	25475-25477	no	_	
164-4	25478-25492	lateralization	_	
164-5	25493-25504	differences	_	
164-6	25505-25512	between	_	
164-7	25513-25519	groups	_	
164-8	25520-25522	in	_	
164-9	25523-25528	their	_	
164-10	25529-25533	data	_	
164-11	25534-25537	set	_	
164-12	25537-25538	.	_	

#Text=Of note, our results were likely not owing to a technical pitfall or instability of the current imaging analysis technology, because the additional analysis using FSL found similar results to the main analysis using FreeSurfer.
165-1	25539-25541	Of	_	
165-2	25542-25546	note	_	
165-3	25546-25547	,	_	
165-4	25548-25551	our	_	
165-5	25552-25559	results	_	
165-6	25560-25564	were	_	
165-7	25565-25571	likely	_	
165-8	25572-25575	not	_	
165-9	25576-25581	owing	_	
165-10	25582-25584	to	_	
165-11	25585-25586	a	_	
165-12	25587-25596	technical	_	
165-13	25597-25604	pitfall	_	
165-14	25605-25607	or	_	
165-15	25608-25619	instability	_	
165-16	25620-25622	of	_	
165-17	25623-25626	the	_	
165-18	25627-25634	current	_	
165-19	25635-25642	imaging	_	
165-20	25643-25651	analysis	_	
165-21	25652-25662	technology	_	
165-22	25662-25663	,	_	
165-23	25664-25671	because	_	
165-24	25672-25675	the	_	
165-25	25676-25686	additional	_	
165-26	25687-25695	analysis	_	
165-27	25696-25701	using	_	
165-28	25702-25705	FSL	_	
165-29	25706-25711	found	_	
165-30	25712-25719	similar	_	
165-31	25720-25727	results	_	
165-32	25728-25730	to	_	
165-33	25731-25734	the	_	
165-34	25735-25739	main	_	
165-35	25740-25748	analysis	_	
165-36	25749-25754	using	_	
165-37	25755-25765	FreeSurfer	_	
165-38	25765-25766	.	_	

#Text=Thus, schizophrenia–control differences in the lateralization of globus pallidus volume could be robust.
166-1	25767-25771	Thus	_	
166-2	25771-25772	,	_	
166-3	25773-25794	schizophrenia–control	_	
166-4	25795-25806	differences	_	
166-5	25807-25809	in	_	
166-6	25810-25813	the	_	
166-7	25814-25828	lateralization	_	
166-8	25829-25831	of	_	
166-9	25832-25838	globus	_	
166-10	25839-25847	pallidus	_	
166-11	25848-25854	volume	_	
166-12	25855-25860	could	_	
166-13	25861-25863	be	_	
166-14	25864-25870	robust	_	
166-15	25870-25871	.	_	

#Text=There are several reports of left globus pallidus abnormalities in schizophrenia using imaging modalities other than structural MRI.
167-1	25872-25877	There	_	
167-2	25878-25881	are	_	
167-3	25882-25889	several	_	
167-4	25890-25897	reports	_	
167-5	25898-25900	of	_	
167-6	25901-25905	left	_	
167-7	25906-25912	globus	_	
167-8	25913-25921	pallidus	_	
167-9	25922-25935	abnormalities	_	
167-10	25936-25938	in	_	
167-11	25939-25952	schizophrenia	_	
167-12	25953-25958	using	_	
167-13	25959-25966	imaging	_	
167-14	25967-25977	modalities	_	
167-15	25978-25983	other	_	
167-16	25984-25988	than	_	
167-17	25989-25999	structural	_	
167-18	26000-26003	MRI	_	
167-19	26003-26004	.	_	

#Text=A positron emission tomography study showed significantly higher blood flow in the left globus pallidus in never-medicated patients with schizophrenia than in controls.
168-1	26005-26006	A	_	
168-2	26007-26015	positron	_	
168-3	26016-26024	emission	_	
168-4	26025-26035	tomography	_	
168-5	26036-26041	study	_	
168-6	26042-26048	showed	_	
168-7	26049-26062	significantly	_	
168-8	26063-26069	higher	_	
168-9	26070-26075	blood	_	
168-10	26076-26080	flow	_	
168-11	26081-26083	in	_	
168-12	26084-26087	the	_	
168-13	26088-26092	left	_	
168-14	26093-26099	globus	_	
168-15	26100-26108	pallidus	_	
168-16	26109-26111	in	_	
168-17	26112-26127	never-medicated	_	
168-18	26128-26136	patients	_	
168-19	26137-26141	with	_	
168-20	26142-26155	schizophrenia	_	
168-21	26156-26160	than	_	
168-22	26161-26163	in	_	
168-23	26164-26172	controls	_	
168-24	26172-26173	.	_	

#Text=Another positron emission tomography study revealed a correlation between the severity of negative symptoms and increased left external globus pallidus activation in schizophrenia.
169-1	26174-26181	Another	_	
169-2	26182-26190	positron	_	
169-3	26191-26199	emission	_	
169-4	26200-26210	tomography	_	
169-5	26211-26216	study	_	
169-6	26217-26225	revealed	_	
169-7	26226-26227	a	_	
169-8	26228-26239	correlation	_	
169-9	26240-26247	between	_	
169-10	26248-26251	the	_	
169-11	26252-26260	severity	_	
169-12	26261-26263	of	_	
169-13	26264-26272	negative	_	
169-14	26273-26281	symptoms	_	
169-15	26282-26285	and	_	
169-16	26286-26295	increased	_	
169-17	26296-26300	left	_	
169-18	26301-26309	external	_	
169-19	26310-26316	globus	_	
169-20	26317-26325	pallidus	_	
169-21	26326-26336	activation	_	
169-22	26337-26339	in	_	
169-23	26340-26353	schizophrenia	_	
169-24	26353-26354	.	_	

#Text=A functional MRI study showed that patients with schizophrenia demonstrated greater activation during procedural learning in the left globus pallidus.
170-1	26355-26356	A	_	
170-2	26357-26367	functional	_	
170-3	26368-26371	MRI	_	
170-4	26372-26377	study	_	
170-5	26378-26384	showed	_	
170-6	26385-26389	that	_	
170-7	26390-26398	patients	_	
170-8	26399-26403	with	_	
170-9	26404-26417	schizophrenia	_	
170-10	26418-26430	demonstrated	_	
170-11	26431-26438	greater	_	
170-12	26439-26449	activation	_	
170-13	26450-26456	during	_	
170-14	26457-26467	procedural	_	
170-15	26468-26476	learning	_	
170-16	26477-26479	in	_	
170-17	26480-26483	the	_	
170-18	26484-26488	left	_	
170-19	26489-26495	globus	_	
170-20	26496-26504	pallidus	_	
170-21	26504-26505	.	_	

#Text=Further, some previous investigations have shown altered connectivity involving the globus pallidus in schizophrenia.
171-1	26506-26513	Further	_	
171-2	26513-26514	,	_	
171-3	26515-26519	some	_	
171-4	26520-26528	previous	_	
171-5	26529-26543	investigations	_	
171-6	26544-26548	have	_	
171-7	26549-26554	shown	_	
171-8	26555-26562	altered	_	
171-9	26563-26575	connectivity	_	
171-10	26576-26585	involving	_	
171-11	26586-26589	the	_	
171-12	26590-26596	globus	_	
171-13	26597-26605	pallidus	_	
171-14	26606-26608	in	_	
171-15	26609-26622	schizophrenia	_	
171-16	26622-26623	.	_	

#Text=A resting-state functional MRI study revealed significantly aberrant interhemispheric connections in the globus pallidus, as well as a negative correlation with bilateral connections of the pallidum and duration of illness in schizophrenia.
172-1	26624-26625	A	_	
172-2	26626-26639	resting-state	_	
172-3	26640-26650	functional	_	
172-4	26651-26654	MRI	_	
172-5	26655-26660	study	_	
172-6	26661-26669	revealed	_	
172-7	26670-26683	significantly	_	
172-8	26684-26692	aberrant	_	
172-9	26693-26709	interhemispheric	_	
172-10	26710-26721	connections	_	
172-11	26722-26724	in	_	
172-12	26725-26728	the	_	
172-13	26729-26735	globus	_	
172-14	26736-26744	pallidus	_	
172-15	26744-26745	,	_	
172-16	26746-26748	as	_	
172-17	26749-26753	well	_	
172-18	26754-26756	as	_	
172-19	26757-26758	a	_	
172-20	26759-26767	negative	_	
172-21	26768-26779	correlation	_	
172-22	26780-26784	with	_	
172-23	26785-26794	bilateral	_	
172-24	26795-26806	connections	_	
172-25	26807-26809	of	_	
172-26	26810-26813	the	_	
172-27	26814-26822	pallidum	_	
172-28	26823-26826	and	_	
172-29	26827-26835	duration	_	
172-30	26836-26838	of	_	
172-31	26839-26846	illness	_	
172-32	26847-26849	in	_	
172-33	26850-26863	schizophrenia	_	
172-34	26863-26864	.	_	

#Text=Finally, a diffusion tensor imaging study showed that patients with schizophrenia have lower-than-normal fractional anisotropy values in the bilateral globus pallidus, implying aberrant microstructures of the globus pallidus.
173-1	26865-26872	Finally	_	
173-2	26872-26873	,	_	
173-3	26874-26875	a	_	
173-4	26876-26885	diffusion	_	
173-5	26886-26892	tensor	_	
173-6	26893-26900	imaging	_	
173-7	26901-26906	study	_	
173-8	26907-26913	showed	_	
173-9	26914-26918	that	_	
173-10	26919-26927	patients	_	
173-11	26928-26932	with	_	
173-12	26933-26946	schizophrenia	_	
173-13	26947-26951	have	_	
173-14	26952-26969	lower-than-normal	_	
173-15	26970-26980	fractional	_	
173-16	26981-26991	anisotropy	_	
173-17	26992-26998	values	_	
173-18	26999-27001	in	_	
173-19	27002-27005	the	_	
173-20	27006-27015	bilateral	_	
173-21	27016-27022	globus	_	
173-22	27023-27031	pallidus	_	
173-23	27031-27032	,	_	
173-24	27033-27041	implying	_	
173-25	27042-27050	aberrant	_	
173-26	27051-27066	microstructures	_	
173-27	27067-27069	of	_	
173-28	27070-27073	the	_	
173-29	27074-27080	globus	_	
173-30	27081-27089	pallidus	_	
173-31	27089-27090	.	_	

#Text=The basal ganglia have important roles in motor function and the reward system, and the globus pallidus externus is in the central position among the loop circuits of the basal ganglia.
174-1	27091-27094	The	_	
174-2	27095-27100	basal	_	
174-3	27101-27108	ganglia	_	
174-4	27109-27113	have	_	
174-5	27114-27123	important	_	
174-6	27124-27129	roles	_	
174-7	27130-27132	in	_	
174-8	27133-27138	motor	_	
174-9	27139-27147	function	_	
174-10	27148-27151	and	_	
174-11	27152-27155	the	_	
174-12	27156-27162	reward	_	
174-13	27163-27169	system	_	
174-14	27169-27170	,	_	
174-15	27171-27174	and	_	
174-16	27175-27178	the	_	
174-17	27179-27185	globus	_	
174-18	27186-27194	pallidus	_	
174-19	27195-27203	externus	_	
174-20	27204-27206	is	_	
174-21	27207-27209	in	_	
174-22	27210-27213	the	_	
174-23	27214-27221	central	_	
174-24	27222-27230	position	_	
174-25	27231-27236	among	_	
174-26	27237-27240	the	_	
174-27	27241-27245	loop	_	
174-28	27246-27254	circuits	_	
174-29	27255-27257	of	_	
174-30	27258-27261	the	_	
174-31	27262-27267	basal	_	
174-32	27268-27275	ganglia	_	
174-33	27275-27276	.	_	

#Text=It has long been known that the basal ganglia use modulatory systems to regulate cerebral cortical activity via a projection to the thalamus.
175-1	27277-27279	It	_	
175-2	27280-27283	has	_	
175-3	27284-27288	long	_	
175-4	27289-27293	been	_	
175-5	27294-27299	known	_	
175-6	27300-27304	that	_	
175-7	27305-27308	the	_	
175-8	27309-27314	basal	_	
175-9	27315-27322	ganglia	_	
175-10	27323-27326	use	_	
175-11	27327-27337	modulatory	_	
175-12	27338-27345	systems	_	
175-13	27346-27348	to	_	
175-14	27349-27357	regulate	_	
175-15	27358-27366	cerebral	_	
175-16	27367-27375	cortical	_	
175-17	27376-27384	activity	_	
175-18	27385-27388	via	_	
175-19	27389-27390	a	_	
175-20	27391-27401	projection	_	
175-21	27402-27404	to	_	
175-22	27405-27408	the	_	
175-23	27409-27417	thalamus	_	
175-24	27417-27418	.	_	

#Text=A recent mouse study described a direct GABAergic (gamma-aminobutyric acidergic) projection from the globus pallidus externus to the frontal cortex, which is exclusively ipsilateral and sensitive to antipsychotic drugs.
176-1	27419-27420	A	_	
176-2	27421-27427	recent	_	
176-3	27428-27433	mouse	_	
176-4	27434-27439	study	_	
176-5	27440-27449	described	_	
176-6	27450-27451	a	_	
176-7	27452-27458	direct	_	
176-8	27459-27468	GABAergic	_	
176-9	27469-27470	(	_	
176-10	27470-27488	gamma-aminobutyric	_	
176-11	27489-27498	acidergic	_	
176-12	27498-27499	)	_	
176-13	27500-27510	projection	_	
176-14	27511-27515	from	_	
176-15	27516-27519	the	_	
176-16	27520-27526	globus	_	
176-17	27527-27535	pallidus	_	
176-18	27536-27544	externus	_	
176-19	27545-27547	to	_	
176-20	27548-27551	the	_	
176-21	27552-27559	frontal	_	
176-22	27560-27566	cortex	_	
176-23	27566-27567	,	_	
176-24	27568-27573	which	_	
176-25	27574-27576	is	_	
176-26	27577-27588	exclusively	_	
176-27	27589-27600	ipsilateral	_	
176-28	27601-27604	and	_	
176-29	27605-27614	sensitive	_	
176-30	27615-27617	to	_	
176-31	27618-27631	antipsychotic	_	
176-32	27632-27637	drugs	_	
176-33	27637-27638	.	_	

#Text=These results imply the existence of altered structural and functional connectivity, especially ipsilateral connectivity, between basal ganglia and frontal cortices in schizophrenia.
177-1	27639-27644	These	_	
177-2	27645-27652	results	_	
177-3	27653-27658	imply	_	
177-4	27659-27662	the	_	
177-5	27663-27672	existence	_	
177-6	27673-27675	of	_	
177-7	27676-27683	altered	_	
177-8	27684-27694	structural	_	
177-9	27695-27698	and	_	
177-10	27699-27709	functional	_	
177-11	27710-27722	connectivity	_	
177-12	27722-27723	,	_	
177-13	27724-27734	especially	_	
177-14	27735-27746	ipsilateral	_	
177-15	27747-27759	connectivity	_	
177-16	27759-27760	,	_	
177-17	27761-27768	between	_	
177-18	27769-27774	basal	_	
177-19	27775-27782	ganglia	_	
177-20	27783-27786	and	_	
177-21	27787-27794	frontal	_	
177-22	27795-27803	cortices	_	
177-23	27804-27806	in	_	
177-24	27807-27820	schizophrenia	_	
177-25	27820-27821	.	_	

#Text=In patients with schizophrenia, altered GABAergic interneuron function resulting in dysfunction of the dorsolateral prefrontal cortex, which is closely associated with impairments in executive functioning such as working memory, may occur ipsilaterally.
178-1	27822-27824	In	_	
178-2	27825-27833	patients	_	
178-3	27834-27838	with	_	
178-4	27839-27852	schizophrenia	_	
178-5	27852-27853	,	_	
178-6	27854-27861	altered	_	
178-7	27862-27871	GABAergic	_	
178-8	27872-27883	interneuron	_	
178-9	27884-27892	function	_	
178-10	27893-27902	resulting	_	
178-11	27903-27905	in	_	
178-12	27906-27917	dysfunction	_	
178-13	27918-27920	of	_	
178-14	27921-27924	the	_	
178-15	27925-27937	dorsolateral	_	
178-16	27938-27948	prefrontal	_	
178-17	27949-27955	cortex	_	
178-18	27955-27956	,	_	
178-19	27957-27962	which	_	
178-20	27963-27965	is	_	
178-21	27966-27973	closely	_	
178-22	27974-27984	associated	_	
178-23	27985-27989	with	_	
178-24	27990-28001	impairments	_	
178-25	28002-28004	in	_	
178-26	28005-28014	executive	_	
178-27	28015-28026	functioning	_	
178-28	28027-28031	such	_	
178-29	28032-28034	as	_	
178-30	28035-28042	working	_	
178-31	28043-28049	memory	_	
178-32	28049-28050	,	_	
178-33	28051-28054	may	_	
178-34	28055-28060	occur	_	
178-35	28061-28074	ipsilaterally	_	
178-36	28074-28075	.	_	

#Text=Thus, it is suggested that there may be aberrant laterality in neural pathways and connectivity patterns related to the globus pallidus in schizophrenia.
179-1	28076-28080	Thus	_	
179-2	28080-28081	,	_	
179-3	28082-28084	it	_	
179-4	28085-28087	is	_	
179-5	28088-28097	suggested	_	
179-6	28098-28102	that	_	
179-7	28103-28108	there	_	
179-8	28109-28112	may	_	
179-9	28113-28115	be	_	
179-10	28116-28124	aberrant	_	
179-11	28125-28135	laterality	_	
179-12	28136-28138	in	_	
179-13	28139-28145	neural	_	
179-14	28146-28154	pathways	_	
179-15	28155-28158	and	_	
179-16	28159-28171	connectivity	_	
179-17	28172-28180	patterns	_	
179-18	28181-28188	related	_	
179-19	28189-28191	to	_	
179-20	28192-28195	the	_	
179-21	28196-28202	globus	_	
179-22	28203-28211	pallidus	_	
179-23	28212-28214	in	_	
179-24	28215-28228	schizophrenia	_	
179-25	28228-28229	.	_	

#Text=Further research is required to elucidate this hypothesis.
180-1	28230-28237	Further	_	
180-2	28238-28246	research	_	
180-3	28247-28249	is	_	
180-4	28250-28258	required	_	
180-5	28259-28261	to	_	
180-6	28262-28271	elucidate	_	
180-7	28272-28276	this	_	
180-8	28277-28287	hypothesis	_	
180-9	28287-28288	.	_	

#Text=A few limitations to the current study should be noted.
181-1	28289-28290	A	_	
181-2	28291-28294	few	_	
181-3	28295-28306	limitations	_	
181-4	28307-28309	to	_	
181-5	28310-28313	the	_	
181-6	28314-28321	current	_	
181-7	28322-28327	study	_	
181-8	28328-28334	should	_	
181-9	28335-28337	be	_	
181-10	28338-28343	noted	_	
181-11	28343-28344	.	_	

#Text=First, possible effects of medically prescribed drugs on subcortical regional volumes in patients with schizophrenia cannot be overlooked.
182-1	28345-28350	First	_	
182-2	28350-28351	,	_	
182-3	28352-28360	possible	_	
182-4	28361-28368	effects	_	
182-5	28369-28371	of	_	
182-6	28372-28381	medically	_	
182-7	28382-28392	prescribed	_	
182-8	28393-28398	drugs	_	
182-9	28399-28401	on	_	
182-10	28402-28413	subcortical	_	
182-11	28414-28422	regional	_	
182-12	28423-28430	volumes	_	
182-13	28431-28433	in	_	
182-14	28434-28442	patients	_	
182-15	28443-28447	with	_	
182-16	28448-28461	schizophrenia	_	
182-17	28462-28468	cannot	_	
182-18	28469-28471	be	_	
182-19	28472-28482	overlooked	_	
182-20	28482-28483	.	_	

#Text=Although few studies reported associations between limbic volumes and antipsychotic medications, several studies have demonstrated increased basal ganglia volume after treatment with neuroleptics (especially typical neuroleptics).
183-1	28484-28492	Although	_	
183-2	28493-28496	few	_	
183-3	28497-28504	studies	_	
183-4	28505-28513	reported	_	
183-5	28514-28526	associations	_	
183-6	28527-28534	between	_	
183-7	28535-28541	limbic	_	
183-8	28542-28549	volumes	_	
183-9	28550-28553	and	_	
183-10	28554-28567	antipsychotic	_	
183-11	28568-28579	medications	_	
183-12	28579-28580	,	_	
183-13	28581-28588	several	_	
183-14	28589-28596	studies	_	
183-15	28597-28601	have	_	
183-16	28602-28614	demonstrated	_	
183-17	28615-28624	increased	_	
183-18	28625-28630	basal	_	
183-19	28631-28638	ganglia	_	
183-20	28639-28645	volume	_	
183-21	28646-28651	after	_	
183-22	28652-28661	treatment	_	
183-23	28662-28666	with	_	
183-24	28667-28679	neuroleptics	_	
183-25	28680-28681	(	_	
183-26	28681-28691	especially	_	
183-27	28692-28699	typical	_	
183-28	28700-28712	neuroleptics	_	
183-29	28712-28713	)	_	
183-30	28713-28714	.	_	

#Text=A review by Ebdrup et al., however, revealed that typical neuroleptics do not increase the volume of the basal ganglia, while atypical neuroleptics do.
184-1	28715-28716	A	_	
184-2	28717-28723	review	_	
184-3	28724-28726	by	_	
184-4	28727-28733	Ebdrup	_	
184-5	28734-28736	et	_	
184-6	28737-28739	al	_	
184-7	28739-28740	.	_	
184-8	28740-28741	,	_	
184-9	28742-28749	however	_	
184-10	28749-28750	,	_	
184-11	28751-28759	revealed	_	
184-12	28760-28764	that	_	
184-13	28765-28772	typical	_	
184-14	28773-28785	neuroleptics	_	
184-15	28786-28788	do	_	
184-16	28789-28792	not	_	
184-17	28793-28801	increase	_	
184-18	28802-28805	the	_	
184-19	28806-28812	volume	_	
184-20	28813-28815	of	_	
184-21	28816-28819	the	_	
184-22	28820-28825	basal	_	
184-23	28826-28833	ganglia	_	
184-24	28833-28834	,	_	
184-25	28835-28840	while	_	
184-26	28841-28849	atypical	_	
184-27	28850-28862	neuroleptics	_	
184-28	28863-28865	do	_	
184-29	28865-28866	.	_	

#Text=A recent meta-analytic study revealed no significant longitudinal differences in caudate volume related to antipsychotic treatment in patients with schizophrenia.
185-1	28867-28868	A	_	
185-2	28869-28875	recent	_	
185-3	28876-28889	meta-analytic	_	
185-4	28890-28895	study	_	
185-5	28896-28904	revealed	_	
185-6	28905-28907	no	_	
185-7	28908-28919	significant	_	
185-8	28920-28932	longitudinal	_	
185-9	28933-28944	differences	_	
185-10	28945-28947	in	_	
185-11	28948-28955	caudate	_	
185-12	28956-28962	volume	_	
185-13	28963-28970	related	_	
185-14	28971-28973	to	_	
185-15	28974-28987	antipsychotic	_	
185-16	28988-28997	treatment	_	
185-17	28998-29000	in	_	
185-18	29001-29009	patients	_	
185-19	29010-29014	with	_	
185-20	29015-29028	schizophrenia	_	
185-21	29028-29029	.	_	

#Text=Thus, results regarding medication-induced changes in subcortical regional volumes in schizophrenia remain controversial and heterogeneous.
186-1	29030-29034	Thus	_	
186-2	29034-29035	,	_	
186-3	29036-29043	results	_	
186-4	29044-29053	regarding	_	
186-5	29054-29072	medication-induced	_	
186-6	29073-29080	changes	_	
186-7	29081-29083	in	_	
186-8	29084-29095	subcortical	_	
186-9	29096-29104	regional	_	
186-10	29105-29112	volumes	_	
186-11	29113-29115	in	_	
186-12	29116-29129	schizophrenia	_	
186-13	29130-29136	remain	_	
186-14	29137-29150	controversial	_	
186-15	29151-29154	and	_	
186-16	29155-29168	heterogeneous	_	
186-17	29168-29169	.	_	

#Text=Second, the results of any meta-analysis must be interpreted cautiously, because of possible confounds such as a statistical paradox.
187-1	29170-29176	Second	_	
187-2	29176-29177	,	_	
187-3	29178-29181	the	_	
187-4	29182-29189	results	_	
187-5	29190-29192	of	_	
187-6	29193-29196	any	_	
187-7	29197-29210	meta-analysis	_	
187-8	29211-29215	must	_	
187-9	29216-29218	be	_	
187-10	29219-29230	interpreted	_	
187-11	29231-29241	cautiously	_	
187-12	29241-29242	,	_	
187-13	29243-29250	because	_	
187-14	29251-29253	of	_	
187-15	29254-29262	possible	_	
187-16	29263-29272	confounds	_	
187-17	29273-29277	such	_	
187-18	29278-29280	as	_	
187-19	29281-29282	a	_	
187-20	29283-29294	statistical	_	
187-21	29295-29302	paradox	_	
187-22	29302-29303	.	_	

#Text=The sample sizes of this study were unequal; therefore, the current meta-analytic results may be unstable.
188-1	29304-29307	The	_	
188-2	29308-29314	sample	_	
188-3	29315-29320	sizes	_	
188-4	29321-29323	of	_	
188-5	29324-29328	this	_	
188-6	29329-29334	study	_	
188-7	29335-29339	were	_	
188-8	29340-29347	unequal	_	
188-9	29347-29348	;	_	
188-10	29349-29358	therefore	_	
188-11	29358-29359	,	_	
188-12	29360-29363	the	_	
188-13	29364-29371	current	_	
188-14	29372-29385	meta-analytic	_	
188-15	29386-29393	results	_	
188-16	29394-29397	may	_	
188-17	29398-29400	be	_	
188-18	29401-29409	unstable	_	
188-19	29409-29410	.	_	

#Text=Third, we did not investigate correlations between subcortical region volumes and clinical characteristics.
189-1	29411-29416	Third	_	
189-2	29416-29417	,	_	
189-3	29418-29420	we	_	
189-4	29421-29424	did	_	
189-5	29425-29428	not	_	
189-6	29429-29440	investigate	_	
189-7	29441-29453	correlations	_	
189-8	29454-29461	between	_	
189-9	29462-29473	subcortical	_	
189-10	29474-29480	region	_	
189-11	29481-29488	volumes	_	
189-12	29489-29492	and	_	
189-13	29493-29501	clinical	_	
189-14	29502-29517	characteristics	_	
189-15	29517-29518	.	_	

#Text=Only the Osaka site was able to provide such detailed clinical characteristics.
190-1	29519-29523	Only	_	
190-2	29524-29527	the	_	
190-3	29528-29533	Osaka	_	
190-4	29534-29538	site	_	
190-5	29539-29542	was	_	
190-6	29543-29547	able	_	
190-7	29548-29550	to	_	
190-8	29551-29558	provide	_	
190-9	29559-29563	such	_	
190-10	29564-29572	detailed	_	
190-11	29573-29581	clinical	_	
190-12	29582-29597	characteristics	_	
190-13	29597-29598	.	_	

#Text=The ENIGMA consortium has already launched a research project studying such associations.
191-1	29599-29602	The	_	
191-2	29603-29609	ENIGMA	_	
191-3	29610-29620	consortium	_	
191-4	29621-29624	has	_	
191-5	29625-29632	already	_	
191-6	29633-29641	launched	_	
191-7	29642-29643	a	_	
191-8	29644-29652	research	_	
191-9	29653-29660	project	_	
191-10	29661-29669	studying	_	
191-11	29670-29674	such	_	
191-12	29675-29687	associations	_	
191-13	29687-29688	.	_	

#Text=The Osaka site supplied its own data set of T1-weighted images and clinical information to this ENIGMA project.
192-1	29689-29692	The	_	
192-2	29693-29698	Osaka	_	
192-3	29699-29703	site	_	
192-4	29704-29712	supplied	_	
192-5	29713-29716	its	_	
192-6	29717-29720	own	_	
192-7	29721-29725	data	_	
192-8	29726-29729	set	_	
192-9	29730-29732	of	_	
192-10	29733-29735	T1	_	
192-11	29735-29736	-	_	
192-12	29736-29744	weighted	_	
192-13	29745-29751	images	_	
192-14	29752-29755	and	_	
192-15	29756-29764	clinical	_	
192-16	29765-29776	information	_	
192-17	29777-29779	to	_	
192-18	29780-29784	this	_	
192-19	29785-29791	ENIGMA	_	
192-20	29792-29799	project	_	
192-21	29799-29800	.	_	

#Text=The results of their study are expected to be published in the near future.
193-1	29801-29804	The	_	
193-2	29805-29812	results	_	
193-3	29813-29815	of	_	
193-4	29816-29821	their	_	
193-5	29822-29827	study	_	
193-6	29828-29831	are	_	
193-7	29832-29840	expected	_	
193-8	29841-29843	to	_	
193-9	29844-29846	be	_	
193-10	29847-29856	published	_	
193-11	29857-29859	in	_	
193-12	29860-29863	the	_	
193-13	29864-29868	near	_	
193-14	29869-29875	future	_	
193-15	29875-29876	.	_	

#Text=In conclusion, we demonstrated reduced bilateral hippocampus, amygdala, thalamus, accumbens and ICVs, but enlarged bilateral caudate, putamen, pallidum and lateral ventricle volumes in schizophrenia.
194-1	29877-29879	In	_	
194-2	29880-29890	conclusion	_	
194-3	29890-29891	,	_	
194-4	29892-29894	we	_	
194-5	29895-29907	demonstrated	_	
194-6	29908-29915	reduced	_	
194-7	29916-29925	bilateral	_	
194-8	29926-29937	hippocampus	_	
194-9	29937-29938	,	_	
194-10	29939-29947	amygdala	_	
194-11	29947-29948	,	_	
194-12	29949-29957	thalamus	_	
194-13	29957-29958	,	_	
194-14	29959-29968	accumbens	_	
194-15	29969-29972	and	_	
194-16	29973-29977	ICVs	_	
194-17	29977-29978	,	_	
194-18	29979-29982	but	_	
194-19	29983-29991	enlarged	_	
194-20	29992-30001	bilateral	_	
194-21	30002-30009	caudate	_	
194-22	30009-30010	,	_	
194-23	30011-30018	putamen	_	
194-24	30018-30019	,	_	
194-25	30020-30028	pallidum	_	
194-26	30029-30032	and	_	
194-27	30033-30040	lateral	_	
194-28	30041-30050	ventricle	_	
194-29	30051-30058	volumes	_	
194-30	30059-30061	in	_	
194-31	30062-30075	schizophrenia	_	
194-32	30075-30076	.	_	

#Text=The rank order of effect sizes for subcortical regional volumetric differences between patients with schizophrenia and healthy subjects reported by van Erp et al. was successfully replicated and confirmed.
195-1	30077-30080	The	_	
195-2	30081-30085	rank	_	
195-3	30086-30091	order	_	
195-4	30092-30094	of	_	
195-5	30095-30101	effect	_	
195-6	30102-30107	sizes	_	
195-7	30108-30111	for	_	
195-8	30112-30123	subcortical	_	
195-9	30124-30132	regional	_	
195-10	30133-30143	volumetric	_	
195-11	30144-30155	differences	_	
195-12	30156-30163	between	_	
195-13	30164-30172	patients	_	
195-14	30173-30177	with	_	
195-15	30178-30191	schizophrenia	_	
195-16	30192-30195	and	_	
195-17	30196-30203	healthy	_	
195-18	30204-30212	subjects	_	
195-19	30213-30221	reported	_	
195-20	30222-30224	by	_	
195-21	30225-30228	van	_	
195-22	30229-30232	Erp	_	
195-23	30233-30235	et	_	
195-24	30236-30238	al	_	
195-25	30238-30239	.	_	
195-26	30240-30243	was	_	
195-27	30244-30256	successfully	_	
195-28	30257-30267	replicated	_	
195-29	30268-30271	and	_	
195-30	30272-30281	confirmed	_	
195-31	30281-30282	.	_	

#Text=Further, we revealed leftward asymmetry for thalamus, lateral ventricle, caudate and putamen volumes, and rightward asymmetry for amygdala and hippocampal volumes both in controls and in patients with schizophrenia.
196-1	30283-30290	Further	_	
196-2	30290-30291	,	_	
196-3	30292-30294	we	_	
196-4	30295-30303	revealed	_	
196-5	30304-30312	leftward	_	
196-6	30313-30322	asymmetry	_	
196-7	30323-30326	for	_	
196-8	30327-30335	thalamus	_	
196-9	30335-30336	,	_	
196-10	30337-30344	lateral	_	
196-11	30345-30354	ventricle	_	
196-12	30354-30355	,	_	
196-13	30356-30363	caudate	_	
196-14	30364-30367	and	_	
196-15	30368-30375	putamen	_	
196-16	30376-30383	volumes	_	
196-17	30383-30384	,	_	
196-18	30385-30388	and	_	
196-19	30389-30398	rightward	_	
196-20	30399-30408	asymmetry	_	
196-21	30409-30412	for	_	
196-22	30413-30421	amygdala	_	
196-23	30422-30425	and	_	
196-24	30426-30437	hippocampal	_	
196-25	30438-30445	volumes	_	
196-26	30446-30450	both	_	
196-27	30451-30453	in	_	
196-28	30454-30462	controls	_	
196-29	30463-30466	and	_	
196-30	30467-30469	in	_	
196-31	30470-30478	patients	_	
196-32	30479-30483	with	_	
196-33	30484-30497	schizophrenia	_	
196-34	30497-30498	.	_	

#Text=Also, we demonstrated schizophrenia-specific leftward asymmetry in globus pallidus volume.
197-1	30499-30503	Also	_	
197-2	30503-30504	,	_	
197-3	30505-30507	we	_	
197-4	30508-30520	demonstrated	_	
197-5	30521-30543	schizophrenia-specific	_	
197-6	30544-30552	leftward	_	
197-7	30553-30562	asymmetry	_	
197-8	30563-30565	in	_	
197-9	30566-30572	globus	_	
197-10	30573-30581	pallidus	_	
197-11	30582-30588	volume	_	
197-12	30588-30589	.	_	

#Text=These findings suggest the possibility of aberrant laterality in neural pathways and connectivity patterns related to the pallidum in schizophrenia.
198-1	30590-30595	These	_	
198-2	30596-30604	findings	_	
198-3	30605-30612	suggest	_	
198-4	30613-30616	the	_	
198-5	30617-30628	possibility	_	
198-6	30629-30631	of	_	
198-7	30632-30640	aberrant	_	
198-8	30641-30651	laterality	_	
198-9	30652-30654	in	_	
198-10	30655-30661	neural	_	
198-11	30662-30670	pathways	_	
198-12	30671-30674	and	_	
198-13	30675-30687	connectivity	_	
198-14	30688-30696	patterns	_	
198-15	30697-30704	related	_	
198-16	30705-30707	to	_	
198-17	30708-30711	the	_	
198-18	30712-30720	pallidum	_	
198-19	30721-30723	in	_	
198-20	30724-30737	schizophrenia	_	
198-21	30737-30738	.	_	

#Text=Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)
#Text=The authors declare no conflict of interest.
199-1	30739-30752	Supplementary	_	
199-2	30753-30764	Information	_	
199-3	30765-30776	accompanies	_	
199-4	30777-30780	the	_	
199-5	30781-30786	paper	_	
199-6	30787-30789	on	_	
199-7	30790-30793	the	_	
199-8	30794-30803	Molecular	_	
199-9	30804-30814	Psychiatry	_	
199-10	30815-30822	website	_	
199-11	30823-30824	(	_	
199-12	30824-30828	http	_	
199-13	30828-30829	:	_	
199-14	30829-30830	/	_	
199-15	30830-30831	/	_	
199-16	30831-30845	www.nature.com	_	
199-17	30845-30846	/	_	
199-18	30846-30848	mp	_	
199-19	30848-30849	)	_	
199-20	30850-30853	The	_	
199-21	30854-30861	authors	_	
199-22	30862-30869	declare	_	
199-23	30870-30872	no	_	
199-24	30873-30881	conflict	_	
199-25	30882-30884	of	_	
199-26	30885-30893	interest	_	
199-27	30893-30894	.	_	

#Text=Neuroanatomy of auditory verbal hallucinations in schizophrenia: a quantitative meta-analysis of voxel-based morphometry studies
#Text=Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients
#Text=Structural and functional brain abnormalities in schizophrenia
#Text=Neural systems for recognizing emotion
#Text=The human basal ganglia modulate frontal-posterior connectivity during attention shifting
#Text=Cognitive-motor interactions of the basal ganglia in development
#Text=Dopaminergic modulation of cognitive control: distinct roles for the prefrontal cortex and the basal ganglia
#Text=Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder
#Text=Meta-analysis of regional brain volumes in schizophrenia
#Text=Subcortical brain volumes relate to neurocognition in schizophrenia and bipolar disorder and healthy controls
#Text=Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study
#Text=Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis
#Text=Abnormalities of thalamic volume and shape in schizophrenia
#Text=Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study
#Text=Ventral striatum gray matter density reduction in patients with schizophrenia and psychotic emotional dysregulation
#Text=Gray matter abnormalities in paranoid schizophrenia and their clinical correlations
#Text=Mapping brain asymmetry
#Text=Left brain, right brain: facts and fantasies
#Text=Statistical analysis of hippocampal asymmetry in schizophrenia
#Text=Asymmetry of the hippocampus and amygdala in MRI volumetric measurements of normal adults
#Text=Neuroanatomical asymmetry patterns in individuals with schizophrenia and their non-psychotic siblings
#Text=MRI-assessed volume of left and right hippocampi in females correlates with the relative length of the second and fourth fingers (the 2D:4D ratio)
#Text=Magnetic resonance imaging of the thalamus in male patients with schizophrenia
#Text=Application of automated MRI volumetric measurement techniques to the ventricular system in schizophrenics and normal controls
#Text=Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis
#Text=Volumetric asymmetry and differential aging effect of the human caudate nucleus in normal individuals: a prospective MR imaging study
#Text=Structural asymmetries in the human brain: a voxel-based statistical analysis of 142 MRI scans
#Text=Age, gender, and hemispheric differences in human striatum: a quantitative review and new data from in vivo MRI morphometry
#Text=MR volumetric analysis of the human basal ganglia: normative data
#Text=Basal ganglia volumes: MR-derived reference ranges and lateralization indices for children and young adults
#Text=Differential aging of the human striatum: a prospective MR imaging study
#Text=Abnormal asymmetry of brain connectivity in schizophrenia
#Text=The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis
#Text=The neuroanatomy of psychotic diathesis: a meta-analytic review
#Text=Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects
#Text=Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data
#Text=EnigmaVis: online interactive visualization of genome-wide association studies of the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium
#Text=Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: a pilot project of the ENIGMA-DTI working group
#Text=Identification of common variants associated with human hippocampal and intracranial volumes
#Text=Multi-site study of additive genetic effects on fractional anisotropy of cerebral white matter: comparing meta and megaanalytical approaches for data pooling
#Text=Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to neurodegenerative disease
#Text=Common genetic variants influence human subcortical brain structures
#Text=Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group
#Text=Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium
#Text=Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies
#Text=Morphometric and volumetric study of caudate and putamen nuclei in normal individuals by MRI: Effect of normal aging, gender and hemispheric differences
#Text=G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences
#Text=Measurement and genetics of human subcortical and hippocampal asymmetries in large datasets
#Text=Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study
#Text=Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis
#Text=Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression
#Text=Structural analysis of the basal ganglia in schizophrenia
#Text=Structural neuroimaging of the basal ganglia in schizophrenic patients: a review
#Text=Focal gray matter density changes in schizophrenia
#Text=Left globus pallidus abnormality in never-medicated patients with schizophrenia
#Text=Severity of negative symptoms in schizophrenia correlated to hyperactivity of the left globus pallidus and the right claustrum.
200-1	30895-30907	Neuroanatomy	_	
200-2	30908-30910	of	_	
200-3	30911-30919	auditory	_	
200-4	30920-30926	verbal	_	
200-5	30927-30941	hallucinations	_	
200-6	30942-30944	in	_	
200-7	30945-30958	schizophrenia	_	
200-8	30958-30959	:	_	
200-9	30960-30961	a	_	
200-10	30962-30974	quantitative	_	
200-11	30975-30988	meta-analysis	_	
200-12	30989-30991	of	_	
200-13	30992-31003	voxel-based	_	
200-14	31004-31015	morphometry	_	
200-15	31016-31023	studies	_	
200-16	31024-31035	Progressive	_	
200-17	31036-31045	pathology	_	
200-18	31046-31048	is	_	
200-19	31049-31061	functionally	_	
200-20	31062-31068	linked	_	
200-21	31069-31071	to	_	
200-22	31072-31075	the	_	
200-23	31076-31083	domains	_	
200-24	31084-31086	of	_	
200-25	31087-31095	language	_	
200-26	31096-31099	and	_	
200-27	31100-31107	emotion	_	
200-28	31107-31108	:	_	
200-29	31109-31122	meta-analysis	_	
200-30	31123-31125	of	_	
200-31	31126-31131	brain	_	
200-32	31132-31141	structure	_	
200-33	31142-31149	changes	_	
200-34	31150-31152	in	_	
200-35	31153-31166	schizophrenia	_	
200-36	31167-31175	patients	_	
200-37	31176-31186	Structural	_	
200-38	31187-31190	and	_	
200-39	31191-31201	functional	_	
200-40	31202-31207	brain	_	
200-41	31208-31221	abnormalities	_	
200-42	31222-31224	in	_	
200-43	31225-31238	schizophrenia	_	
200-44	31239-31245	Neural	_	
200-45	31246-31253	systems	_	
200-46	31254-31257	for	_	
200-47	31258-31269	recognizing	_	
200-48	31270-31277	emotion	_	
200-49	31278-31281	The	_	
200-50	31282-31287	human	_	
200-51	31288-31293	basal	_	
200-52	31294-31301	ganglia	_	
200-53	31302-31310	modulate	_	
200-54	31311-31328	frontal-posterior	_	
200-55	31329-31341	connectivity	_	
200-56	31342-31348	during	_	
200-57	31349-31358	attention	_	
200-58	31359-31367	shifting	_	
200-59	31368-31383	Cognitive-motor	_	
200-60	31384-31396	interactions	_	
200-61	31397-31399	of	_	
200-62	31400-31403	the	_	
200-63	31404-31409	basal	_	
200-64	31410-31417	ganglia	_	
200-65	31418-31420	in	_	
200-66	31421-31432	development	_	
200-67	31433-31445	Dopaminergic	_	
200-68	31446-31456	modulation	_	
200-69	31457-31459	of	_	
200-70	31460-31469	cognitive	_	
200-71	31470-31477	control	_	
200-72	31477-31478	:	_	
200-73	31479-31487	distinct	_	
200-74	31488-31493	roles	_	
200-75	31494-31497	for	_	
200-76	31498-31501	the	_	
200-77	31502-31512	prefrontal	_	
200-78	31513-31519	cortex	_	
200-79	31520-31523	and	_	
200-80	31524-31527	the	_	
200-81	31528-31533	basal	_	
200-82	31534-31541	ganglia	_	
200-83	31542-31550	Cortical	_	
200-84	31551-31560	thickness	_	
200-85	31561-31564	and	_	
200-86	31565-31576	subcortical	_	
200-87	31577-31584	volumes	_	
200-88	31585-31587	in	_	
200-89	31588-31601	schizophrenia	_	
200-90	31602-31605	and	_	
200-91	31606-31613	bipolar	_	
200-92	31614-31622	disorder	_	
200-93	31623-31636	Meta-analysis	_	
200-94	31637-31639	of	_	
200-95	31640-31648	regional	_	
200-96	31649-31654	brain	_	
200-97	31655-31662	volumes	_	
200-98	31663-31665	in	_	
200-99	31666-31679	schizophrenia	_	
200-100	31680-31691	Subcortical	_	
200-101	31692-31697	brain	_	
200-102	31698-31705	volumes	_	
200-103	31706-31712	relate	_	
200-104	31713-31715	to	_	
200-105	31716-31730	neurocognition	_	
200-106	31731-31733	in	_	
200-107	31734-31747	schizophrenia	_	
200-108	31748-31751	and	_	
200-109	31752-31759	bipolar	_	
200-110	31760-31768	disorder	_	
200-111	31769-31772	and	_	
200-112	31773-31780	healthy	_	
200-113	31781-31789	controls	_	
200-114	31790-31800	Structural	_	
200-115	31801-31811	correlates	_	
200-116	31812-31814	of	_	
200-117	31815-31833	psychopathological	_	
200-118	31834-31841	symptom	_	
200-119	31842-31852	dimensions	_	
200-120	31853-31855	in	_	
200-121	31856-31869	schizophrenia	_	
200-122	31869-31870	:	_	
200-123	31871-31872	a	_	
200-124	31873-31884	voxel-based	_	
200-125	31885-31897	morphometric	_	
200-126	31898-31903	study	_	
200-127	31904-31919	Neuroanatomical	_	
200-128	31920-31933	abnormalities	_	
200-129	31934-31936	in	_	
200-130	31937-31950	schizophrenia	_	
200-131	31950-31951	:	_	
200-132	31952-31953	a	_	
200-133	31954-31964	multimodal	_	
200-134	31965-31974	voxelwise	_	
200-135	31975-31988	meta-analysis	_	
200-136	31989-31992	and	_	
200-137	31993-32008	meta-regression	_	
200-138	32009-32017	analysis	_	
200-139	32018-32031	Abnormalities	_	
200-140	32032-32034	of	_	
200-141	32035-32043	thalamic	_	
200-142	32044-32050	volume	_	
200-143	32051-32054	and	_	
200-144	32055-32060	shape	_	
200-145	32061-32063	in	_	
200-146	32064-32077	schizophrenia	_	
200-147	32078-32088	Structural	_	
200-148	32089-32094	brain	_	
200-149	32095-32106	alterations	_	
200-150	32107-32109	at	_	
200-151	32110-32119	different	_	
200-152	32120-32126	stages	_	
200-153	32127-32129	of	_	
200-154	32130-32143	schizophrenia	_	
200-155	32143-32144	:	_	
200-156	32145-32146	a	_	
200-157	32147-32158	voxel-based	_	
200-158	32159-32171	morphometric	_	
200-159	32172-32177	study	_	
200-160	32178-32185	Ventral	_	
200-161	32186-32194	striatum	_	
200-162	32195-32199	gray	_	
200-163	32200-32206	matter	_	
200-164	32207-32214	density	_	
200-165	32215-32224	reduction	_	
200-166	32225-32227	in	_	
200-167	32228-32236	patients	_	
200-168	32237-32241	with	_	
200-169	32242-32255	schizophrenia	_	
200-170	32256-32259	and	_	
200-171	32260-32269	psychotic	_	
200-172	32270-32279	emotional	_	
200-173	32280-32293	dysregulation	_	
200-174	32294-32298	Gray	_	
200-175	32299-32305	matter	_	
200-176	32306-32319	abnormalities	_	
200-177	32320-32322	in	_	
200-178	32323-32331	paranoid	_	
200-179	32332-32345	schizophrenia	_	
200-180	32346-32349	and	_	
200-181	32350-32355	their	_	
200-182	32356-32364	clinical	_	
200-183	32365-32377	correlations	_	
200-184	32378-32385	Mapping	_	
200-185	32386-32391	brain	_	
200-186	32392-32401	asymmetry	_	
200-187	32402-32406	Left	_	
200-188	32407-32412	brain	_	
200-189	32412-32413	,	_	
200-190	32414-32419	right	_	
200-191	32420-32425	brain	_	
200-192	32425-32426	:	_	
200-193	32427-32432	facts	_	
200-194	32433-32436	and	_	
200-195	32437-32446	fantasies	_	
200-196	32447-32458	Statistical	_	
200-197	32459-32467	analysis	_	
200-198	32468-32470	of	_	
200-199	32471-32482	hippocampal	_	
200-200	32483-32492	asymmetry	_	
200-201	32493-32495	in	_	
200-202	32496-32509	schizophrenia	_	
200-203	32510-32519	Asymmetry	_	
200-204	32520-32522	of	_	
200-205	32523-32526	the	_	
200-206	32527-32538	hippocampus	_	
200-207	32539-32542	and	_	
200-208	32543-32551	amygdala	_	
200-209	32552-32554	in	_	
200-210	32555-32558	MRI	_	
200-211	32559-32569	volumetric	_	
200-212	32570-32582	measurements	_	
200-213	32583-32585	of	_	
200-214	32586-32592	normal	_	
200-215	32593-32599	adults	_	
200-216	32600-32615	Neuroanatomical	_	
200-217	32616-32625	asymmetry	_	
200-218	32626-32634	patterns	_	
200-219	32635-32637	in	_	
200-220	32638-32649	individuals	_	
200-221	32650-32654	with	_	
200-222	32655-32668	schizophrenia	_	
200-223	32669-32672	and	_	
200-224	32673-32678	their	_	
200-225	32679-32692	non-psychotic	_	
200-226	32693-32701	siblings	_	
200-227	32702-32714	MRI-assessed	_	
200-228	32715-32721	volume	_	
200-229	32722-32724	of	_	
200-230	32725-32729	left	_	
200-231	32730-32733	and	_	
200-232	32734-32739	right	_	
200-233	32740-32750	hippocampi	_	
200-234	32751-32753	in	_	
200-235	32754-32761	females	_	
200-236	32762-32772	correlates	_	
200-237	32773-32777	with	_	
200-238	32778-32781	the	_	
200-239	32782-32790	relative	_	
200-240	32791-32797	length	_	
200-241	32798-32800	of	_	
200-242	32801-32804	the	_	
200-243	32805-32811	second	_	
200-244	32812-32815	and	_	
200-245	32816-32822	fourth	_	
200-246	32823-32830	fingers	_	
200-247	32831-32832	(	_	
200-248	32832-32835	the	_	
200-249	32836-32838	2D	_	
200-250	32838-32839	:	_	
200-251	32839-32841	4D	_	
200-252	32842-32847	ratio	_	
200-253	32847-32848	)	_	
200-254	32849-32857	Magnetic	_	
200-255	32858-32867	resonance	_	
200-256	32868-32875	imaging	_	
200-257	32876-32878	of	_	
200-258	32879-32882	the	_	
200-259	32883-32891	thalamus	_	
200-260	32892-32894	in	_	
200-261	32895-32899	male	_	
200-262	32900-32908	patients	_	
200-263	32909-32913	with	_	
200-264	32914-32927	schizophrenia	_	
200-265	32928-32939	Application	_	
200-266	32940-32942	of	_	
200-267	32943-32952	automated	_	
200-268	32953-32956	MRI	_	
200-269	32957-32967	volumetric	_	
200-270	32968-32979	measurement	_	
200-271	32980-32990	techniques	_	
200-272	32991-32993	to	_	
200-273	32994-32997	the	_	
200-274	32998-33009	ventricular	_	
200-275	33010-33016	system	_	
200-276	33017-33019	in	_	
200-277	33020-33034	schizophrenics	_	
200-278	33035-33038	and	_	
200-279	33039-33045	normal	_	
200-280	33046-33054	controls	_	
200-281	33055-33065	Handedness	_	
200-282	33065-33066	,	_	
200-283	33067-33075	language	_	
200-284	33076-33090	lateralisation	_	
200-285	33091-33094	and	_	
200-286	33095-33105	anatomical	_	
200-287	33106-33115	asymmetry	_	
200-288	33116-33118	in	_	
200-289	33119-33132	schizophrenia	_	
200-290	33132-33133	:	_	
200-291	33134-33147	meta-analysis	_	
200-292	33148-33158	Volumetric	_	
200-293	33159-33168	asymmetry	_	
200-294	33169-33172	and	_	
200-295	33173-33185	differential	_	
200-296	33186-33191	aging	_	
200-297	33192-33198	effect	_	
200-298	33199-33201	of	_	
200-299	33202-33205	the	_	
200-300	33206-33211	human	_	
200-301	33212-33219	caudate	_	
200-302	33220-33227	nucleus	_	
200-303	33228-33230	in	_	
200-304	33231-33237	normal	_	
200-305	33238-33249	individuals	_	
200-306	33249-33250	:	_	
200-307	33251-33252	a	_	
200-308	33253-33264	prospective	_	
200-309	33265-33267	MR	_	
200-310	33268-33275	imaging	_	
200-311	33276-33281	study	_	
200-312	33282-33292	Structural	_	
200-313	33293-33304	asymmetries	_	
200-314	33305-33307	in	_	
200-315	33308-33311	the	_	
200-316	33312-33317	human	_	
200-317	33318-33323	brain	_	
200-318	33323-33324	:	_	
200-319	33325-33326	a	_	
200-320	33327-33338	voxel-based	_	
200-321	33339-33350	statistical	_	
200-322	33351-33359	analysis	_	
200-323	33360-33362	of	_	
200-324	33363-33366	142	_	
200-325	33367-33370	MRI	_	
200-326	33371-33376	scans	_	
200-327	33377-33380	Age	_	
200-328	33380-33381	,	_	
200-329	33382-33388	gender	_	
200-330	33388-33389	,	_	
200-331	33390-33393	and	_	
200-332	33394-33405	hemispheric	_	
200-333	33406-33417	differences	_	
200-334	33418-33420	in	_	
200-335	33421-33426	human	_	
200-336	33427-33435	striatum	_	
200-337	33435-33436	:	_	
200-338	33437-33438	a	_	
200-339	33439-33451	quantitative	_	
200-340	33452-33458	review	_	
200-341	33459-33462	and	_	
200-342	33463-33466	new	_	
200-343	33467-33471	data	_	
200-344	33472-33476	from	_	
200-345	33477-33479	in	_	
200-346	33480-33484	vivo	_	
200-347	33485-33488	MRI	_	
200-348	33489-33500	morphometry	_	
200-349	33501-33503	MR	_	
200-350	33504-33514	volumetric	_	
200-351	33515-33523	analysis	_	
200-352	33524-33526	of	_	
200-353	33527-33530	the	_	
200-354	33531-33536	human	_	
200-355	33537-33542	basal	_	
200-356	33543-33550	ganglia	_	
200-357	33550-33551	:	_	
200-358	33552-33561	normative	_	
200-359	33562-33566	data	_	
200-360	33567-33572	Basal	_	
200-361	33573-33580	ganglia	_	
200-362	33581-33588	volumes	_	
200-363	33588-33589	:	_	
200-364	33590-33600	MR-derived	_	
200-365	33601-33610	reference	_	
200-366	33611-33617	ranges	_	
200-367	33618-33621	and	_	
200-368	33622-33636	lateralization	_	
200-369	33637-33644	indices	_	
200-370	33645-33648	for	_	
200-371	33649-33657	children	_	
200-372	33658-33661	and	_	
200-373	33662-33667	young	_	
200-374	33668-33674	adults	_	
200-375	33675-33687	Differential	_	
200-376	33688-33693	aging	_	
200-377	33694-33696	of	_	
200-378	33697-33700	the	_	
200-379	33701-33706	human	_	
200-380	33707-33715	striatum	_	
200-381	33715-33716	:	_	
200-382	33717-33718	a	_	
200-383	33719-33730	prospective	_	
200-384	33731-33733	MR	_	
200-385	33734-33741	imaging	_	
200-386	33742-33747	study	_	
200-387	33748-33756	Abnormal	_	
200-388	33757-33766	asymmetry	_	
200-389	33767-33769	of	_	
200-390	33770-33775	brain	_	
200-391	33776-33788	connectivity	_	
200-392	33789-33791	in	_	
200-393	33792-33805	schizophrenia	_	
200-394	33806-33809	The	_	
200-395	33810-33817	anatomy	_	
200-396	33818-33820	of	_	
200-397	33821-33834	first-episode	_	
200-398	33835-33838	and	_	
200-399	33839-33846	chronic	_	
200-400	33847-33860	schizophrenia	_	
200-401	33860-33861	:	_	
200-402	33862-33864	an	_	
200-403	33865-33875	anatomical	_	
200-404	33876-33886	likelihood	_	
200-405	33887-33897	estimation	_	
200-406	33898-33911	meta-analysis	_	
200-407	33912-33915	The	_	
200-408	33916-33928	neuroanatomy	_	
200-409	33929-33931	of	_	
200-410	33932-33941	psychotic	_	
200-411	33942-33951	diathesis	_	
200-412	33951-33952	:	_	
200-413	33953-33954	a	_	
200-414	33955-33968	meta-analytic	_	
200-415	33969-33975	review	_	
200-416	33976-33981	Brain	_	
200-417	33982-33989	volumes	_	
200-418	33990-33992	in	_	
200-419	33993-34006	schizophrenia	_	
200-420	34006-34007	:	_	
200-421	34008-34009	a	_	
200-422	34010-34023	meta-analysis	_	
200-423	34024-34026	in	_	
200-424	34027-34031	over	_	
200-425	34032-34034	18	_	
200-426	34035-34038	000	_	
200-427	34039-34047	subjects	_	
200-428	34048-34058	Structural	_	
200-429	34059-34067	magnetic	_	
200-430	34068-34077	resonance	_	
200-431	34078-34085	imaging	_	
200-432	34086-34088	in	_	
200-433	34089-34096	bipolar	_	
200-434	34097-34105	disorder	_	
200-435	34105-34106	:	_	
200-436	34107-34109	an	_	
200-437	34110-34123	international	_	
200-438	34124-34137	collaborative	_	
200-439	34138-34151	mega-analysis	_	
200-440	34152-34154	of	_	
200-441	34155-34165	individual	_	
200-442	34166-34171	adult	_	
200-443	34172-34179	patient	_	
200-444	34180-34184	data	_	
200-445	34185-34194	EnigmaVis	_	
200-446	34194-34195	:	_	
200-447	34196-34202	online	_	
200-448	34203-34214	interactive	_	
200-449	34215-34228	visualization	_	
200-450	34229-34231	of	_	
200-451	34232-34243	genome-wide	_	
200-452	34244-34255	association	_	
200-453	34256-34263	studies	_	
200-454	34264-34266	of	_	
200-455	34267-34270	the	_	
200-456	34271-34280	Enhancing	_	
200-457	34281-34293	NeuroImaging	_	
200-458	34294-34302	Genetics	_	
200-459	34303-34310	through	_	
200-460	34311-34324	Meta-Analysis	_	
200-461	34325-34326	(	_	
200-462	34326-34332	ENIGMA	_	
200-463	34332-34333	)	_	
200-464	34334-34344	consortium	_	
200-465	34345-34355	Multi-site	_	
200-466	34356-34363	genetic	_	
200-467	34364-34372	analysis	_	
200-468	34373-34375	of	_	
200-469	34376-34385	diffusion	_	
200-470	34386-34392	images	_	
200-471	34393-34396	and	_	
200-472	34397-34406	voxelwise	_	
200-473	34407-34419	heritability	_	
200-474	34420-34428	analysis	_	
200-475	34428-34429	:	_	
200-476	34430-34431	a	_	
200-477	34432-34437	pilot	_	
200-478	34438-34445	project	_	
200-479	34446-34448	of	_	
200-480	34449-34452	the	_	
200-481	34453-34463	ENIGMA-DTI	_	
200-482	34464-34471	working	_	
200-483	34472-34477	group	_	
200-484	34478-34492	Identification	_	
200-485	34493-34495	of	_	
200-486	34496-34502	common	_	
200-487	34503-34511	variants	_	
200-488	34512-34522	associated	_	
200-489	34523-34527	with	_	
200-490	34528-34533	human	_	
200-491	34534-34545	hippocampal	_	
200-492	34546-34549	and	_	
200-493	34550-34562	intracranial	_	
200-494	34563-34570	volumes	_	
200-495	34571-34581	Multi-site	_	
200-496	34582-34587	study	_	
200-497	34588-34590	of	_	
200-498	34591-34599	additive	_	
200-499	34600-34607	genetic	_	
200-500	34608-34615	effects	_	
200-501	34616-34618	on	_	
200-502	34619-34629	fractional	_	
200-503	34630-34640	anisotropy	_	
200-504	34641-34643	of	_	
200-505	34644-34652	cerebral	_	
200-506	34653-34658	white	_	
200-507	34659-34665	matter	_	
200-508	34665-34666	:	_	
200-509	34667-34676	comparing	_	
200-510	34677-34681	meta	_	
200-511	34682-34685	and	_	
200-512	34686-34700	megaanalytical	_	
200-513	34701-34711	approaches	_	
200-514	34712-34715	for	_	
200-515	34716-34720	data	_	
200-516	34721-34728	pooling	_	
200-517	34729-34734	Joint	_	
200-518	34735-34742	genetic	_	
200-519	34743-34751	analysis	_	
200-520	34752-34754	of	_	
200-521	34755-34766	hippocampal	_	
200-522	34767-34771	size	_	
200-523	34772-34774	in	_	
200-524	34775-34780	mouse	_	
200-525	34781-34784	and	_	
200-526	34785-34790	human	_	
200-527	34791-34801	identifies	_	
200-528	34802-34803	a	_	
200-529	34804-34809	novel	_	
200-530	34810-34814	gene	_	
200-531	34815-34821	linked	_	
200-532	34822-34824	to	_	
200-533	34825-34842	neurodegenerative	_	
200-534	34843-34850	disease	_	
200-535	34851-34857	Common	_	
200-536	34858-34865	genetic	_	
200-537	34866-34874	variants	_	
200-538	34875-34884	influence	_	
200-539	34885-34890	human	_	
200-540	34891-34902	subcortical	_	
200-541	34903-34908	brain	_	
200-542	34909-34919	structures	_	
200-543	34920-34931	Subcortical	_	
200-544	34932-34937	brain	_	
200-545	34938-34949	alterations	_	
200-546	34950-34952	in	_	
200-547	34953-34958	major	_	
200-548	34959-34969	depressive	_	
200-549	34970-34978	disorder	_	
200-550	34978-34979	:	_	
200-551	34980-34988	findings	_	
200-552	34989-34993	from	_	
200-553	34994-34997	the	_	
200-554	34998-35004	ENIGMA	_	
200-555	35005-35010	Major	_	
200-556	35011-35021	Depressive	_	
200-557	35022-35030	Disorder	_	
200-558	35031-35038	working	_	
200-559	35039-35044	group	_	
200-560	35045-35056	Subcortical	_	
200-561	35057-35062	brain	_	
200-562	35063-35069	volume	_	
200-563	35070-35083	abnormalities	_	
200-564	35084-35086	in	_	
200-565	35087-35091	2028	_	
200-566	35092-35103	individuals	_	
200-567	35104-35108	with	_	
200-568	35109-35122	schizophrenia	_	
200-569	35123-35126	and	_	
200-570	35127-35131	2540	_	
200-571	35132-35139	healthy	_	
200-572	35140-35148	controls	_	
200-573	35149-35152	via	_	
200-574	35153-35156	the	_	
200-575	35157-35163	ENIGMA	_	
200-576	35164-35174	consortium	_	
200-577	35175-35189	Random-effects	_	
200-578	35190-35195	model	_	
200-579	35196-35201	aimed	_	
200-580	35202-35204	at	_	
200-581	35205-35216	discovering	_	
200-582	35217-35229	associations	_	
200-583	35230-35232	in	_	
200-584	35233-35246	meta-analysis	_	
200-585	35247-35249	of	_	
200-586	35250-35261	genome-wide	_	
200-587	35262-35273	association	_	
200-588	35274-35281	studies	_	
200-589	35282-35294	Morphometric	_	
200-590	35295-35298	and	_	
200-591	35299-35309	volumetric	_	
200-592	35310-35315	study	_	
200-593	35316-35318	of	_	
200-594	35319-35326	caudate	_	
200-595	35327-35330	and	_	
200-596	35331-35338	putamen	_	
200-597	35339-35345	nuclei	_	
200-598	35346-35348	in	_	
200-599	35349-35355	normal	_	
200-600	35356-35367	individuals	_	
200-601	35368-35370	by	_	
200-602	35371-35374	MRI	_	
200-603	35374-35375	:	_	
200-604	35376-35382	Effect	_	
200-605	35383-35385	of	_	
200-606	35386-35392	normal	_	
200-607	35393-35398	aging	_	
200-608	35398-35399	,	_	
200-609	35400-35406	gender	_	
200-610	35407-35410	and	_	
200-611	35411-35422	hemispheric	_	
200-612	35423-35434	differences	_	
200-613	35435-35436	G	_	
200-614	35436-35437	*	_	
200-615	35437-35442	Power	_	
200-616	35443-35444	3	_	
200-617	35444-35445	:	_	
200-618	35446-35447	a	_	
200-619	35448-35456	flexible	_	
200-620	35457-35468	statistical	_	
200-621	35469-35474	power	_	
200-622	35475-35483	analysis	_	
200-623	35484-35491	program	_	
200-624	35492-35495	for	_	
200-625	35496-35499	the	_	
200-626	35500-35506	social	_	
200-627	35506-35507	,	_	
200-628	35508-35518	behavioral	_	
200-629	35518-35519	,	_	
200-630	35520-35523	and	_	
200-631	35524-35534	biomedical	_	
200-632	35535-35543	sciences	_	
200-633	35544-35555	Measurement	_	
200-634	35556-35559	and	_	
200-635	35560-35568	genetics	_	
200-636	35569-35571	of	_	
200-637	35572-35577	human	_	
200-638	35578-35589	subcortical	_	
200-639	35590-35593	and	_	
200-640	35594-35605	hippocampal	_	
200-641	35606-35617	asymmetries	_	
200-642	35618-35620	in	_	
200-643	35621-35626	large	_	
200-644	35627-35635	datasets	_	
200-645	35636-35643	Caudate	_	
200-646	35643-35644	,	_	
200-647	35645-35652	putamen	_	
200-648	35652-35653	,	_	
200-649	35654-35657	and	_	
200-650	35658-35664	globus	_	
200-651	35665-35673	pallidus	_	
200-652	35674-35680	volume	_	
200-653	35681-35683	in	_	
200-654	35684-35697	schizophrenia	_	
200-655	35697-35698	:	_	
200-656	35699-35700	a	_	
200-657	35701-35713	quantitative	_	
200-658	35714-35717	MRI	_	
200-659	35718-35723	study	_	
200-660	35724-35737	Meta-analysis	_	
200-661	35738-35740	of	_	
200-662	35741-35745	gray	_	
200-663	35746-35752	matter	_	
200-664	35753-35762	anomalies	_	
200-665	35763-35765	in	_	
200-666	35766-35779	schizophrenia	_	
200-667	35779-35780	:	_	
200-668	35781-35792	application	_	
200-669	35793-35795	of	_	
200-670	35796-35804	anatomic	_	
200-671	35805-35815	likelihood	_	
200-672	35816-35826	estimation	_	
200-673	35827-35830	and	_	
200-674	35831-35838	network	_	
200-675	35839-35847	analysis	_	
200-676	35848-35861	Morphological	_	
200-677	35862-35872	correlates	_	
200-678	35873-35875	to	_	
200-679	35876-35885	cognitive	_	
200-680	35886-35897	dysfunction	_	
200-681	35898-35900	in	_	
200-682	35901-35914	schizophrenia	_	
200-683	35915-35917	as	_	
200-684	35918-35925	studied	_	
200-685	35926-35930	with	_	
200-686	35931-35939	Bayesian	_	
200-687	35940-35950	regression	_	
200-688	35951-35961	Structural	_	
200-689	35962-35970	analysis	_	
200-690	35971-35973	of	_	
200-691	35974-35977	the	_	
200-692	35978-35983	basal	_	
200-693	35984-35991	ganglia	_	
200-694	35992-35994	in	_	
200-695	35995-36008	schizophrenia	_	
200-696	36009-36019	Structural	_	
200-697	36020-36032	neuroimaging	_	
200-698	36033-36035	of	_	
200-699	36036-36039	the	_	
200-700	36040-36045	basal	_	
200-701	36046-36053	ganglia	_	
200-702	36054-36056	in	_	
200-703	36057-36070	schizophrenic	_	
200-704	36071-36079	patients	_	
200-705	36079-36080	:	_	
200-706	36081-36082	a	_	
200-707	36083-36089	review	_	
200-708	36090-36095	Focal	_	
200-709	36096-36100	gray	_	
200-710	36101-36107	matter	_	
200-711	36108-36115	density	_	
200-712	36116-36123	changes	_	
200-713	36124-36126	in	_	
200-714	36127-36140	schizophrenia	_	
200-715	36141-36145	Left	_	
200-716	36146-36152	globus	_	
200-717	36153-36161	pallidus	_	
200-718	36162-36173	abnormality	_	
200-719	36174-36176	in	_	
200-720	36177-36192	never-medicated	_	
200-721	36193-36201	patients	_	
200-722	36202-36206	with	_	
200-723	36207-36220	schizophrenia	_	
200-724	36221-36229	Severity	_	
200-725	36230-36232	of	_	
200-726	36233-36241	negative	_	
200-727	36242-36250	symptoms	_	
200-728	36251-36253	in	_	
200-729	36254-36267	schizophrenia	_	
200-730	36268-36278	correlated	_	
200-731	36279-36281	to	_	
200-732	36282-36295	hyperactivity	_	
200-733	36296-36298	of	_	
200-734	36299-36302	the	_	
200-735	36303-36307	left	_	
200-736	36308-36314	globus	_	
200-737	36315-36323	pallidus	_	
200-738	36324-36327	and	_	
200-739	36328-36331	the	_	
200-740	36332-36337	right	_	
200-741	36338-36347	claustrum	_	
200-742	36347-36348	.	_	

#Text=A PET study
#Text=Procedural learning in schizophrenia investigated with functional magnetic resonance imaging
#Text=The diminished interhemispheric connectivity correlates with negative symptoms and cognitive impairment in first-episode schizophrenia
#Text=Abnormal microstructures of the basal ganglia in schizophrenia revealed by diffusion tensor imaging
#Text=Deep-brain stimulation for basal ganglia disorders
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Functional connectivity and integrative properties of globus pallidus neurons
#Text=Computational models of basal-ganglia pathway functions: focus on functional neuroanatomy
#Text=A direct GABAergic output from the basal ganglia to frontal cortex
#Text=Cortical inhibitory neurons and schizophrenia
#Text=Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia.
201-1	36349-36350	A	_	
201-2	36351-36354	PET	_	
201-3	36355-36360	study	_	
201-4	36361-36371	Procedural	_	
201-5	36372-36380	learning	_	
201-6	36381-36383	in	_	
201-7	36384-36397	schizophrenia	_	
201-8	36398-36410	investigated	_	
201-9	36411-36415	with	_	
201-10	36416-36426	functional	_	
201-11	36427-36435	magnetic	_	
201-12	36436-36445	resonance	_	
201-13	36446-36453	imaging	_	
201-14	36454-36457	The	_	
201-15	36458-36468	diminished	_	
201-16	36469-36485	interhemispheric	_	
201-17	36486-36498	connectivity	_	
201-18	36499-36509	correlates	_	
201-19	36510-36514	with	_	
201-20	36515-36523	negative	_	
201-21	36524-36532	symptoms	_	
201-22	36533-36536	and	_	
201-23	36537-36546	cognitive	_	
201-24	36547-36557	impairment	_	
201-25	36558-36560	in	_	
201-26	36561-36574	first-episode	_	
201-27	36575-36588	schizophrenia	_	
201-28	36589-36597	Abnormal	_	
201-29	36598-36613	microstructures	_	
201-30	36614-36616	of	_	
201-31	36617-36620	the	_	
201-32	36621-36626	basal	_	
201-33	36627-36634	ganglia	_	
201-34	36635-36637	in	_	
201-35	36638-36651	schizophrenia	_	
201-36	36652-36660	revealed	_	
201-37	36661-36663	by	_	
201-38	36664-36673	diffusion	_	
201-39	36674-36680	tensor	_	
201-40	36681-36688	imaging	_	
201-41	36689-36699	Deep-brain	_	
201-42	36700-36711	stimulation	_	
201-43	36712-36715	for	_	
201-44	36716-36721	basal	_	
201-45	36722-36729	ganglia	_	
201-46	36730-36739	disorders	_	
201-47	36740-36743	The	_	
201-48	36744-36750	reward	_	
201-49	36751-36758	circuit	_	
201-50	36758-36759	:	_	
201-51	36760-36767	linking	_	
201-52	36768-36775	primate	_	
201-53	36776-36783	anatomy	_	
201-54	36784-36787	and	_	
201-55	36788-36793	human	_	
201-56	36794-36801	imaging	_	
201-57	36802-36812	Functional	_	
201-58	36813-36825	connectivity	_	
201-59	36826-36829	and	_	
201-60	36830-36841	integrative	_	
201-61	36842-36852	properties	_	
201-62	36853-36855	of	_	
201-63	36856-36862	globus	_	
201-64	36863-36871	pallidus	_	
201-65	36872-36879	neurons	_	
201-66	36880-36893	Computational	_	
201-67	36894-36900	models	_	
201-68	36901-36903	of	_	
201-69	36904-36917	basal-ganglia	_	
201-70	36918-36925	pathway	_	
201-71	36926-36935	functions	_	
201-72	36935-36936	:	_	
201-73	36937-36942	focus	_	
201-74	36943-36945	on	_	
201-75	36946-36956	functional	_	
201-76	36957-36969	neuroanatomy	_	
201-77	36970-36971	A	_	
201-78	36972-36978	direct	_	
201-79	36979-36988	GABAergic	_	
201-80	36989-36995	output	_	
201-81	36996-37000	from	_	
201-82	37001-37004	the	_	
201-83	37005-37010	basal	_	
201-84	37011-37018	ganglia	_	
201-85	37019-37021	to	_	
201-86	37022-37029	frontal	_	
201-87	37030-37036	cortex	_	
201-88	37037-37045	Cortical	_	
201-89	37046-37056	inhibitory	_	
201-90	37057-37064	neurons	_	
201-91	37065-37068	and	_	
201-92	37069-37082	schizophrenia	_	
201-93	37083-37094	Physiologic	_	
201-94	37095-37106	dysfunction	_	
201-95	37107-37109	of	_	
201-96	37110-37122	dorsolateral	_	
201-97	37123-37133	prefrontal	_	
201-98	37134-37140	cortex	_	
201-99	37141-37143	in	_	
201-100	37144-37157	schizophrenia	_	
201-101	37157-37158	.	_	

#Text=I.
202-1	37159-37160	I	_	
202-2	37160-37161	.	_	

#Text=Regional cerebral blood flow evidence
#Text=A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia
#Text=Do antipsychotic drugs affect brain structure?
203-1	37162-37170	Regional	_	
203-2	37171-37179	cerebral	_	
203-3	37180-37185	blood	_	
203-4	37186-37190	flow	_	
203-5	37191-37199	evidence	_	
203-6	37200-37201	A	_	
203-7	37202-37214	longitudinal	_	
203-8	37215-37220	study	_	
203-9	37221-37223	on	_	
203-10	37224-37227	the	_	
203-11	37228-37235	effects	_	
203-12	37236-37238	of	_	
203-13	37239-37246	typical	_	
203-14	37247-37253	versus	_	
203-15	37254-37262	atypical	_	
203-16	37263-37276	antipsychotic	_	
203-17	37277-37282	drugs	_	
203-18	37283-37285	on	_	
203-19	37286-37297	hippocampal	_	
203-20	37298-37304	volume	_	
203-21	37305-37307	in	_	
203-22	37308-37321	schizophrenia	_	
203-23	37322-37324	Do	_	
203-24	37325-37338	antipsychotic	_	
203-25	37339-37344	drugs	_	
203-26	37345-37351	affect	_	
203-27	37352-37357	brain	_	
203-28	37358-37367	structure	_	
203-29	37367-37368	?	_	

#Text=A systematic and critical review of MRI findings
#Text=The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?
204-1	37369-37370	A	_	
204-2	37371-37381	systematic	_	
204-3	37382-37385	and	_	
204-4	37386-37394	critical	_	
204-5	37395-37401	review	_	
204-6	37402-37404	of	_	
204-7	37405-37408	MRI	_	
204-8	37409-37417	findings	_	
204-9	37418-37421	The	_	
204-10	37422-37429	effects	_	
204-11	37430-37432	of	_	
204-12	37433-37447	antipsychotics	_	
204-13	37448-37450	on	_	
204-14	37451-37454	the	_	
204-15	37455-37460	brain	_	
204-16	37460-37461	:	_	
204-17	37462-37466	what	_	
204-18	37467-37471	have	_	
204-19	37472-37474	we	_	
204-20	37475-37481	learnt	_	
204-21	37482-37486	from	_	
204-22	37487-37497	structural	_	
204-23	37498-37505	imaging	_	
204-24	37506-37508	of	_	
204-25	37509-37522	schizophrenia	_	
204-26	37522-37523	?	_	

#Text=—a systematic review
#Text=Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review
#Text=Progressive brain changes in schizophrenia related to antipsychotic treatment?
205-1	37523-37524	—	_	
205-2	37524-37525	a	_	
205-3	37526-37536	systematic	_	
205-4	37537-37543	review	_	
205-5	37544-37554	Volumetric	_	
205-6	37555-37562	changes	_	
205-7	37563-37565	in	_	
205-8	37566-37569	the	_	
205-9	37570-37575	basal	_	
205-10	37576-37583	ganglia	_	
205-11	37584-37589	after	_	
205-12	37590-37603	antipsychotic	_	
205-13	37604-37615	monotherapy	_	
205-14	37615-37616	:	_	
205-15	37617-37618	a	_	
205-16	37619-37629	systematic	_	
205-17	37630-37636	review	_	
205-18	37637-37648	Progressive	_	
205-19	37649-37654	brain	_	
205-20	37655-37662	changes	_	
205-21	37663-37665	in	_	
205-22	37666-37679	schizophrenia	_	
205-23	37680-37687	related	_	
205-24	37688-37690	to	_	
205-25	37691-37704	antipsychotic	_	
205-26	37705-37714	treatment	_	
205-27	37714-37715	?	_	

#Text=A meta-analysis of longitudinal MRI studies
#Text=Simpson's paradox visualized: the example of the rosiglitazone meta-analysis
#Text=Supplementary Material
#Text=Flow chart of protocol selection into the current meta-analytic study.
206-1	37716-37717	A	_	
206-2	37718-37731	meta-analysis	_	
206-3	37732-37734	of	_	
206-4	37735-37747	longitudinal	_	
206-5	37748-37751	MRI	_	
206-6	37752-37759	studies	_	
206-7	37760-37769	Simpson's	_	
206-8	37770-37777	paradox	_	
206-9	37778-37788	visualized	_	
206-10	37788-37789	:	_	
206-11	37790-37793	the	_	
206-12	37794-37801	example	_	
206-13	37802-37804	of	_	
206-14	37805-37808	the	_	
206-15	37809-37822	rosiglitazone	_	
206-16	37823-37836	meta-analysis	_	
206-17	37837-37850	Supplementary	_	
206-18	37851-37859	Material	_	
206-19	37860-37864	Flow	_	
206-20	37865-37870	chart	_	
206-21	37871-37873	of	_	
206-22	37874-37882	protocol	_	
206-23	37883-37892	selection	_	
206-24	37893-37897	into	_	
206-25	37898-37901	the	_	
206-26	37902-37909	current	_	
206-27	37910-37923	meta-analytic	_	
206-28	37924-37929	study	_	
206-29	37929-37930	.	_	

#Text=HC, healthy control; MRI, magnetic resonance imaging; SZ, schizophrenia.
207-1	37931-37933	HC	_	
207-2	37933-37934	,	_	
207-3	37935-37942	healthy	_	
207-4	37943-37950	control	_	
207-5	37950-37951	;	_	
207-6	37952-37955	MRI	_	
207-7	37955-37956	,	_	
207-8	37957-37965	magnetic	_	
207-9	37966-37975	resonance	_	
207-10	37976-37983	imaging	_	
207-11	37983-37984	;	_	
207-12	37985-37987	SZ	_	
207-13	37987-37988	,	_	
207-14	37989-38002	schizophrenia	_	
207-15	38002-38003	.	_	

#Text=Meta-analytic overall effect sizes (Cohen's d)±standard errors for subcortical regional volume differences between patients with schizophrenia and healthy controls.
208-1	38004-38017	Meta-analytic	_	
208-2	38018-38025	overall	_	
208-3	38026-38032	effect	_	
208-4	38033-38038	sizes	_	
208-5	38039-38040	(	_	
208-6	38040-38047	Cohen's	_	
208-7	38048-38049	d	_	
208-8	38049-38050	)	_	
208-9	38050-38051	±	_	
208-10	38051-38059	standard	_	
208-11	38060-38066	errors	_	
208-12	38067-38070	for	_	
208-13	38071-38082	subcortical	_	
208-14	38083-38091	regional	_	
208-15	38092-38098	volume	_	
208-16	38099-38110	differences	_	
208-17	38111-38118	between	_	
208-18	38119-38127	patients	_	
208-19	38128-38132	with	_	
208-20	38133-38146	schizophrenia	_	
208-21	38147-38150	and	_	
208-22	38151-38158	healthy	_	
208-23	38159-38167	controls	_	
208-24	38167-38168	.	_	

#Text=Results of the van Erp et al. study from ENIGMA-SZ (blue-colored bars) and those of the current study from COCORO (pink-colored bars) are merged.
209-1	38169-38176	Results	_	
209-2	38177-38179	of	_	
209-3	38180-38183	the	_	
209-4	38184-38187	van	_	
209-5	38188-38191	Erp	_	
209-6	38192-38194	et	_	
209-7	38195-38197	al	_	
209-8	38197-38198	.	_	
209-9	38199-38204	study	_	
209-10	38205-38209	from	_	
209-11	38210-38219	ENIGMA-SZ	_	
209-12	38220-38221	(	_	
209-13	38221-38233	blue-colored	_	
209-14	38234-38238	bars	_	
209-15	38238-38239	)	_	
209-16	38240-38243	and	_	
209-17	38244-38249	those	_	
209-18	38250-38252	of	_	
209-19	38253-38256	the	_	
209-20	38257-38264	current	_	
209-21	38265-38270	study	_	
209-22	38271-38275	from	_	
209-23	38276-38282	COCORO	_	
209-24	38283-38284	(	_	
209-25	38284-38296	pink-colored	_	
209-26	38297-38301	bars	_	
209-27	38301-38302	)	_	
209-28	38303-38306	are	_	
209-29	38307-38313	merged	_	
209-30	38313-38314	.	_	

#Text=Between-group differences in subcortical volumes adjusted for age, sex and intracranial volume, as well as differences in intracranial volume adjusted for age and sex, were included into the meta-analysis and overall differences were obtained.
210-1	38315-38328	Between-group	_	
210-2	38329-38340	differences	_	
210-3	38341-38343	in	_	
210-4	38344-38355	subcortical	_	
210-5	38356-38363	volumes	_	
210-6	38364-38372	adjusted	_	
210-7	38373-38376	for	_	
210-8	38377-38380	age	_	
210-9	38380-38381	,	_	
210-10	38382-38385	sex	_	
210-11	38386-38389	and	_	
210-12	38390-38402	intracranial	_	
210-13	38403-38409	volume	_	
210-14	38409-38410	,	_	
210-15	38411-38413	as	_	
210-16	38414-38418	well	_	
210-17	38419-38421	as	_	
210-18	38422-38433	differences	_	
210-19	38434-38436	in	_	
210-20	38437-38449	intracranial	_	
210-21	38450-38456	volume	_	
210-22	38457-38465	adjusted	_	
210-23	38466-38469	for	_	
210-24	38470-38473	age	_	
210-25	38474-38477	and	_	
210-26	38478-38481	sex	_	
210-27	38481-38482	,	_	
210-28	38483-38487	were	_	
210-29	38488-38496	included	_	
210-30	38497-38501	into	_	
210-31	38502-38505	the	_	
210-32	38506-38519	meta-analysis	_	
210-33	38520-38523	and	_	
210-34	38524-38531	overall	_	
210-35	38532-38543	differences	_	
210-36	38544-38548	were	_	
210-37	38549-38557	obtained	_	
210-38	38557-38558	.	_	

#Text=The corresponding forest plots are described in Supplementary Figures 3a–q.
211-1	38559-38562	The	_	
211-2	38563-38576	corresponding	_	
211-3	38577-38583	forest	_	
211-4	38584-38589	plots	_	
211-5	38590-38593	are	_	
211-6	38594-38603	described	_	
211-7	38604-38606	in	_	
211-8	38607-38620	Supplementary	_	
211-9	38621-38628	Figures	_	
211-10	38629-38633	3a–q	_	
211-11	38633-38634	.	_	

#Text=An overall effect size was calculated as the ratio of the overall difference to the pooled standard deviation.
212-1	38635-38637	An	_	
212-2	38638-38645	overall	_	
212-3	38646-38652	effect	_	
212-4	38653-38657	size	_	
212-5	38658-38661	was	_	
212-6	38662-38672	calculated	_	
212-7	38673-38675	as	_	
212-8	38676-38679	the	_	
212-9	38680-38685	ratio	_	
212-10	38686-38688	of	_	
212-11	38689-38692	the	_	
212-12	38693-38700	overall	_	
212-13	38701-38711	difference	_	
212-14	38712-38714	to	_	
212-15	38715-38718	the	_	
212-16	38719-38725	pooled	_	
212-17	38726-38734	standard	_	
212-18	38735-38744	deviation	_	
212-19	38744-38745	.	_	

#Text=A positive effect size means that patients with schizophrenia had larger volumes than healthy controls. accumb, accumbens; amyg, amygdala; caud, caudate; COCORO, Cognitive Genetics Collaborative Research Organization; ENIGMA, Enhancing Neuro Imaging Genetics through Meta-Analysis; ENIGMA-SZ, ENIGMA Schizophrenia Working Group; hippo, hippocampus; ICV, intracranial volume; L, left; LatVent, lateral ventricle; pal, pallidum; put, putamen; R, right; thal, thalamus.
213-1	38746-38747	A	_	
213-2	38748-38756	positive	_	
213-3	38757-38763	effect	_	
213-4	38764-38768	size	_	
213-5	38769-38774	means	_	
213-6	38775-38779	that	_	
213-7	38780-38788	patients	_	
213-8	38789-38793	with	_	
213-9	38794-38807	schizophrenia	_	
213-10	38808-38811	had	_	
213-11	38812-38818	larger	_	
213-12	38819-38826	volumes	_	
213-13	38827-38831	than	_	
213-14	38832-38839	healthy	_	
213-15	38840-38848	controls	_	
213-16	38848-38849	.	_	
213-17	38850-38856	accumb	_	
213-18	38856-38857	,	_	
213-19	38858-38867	accumbens	_	
213-20	38867-38868	;	_	
213-21	38869-38873	amyg	_	
213-22	38873-38874	,	_	
213-23	38875-38883	amygdala	_	
213-24	38883-38884	;	_	
213-25	38885-38889	caud	_	
213-26	38889-38890	,	_	
213-27	38891-38898	caudate	_	
213-28	38898-38899	;	_	
213-29	38900-38906	COCORO	_	
213-30	38906-38907	,	_	
213-31	38908-38917	Cognitive	_	
213-32	38918-38926	Genetics	_	
213-33	38927-38940	Collaborative	_	
213-34	38941-38949	Research	_	
213-35	38950-38962	Organization	_	
213-36	38962-38963	;	_	
213-37	38964-38970	ENIGMA	_	
213-38	38970-38971	,	_	
213-39	38972-38981	Enhancing	_	
213-40	38982-38987	Neuro	_	
213-41	38988-38995	Imaging	_	
213-42	38996-39004	Genetics	_	
213-43	39005-39012	through	_	
213-44	39013-39026	Meta-Analysis	_	
213-45	39026-39027	;	_	
213-46	39028-39037	ENIGMA-SZ	_	
213-47	39037-39038	,	_	
213-48	39039-39045	ENIGMA	_	
213-49	39046-39059	Schizophrenia	_	
213-50	39060-39067	Working	_	
213-51	39068-39073	Group	_	
213-52	39073-39074	;	_	
213-53	39075-39080	hippo	_	
213-54	39080-39081	,	_	
213-55	39082-39093	hippocampus	_	
213-56	39093-39094	;	_	
213-57	39095-39098	ICV	_	
213-58	39098-39099	,	_	
213-59	39100-39112	intracranial	_	
213-60	39113-39119	volume	_	
213-61	39119-39120	;	_	
213-62	39121-39122	L	_	
213-63	39122-39123	,	_	
213-64	39124-39128	left	_	
213-65	39128-39129	;	_	
213-66	39130-39137	LatVent	_	
213-67	39137-39138	,	_	
213-68	39139-39146	lateral	_	
213-69	39147-39156	ventricle	_	
213-70	39156-39157	;	_	
213-71	39158-39161	pal	_	
213-72	39161-39162	,	_	
213-73	39163-39171	pallidum	_	
213-74	39171-39172	;	_	
213-75	39173-39176	put	_	
213-76	39176-39177	,	_	
213-77	39178-39185	putamen	_	
213-78	39185-39186	;	_	
213-79	39187-39188	R	_	
213-80	39188-39189	,	_	
213-81	39190-39195	right	_	
213-82	39195-39196	;	_	
213-83	39197-39201	thal	_	
213-84	39201-39202	,	_	
213-85	39203-39211	thalamus	_	
213-86	39211-39212	.	_	

#Text=Within-group meta-analytic overall effect sizes (Cohen's d)±standard errors for laterality indices (LIs) of subcortical regional volumes in healthy controls (white bars) and in patients with schizophrenia (gray bars).
214-1	39213-39225	Within-group	_	
214-2	39226-39239	meta-analytic	_	
214-3	39240-39247	overall	_	
214-4	39248-39254	effect	_	
214-5	39255-39260	sizes	_	
214-6	39261-39262	(	_	
214-7	39262-39269	Cohen's	_	
214-8	39270-39271	d	_	
214-9	39271-39272	)	_	
214-10	39272-39273	±	_	
214-11	39273-39281	standard	_	
214-12	39282-39288	errors	_	
214-13	39289-39292	for	_	
214-14	39293-39303	laterality	_	
214-15	39304-39311	indices	_	
214-16	39312-39313	(	_	
214-17	39313-39316	LIs	_	
214-18	39316-39317	)	_	
214-19	39318-39320	of	_	
214-20	39321-39332	subcortical	_	
214-21	39333-39341	regional	_	
214-22	39342-39349	volumes	_	
214-23	39350-39352	in	_	
214-24	39353-39360	healthy	_	
214-25	39361-39369	controls	_	
214-26	39370-39371	(	_	
214-27	39371-39376	white	_	
214-28	39377-39381	bars	_	
214-29	39381-39382	)	_	
214-30	39383-39386	and	_	
214-31	39387-39389	in	_	
214-32	39390-39398	patients	_	
214-33	39399-39403	with	_	
214-34	39404-39417	schizophrenia	_	
214-35	39418-39419	(	_	
214-36	39419-39423	gray	_	
214-37	39424-39428	bars	_	
214-38	39428-39429	)	_	
214-39	39429-39430	.	_	

#Text=An LI was defined as the ratio [(left−right)/(left+right)].
215-1	39431-39433	An	_	
215-2	39434-39436	LI	_	
215-3	39437-39440	was	_	
215-4	39441-39448	defined	_	
215-5	39449-39451	as	_	
215-6	39452-39455	the	_	
215-7	39456-39461	ratio	_	
215-8	39462-39463	[	_	
215-9	39463-39464	(	_	
215-10	39464-39468	left	_	
215-11	39468-39469	−	_	
215-12	39469-39474	right	_	
215-13	39474-39475	)	_	
215-14	39475-39476	/	_	
215-15	39476-39477	(	_	
215-16	39477-39481	left	_	
215-17	39481-39482	+	_	
215-18	39482-39487	right	_	
215-19	39487-39488	)	_	
215-20	39488-39489	]	_	
215-21	39489-39490	.	_	

#Text=In each group, mean LIs and their standard errors were entered into the meta-analysis and an overall mean was obtained.
216-1	39491-39493	In	_	
216-2	39494-39498	each	_	
216-3	39499-39504	group	_	
216-4	39504-39505	,	_	
216-5	39506-39510	mean	_	
216-6	39511-39514	LIs	_	
216-7	39515-39518	and	_	
216-8	39519-39524	their	_	
216-9	39525-39533	standard	_	
216-10	39534-39540	errors	_	
216-11	39541-39545	were	_	
216-12	39546-39553	entered	_	
216-13	39554-39558	into	_	
216-14	39559-39562	the	_	
216-15	39563-39576	meta-analysis	_	
216-16	39577-39580	and	_	
216-17	39581-39583	an	_	
216-18	39584-39591	overall	_	
216-19	39592-39596	mean	_	
216-20	39597-39600	was	_	
216-21	39601-39609	obtained	_	
216-22	39609-39610	.	_	

#Text=The corresponding forest plots are described in Supplementary Figures 4a–h and 5a–h.
217-1	39611-39614	The	_	
217-2	39615-39628	corresponding	_	
217-3	39629-39635	forest	_	
217-4	39636-39641	plots	_	
217-5	39642-39645	are	_	
217-6	39646-39655	described	_	
217-7	39656-39658	in	_	
217-8	39659-39672	Supplementary	_	
217-9	39673-39680	Figures	_	
217-10	39681-39685	4a–h	_	
217-11	39686-39689	and	_	
217-12	39690-39694	5a–h	_	
217-13	39694-39695	.	_	

#Text=An overall effect size for LIs was calculated as the ratio of the overall mean LIs to the overall standard deviation.
218-1	39696-39698	An	_	
218-2	39699-39706	overall	_	
218-3	39707-39713	effect	_	
218-4	39714-39718	size	_	
218-5	39719-39722	for	_	
218-6	39723-39726	LIs	_	
218-7	39727-39730	was	_	
218-8	39731-39741	calculated	_	
218-9	39742-39744	as	_	
218-10	39745-39748	the	_	
218-11	39749-39754	ratio	_	
218-12	39755-39757	of	_	
218-13	39758-39761	the	_	
218-14	39762-39769	overall	_	
218-15	39770-39774	mean	_	
218-16	39775-39778	LIs	_	
218-17	39779-39781	to	_	
218-18	39782-39785	the	_	
218-19	39786-39793	overall	_	
218-20	39794-39802	standard	_	
218-21	39803-39812	deviation	_	
218-22	39812-39813	.	_	

#Text=A positive effect size demonstrates a leftward asymmetry. accumb, accumbens; amyg, amygdala; caud, caudate; hippo, hippocampus; LatVent, lateral ventricle; pal, pallidum; put, putamen; thal, thalamus.
219-1	39814-39815	A	_	
219-2	39816-39824	positive	_	
219-3	39825-39831	effect	_	
219-4	39832-39836	size	_	
219-5	39837-39849	demonstrates	_	
219-6	39850-39851	a	_	
219-7	39852-39860	leftward	_	
219-8	39861-39870	asymmetry	_	
219-9	39870-39871	.	_	
219-10	39872-39878	accumb	_	
219-11	39878-39879	,	_	
219-12	39880-39889	accumbens	_	
219-13	39889-39890	;	_	
219-14	39891-39895	amyg	_	
219-15	39895-39896	,	_	
219-16	39897-39905	amygdala	_	
219-17	39905-39906	;	_	
219-18	39907-39911	caud	_	
219-19	39911-39912	,	_	
219-20	39913-39920	caudate	_	
219-21	39920-39921	;	_	
219-22	39922-39927	hippo	_	
219-23	39927-39928	,	_	
219-24	39929-39940	hippocampus	_	
219-25	39940-39941	;	_	
219-26	39942-39949	LatVent	_	
219-27	39949-39950	,	_	
219-28	39951-39958	lateral	_	
219-29	39959-39968	ventricle	_	
219-30	39968-39969	;	_	
219-31	39970-39973	pal	_	
219-32	39973-39974	,	_	
219-33	39975-39983	pallidum	_	
219-34	39983-39984	;	_	
219-35	39985-39988	put	_	
219-36	39988-39989	,	_	
219-37	39990-39997	putamen	_	
219-38	39997-39998	;	_	
219-39	39999-40003	thal	_	
219-40	40003-40004	,	_	
219-41	40005-40013	thalamus	_	
219-42	40013-40014	.	_	

#Text=Basic characteristics of the included protocols
#Text=Protocol name\tHC\tSZ\tVendor\tMFS\t \t \t \t \t \tAge\t \t \t \tAge\t \t \t \t \tN\tMale\tFemale\tMean\ts.d.
220-1	40015-40020	Basic	_	
220-2	40021-40036	characteristics	_	
220-3	40037-40039	of	_	
220-4	40040-40043	the	_	
220-5	40044-40052	included	_	
220-6	40053-40062	protocols	_	
220-7	40063-40071	Protocol	_	
220-8	40072-40076	name	_	
220-9	40077-40079	HC	_	
220-10	40080-40082	SZ	_	
220-11	40083-40089	Vendor	_	
220-12	40090-40093	MFS	_	
220-13	40096-40103	 	 	 	 	_	
220-14	40104-40107	Age	_	
220-15	40108-40113	 	 	 	_	
220-16	40114-40117	Age	_	
220-17	40118-40125	 	 	 	 	_	
220-18	40126-40127	N	_	
220-19	40128-40132	Male	_	
220-20	40133-40139	Female	_	
220-21	40140-40144	Mean	_	
220-22	40145-40148	s.d	_	
220-23	40148-40149	.	_	

#Text=N\tMale\tFemale\tMean\ts.d.\t \t \t \t01.
221-1	40150-40151	N	_	
221-2	40152-40156	Male	_	
221-3	40157-40163	Female	_	
221-4	40164-40168	Mean	_	
221-5	40169-40172	s.d	_	
221-6	40172-40173	.	_	
221-7	40174-40177	 	 	_	
221-8	40180-40182	01	_	
221-9	40182-40183	.	_	

#Text=Osaka_A\t404\t187\t217\t35.4\t12.6\t136\t80\t56\t36.4\t12.6\tGE\t1.5 T\t \t02.
222-1	40184-40191	Osaka_A	_	
222-2	40192-40195	404	_	
222-3	40196-40199	187	_	
222-4	40200-40203	217	_	
222-5	40204-40208	35.4	_	
222-6	40209-40213	12.6	_	
222-7	40214-40217	136	_	
222-8	40218-40220	80	_	
222-9	40221-40223	56	_	
222-10	40224-40228	36.4	_	
222-11	40229-40233	12.6	_	
222-12	40234-40236	GE	_	
222-13	40237-40240	1.5	_	
222-14	40241-40242	T	_	
222-15	40245-40247	02	_	
222-16	40247-40248	.	_	

#Text=Tokyo_A\t233\t143\t90\t34.4\t11.5\t102\t57\t45\t33.3\t9.5\tGE\t1.5 T\t \t03.
223-1	40249-40256	Tokyo_A	_	
223-2	40257-40260	233	_	
223-3	40261-40264	143	_	
223-4	40265-40267	90	_	
223-5	40268-40272	34.4	_	
223-6	40273-40277	11.5	_	
223-7	40278-40281	102	_	
223-8	40282-40284	57	_	
223-9	40285-40287	45	_	
223-10	40288-40292	33.3	_	
223-11	40293-40296	9.5	_	
223-12	40297-40299	GE	_	
223-13	40300-40303	1.5	_	
223-14	40304-40305	T	_	
223-15	40308-40310	03	_	
223-16	40310-40311	.	_	

#Text=Osaka_B\t237\t131\t106\t31.4\t13.2\t79\t35\t44\t33.1\t12.0\tGE\t3.0 T\t \t04.
224-1	40312-40319	Osaka_B	_	
224-2	40320-40323	237	_	
224-3	40324-40327	131	_	
224-4	40328-40331	106	_	
224-5	40332-40336	31.4	_	
224-6	40337-40341	13.2	_	
224-7	40342-40344	79	_	
224-8	40345-40347	35	_	
224-9	40348-40350	44	_	
224-10	40351-40355	33.1	_	
224-11	40356-40360	12.0	_	
224-12	40361-40363	GE	_	
224-13	40364-40367	3.0	_	
224-14	40368-40369	T	_	
224-15	40372-40374	04	_	
224-16	40374-40375	.	_	

#Text=Toyama_A\t118\t63\t55\t25.9\t6.3\t117\t60\t57\t26.7\t6.3\tSiemens\t1.5 T\t \t05.
225-1	40376-40384	Toyama_A	_	
225-2	40385-40388	118	_	
225-3	40389-40391	63	_	
225-4	40392-40394	55	_	
225-5	40395-40399	25.9	_	
225-6	40400-40403	6.3	_	
225-7	40404-40407	117	_	
225-8	40408-40410	60	_	
225-9	40411-40413	57	_	
225-10	40414-40418	26.7	_	
225-11	40419-40422	6.3	_	
225-12	40423-40430	Siemens	_	
225-13	40431-40434	1.5	_	
225-14	40435-40436	T	_	
225-15	40439-40441	05	_	
225-16	40441-40442	.	_	

#Text=Kyoto\t111\t63\t48\t31.9\t10.6\t85\t45\t40\t35.9\t9.2\tSiemens\t3.0 T\t \t06.
226-1	40443-40448	Kyoto	_	
226-2	40449-40452	111	_	
226-3	40453-40455	63	_	
226-4	40456-40458	48	_	
226-5	40459-40463	31.9	_	
226-6	40464-40468	10.6	_	
226-7	40469-40471	85	_	
226-8	40472-40474	45	_	
226-9	40475-40477	40	_	
226-10	40478-40482	35.9	_	
226-11	40483-40486	9.2	_	
226-12	40487-40494	Siemens	_	
226-13	40495-40498	3.0	_	
226-14	40499-40500	T	_	
226-15	40503-40505	06	_	
226-16	40505-40506	.	_	

#Text=Hokkaido\t35\t15\t20\t48.3\t12.0\t117\t43\t74\t35.1\t12.4\tSiemens\t1.5 T\t \t07.
227-1	40507-40515	Hokkaido	_	
227-2	40516-40518	35	_	
227-3	40519-40521	15	_	
227-4	40522-40524	20	_	
227-5	40525-40529	48.3	_	
227-6	40530-40534	12.0	_	
227-7	40535-40538	117	_	
227-8	40539-40541	43	_	
227-9	40542-40544	74	_	
227-10	40545-40549	35.1	_	
227-11	40550-40554	12.4	_	
227-12	40555-40562	Siemens	_	
227-13	40563-40566	1.5	_	
227-14	40567-40568	T	_	
227-15	40571-40573	07	_	
227-16	40573-40574	.	_	

#Text=Tokyo_B\t83\t57\t26\t28.7\t5.5\t45\t30\t15\t31.2\t9.0\tGE\t3.0 T\t \t08.
228-1	40575-40582	Tokyo_B	_	
228-2	40583-40585	83	_	
228-3	40586-40588	57	_	
228-4	40589-40591	26	_	
228-5	40592-40596	28.7	_	
228-6	40597-40600	5.5	_	
228-7	40601-40603	45	_	
228-8	40604-40606	30	_	
228-9	40607-40609	15	_	
228-10	40610-40614	31.2	_	
228-11	40615-40618	9.0	_	
228-12	40619-40621	GE	_	
228-13	40622-40625	3.0	_	
228-14	40626-40627	T	_	
228-15	40630-40632	08	_	
228-16	40632-40633	.	_	

#Text=Yamaguchi\t91\t18\t73\t49.5\t16.1\t28\t5\t23\t55.5\t8.0\tSiemens\t1.5 T\t \t09.
229-1	40634-40643	Yamaguchi	_	
229-2	40644-40646	91	_	
229-3	40647-40649	18	_	
229-4	40650-40652	73	_	
229-5	40653-40657	49.5	_	
229-6	40658-40662	16.1	_	
229-7	40663-40665	28	_	
229-8	40666-40667	5	_	
229-9	40668-40670	23	_	
229-10	40671-40675	55.5	_	
229-11	40676-40679	8.0	_	
229-12	40680-40687	Siemens	_	
229-13	40688-40691	1.5	_	
229-14	40692-40693	T	_	
229-15	40696-40698	09	_	
229-16	40698-40699	.	_	

#Text=Nagoya_A\t68\t38\t30\t37.7\t9.8\t43\t26\t17\t43.6\t10.6\tSiemens\t3.0 T\t \t10.
230-1	40700-40708	Nagoya_A	_	
230-2	40709-40711	68	_	
230-3	40712-40714	38	_	
230-4	40715-40717	30	_	
230-5	40718-40722	37.7	_	
230-6	40723-40726	9.8	_	
230-7	40727-40729	43	_	
230-8	40730-40732	26	_	
230-9	40733-40735	17	_	
230-10	40736-40740	43.6	_	
230-11	40741-40745	10.6	_	
230-12	40746-40753	Siemens	_	
230-13	40754-40757	3.0	_	
230-14	40758-40759	T	_	
230-15	40762-40764	10	_	
230-16	40764-40765	.	_	

#Text=Kyushu_A\t78\t36\t42\t33.2\t11.9\t31\t9\t22\t39.4\t9.5\tPhilips\t3.0 T\t \t11.
231-1	40766-40774	Kyushu_A	_	
231-2	40775-40777	78	_	
231-3	40778-40780	36	_	
231-4	40781-40783	42	_	
231-5	40784-40788	33.2	_	
231-6	40789-40793	11.9	_	
231-7	40794-40796	31	_	
231-8	40797-40798	9	_	
231-9	40799-40801	22	_	
231-10	40802-40806	39.4	_	
231-11	40807-40810	9.5	_	
231-12	40811-40818	Philips	_	
231-13	40819-40822	3.0	_	
231-14	40823-40824	T	_	
231-15	40827-40829	11	_	
231-16	40829-40830	.	_	

#Text=Kanazawa-med\t53\t32\t21\t35.9\t11.7\t34\t14\t20\t35.9\t9.5\tSiemens\t3.0 T\t \t12.
232-1	40831-40843	Kanazawa-med	_	
232-2	40844-40846	53	_	
232-3	40847-40849	32	_	
232-4	40850-40852	21	_	
232-5	40853-40857	35.9	_	
232-6	40858-40862	11.7	_	
232-7	40863-40865	34	_	
232-8	40866-40868	14	_	
232-9	40869-40871	20	_	
232-10	40872-40876	35.9	_	
232-11	40877-40880	9.5	_	
232-12	40881-40888	Siemens	_	
232-13	40889-40892	3.0	_	
232-14	40893-40894	T	_	
232-15	40897-40899	12	_	
232-16	40899-40900	.	_	

#Text=UOEH\t54\t36\t18\t36.6\t12.0\t15\t6\t9\t28.0\t13.4\tGE\t3.0 T\t \t13.
233-1	40901-40905	UOEH	_	
233-2	40906-40908	54	_	
233-3	40909-40911	36	_	
233-4	40912-40914	18	_	
233-5	40915-40919	36.6	_	
233-6	40920-40924	12.0	_	
233-7	40925-40927	15	_	
233-8	40928-40929	6	_	
233-9	40930-40931	9	_	
233-10	40932-40936	28.0	_	
233-11	40937-40941	13.4	_	
233-12	40942-40944	GE	_	
233-13	40945-40948	3.0	_	
233-14	40949-40950	T	_	
233-15	40953-40955	13	_	
233-16	40955-40956	.	_	

#Text=Yaesu_A\t47\t17\t30\t38.8\t9.0\t11\t6\t5\t38.4\t4.2\tPhilips\t3.0 T\t \t14.
234-1	40957-40964	Yaesu_A	_	
234-2	40965-40967	47	_	
234-3	40968-40970	17	_	
234-4	40971-40973	30	_	
234-5	40974-40978	38.8	_	
234-6	40979-40982	9.0	_	
234-7	40983-40985	11	_	
234-8	40986-40987	6	_	
234-9	40988-40989	5	_	
234-10	40990-40994	38.4	_	
234-11	40995-40998	4.2	_	
234-12	40999-41006	Philips	_	
234-13	41007-41010	3.0	_	
234-14	41011-41012	T	_	
234-15	41015-41017	14	_	
234-16	41017-41018	.	_	

#Text=Tokyo_C\t41\t25\t16\t28.8\t7.5\t15\t8\t7\t30.5\t12.7\tGE\t3.0 T\t \t15.
235-1	41019-41026	Tokyo_C	_	
235-2	41027-41029	41	_	
235-3	41030-41032	25	_	
235-4	41033-41035	16	_	
235-5	41036-41040	28.8	_	
235-6	41041-41044	7.5	_	
235-7	41045-41047	15	_	
235-8	41048-41049	8	_	
235-9	41050-41051	7	_	
235-10	41052-41056	30.5	_	
235-11	41057-41061	12.7	_	
235-12	41062-41064	GE	_	
235-13	41065-41068	3.0	_	
235-14	41069-41070	T	_	
235-15	41073-41075	15	_	
235-16	41075-41076	.	_	

#Text=Kyushu_B\t27\t11\t16\t34.6\t13.8\t26\t14\t12\t35.5\t11.0\tPhilips\t3.0 T\t \tTotal\t1680\t872\t808\t34.5\t12.7\t884\t438\t446\t34.8\t11.7\t \t \t \t
#Text=Abbreviations: HC, healthy control; MFS, magnetic field strength; SZ, schizophrenia.
236-1	41077-41085	Kyushu_B	_	
236-2	41086-41088	27	_	
236-3	41089-41091	11	_	
236-4	41092-41094	16	_	
236-5	41095-41099	34.6	_	
236-6	41100-41104	13.8	_	
236-7	41105-41107	26	_	
236-8	41108-41110	14	_	
236-9	41111-41113	12	_	
236-10	41114-41118	35.5	_	
236-11	41119-41123	11.0	_	
236-12	41124-41131	Philips	_	
236-13	41132-41135	3.0	_	
236-14	41136-41137	T	_	
236-15	41140-41145	Total	_	
236-16	41146-41150	1680	_	
236-17	41151-41154	872	_	
236-18	41155-41158	808	_	
236-19	41159-41163	34.5	_	
236-20	41164-41168	12.7	_	
236-21	41169-41172	884	_	
236-22	41173-41176	438	_	
236-23	41177-41180	446	_	
236-24	41181-41185	34.8	_	
236-25	41186-41190	11.7	_	
236-26	41191-41194	 	 	_	
236-27	41198-41211	Abbreviations	_	
236-28	41211-41212	:	_	
236-29	41213-41215	HC	_	
236-30	41215-41216	,	_	
236-31	41217-41224	healthy	_	
236-32	41225-41232	control	_	
236-33	41232-41233	;	_	
236-34	41234-41237	MFS	_	
236-35	41237-41238	,	_	
236-36	41239-41247	magnetic	_	
236-37	41248-41253	field	_	
236-38	41254-41262	strength	_	
236-39	41262-41263	;	_	
236-40	41264-41266	SZ	_	
236-41	41266-41267	,	_	
236-42	41268-41281	schizophrenia	_	
236-43	41281-41282	.	_	
